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 β-catenin plays multiple roles in liver health and disease through regulation of 
proliferation, differentiation and metabolism. Elucidating the molecular basis of how β-catenin 
regulates these diverse functions and others is the subject of this dissertation.  
While β-catenin signaling undergoes temporal activation and its loss dampens liver 
regeneration (LR), the impact of stimulating this pathway remains unknown. We utilized 
transgenic (TG) mice expressing Ser45 mutated β-catenin in hepatocytes to show a growth 
advantage both in vitro and during LR through cyclin-D1 regulation. Additionally, 
hydrodynamic delivery of Wnt-1 gene delivery induced β-catenin activation and hepatocyte 
proliferation during LR.   
Regucalcin or senescence marker protein-30 (SMP30) was identified as a β-catenin target 
in the liver through the use of hepatocyte-specific β-catenin conditional knockout (KO) mice. 
SMP30 is a critical enzyme for the synthesis of ascorbic acid in murine hepatocytes, and its loss 
led to lower serum ascorbate levels in KO. KO hepatocytes displayed massive apoptosis in 
culture, which was blocked by addition of ascorbate to culture media.  Additionally, apoptosis in 
HepG2 cells due to regucalcin knockdown was rescued by anti-oxidants.  Thus, one mechanism 
of how β-catenin regulates hepatocyte redox state and survival is through the control of 
regucalcin expression. 
KO livers displayed a basal increase in number of apoptotic hepatocytes.  We explored 
the susceptibility of KO and wildtype (WT) controls to activation of the TNF-α mediated 
apoptotic pathway. Paradoxically, KO mice are refractory to D-galactosamine (GalN)/LPS, 
Actinomycin D (ActD)/LPS and GalN/TNF-α treatments showing lower morbidity than WT.  
NF-κB, a major pro-survival factor and its transcriptional targets were increased in KO basally 
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and after injury due to lack of β-catenin-p65 association, presence of increased basal 
inflammation and oxidative stress and increased TLR4 expression in KO livers.  Additionally, 
p65 activation occurred earlier in KO than WT after LPS stimulation. Thus, paradoxical 
protection from TNF-α-mediated apoptosis in KOs occurs owing to pre-existing NF-κB 
activation that ‘primes’ the liver for protection against exogenous insult. 
Thus, we have identified β-catenin as a pleiotropic factor regulating cell proliferation, 
cellular redox state and cell survival through specific genetic targets and protein-protein 
interactions. These findings have broad implications in acute and chronic hepatic diseases. 
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1.0  INTRODUCTION 
1.1 THE WNT/ΒETA-CATENIN SIGNALING PATHWAY 
1.1.1 The canonical Wnt pathway 
Because of its essential role in regulating developmental decisions as well as adult tissue 
homeostasis, the Wnt/β-catenin signaling pathway has been the subject of extensive research for 
the past two decades [1].  Characterization of this evolutionarily well-conserved pathway has 
shown that Wnt signaling is indispensible in processes as diverse as cell fate, development, 
differentiation, growth, survival, regeneration, and self-renewal [2-6].  Mutations in Wnt 
pathway components have also been implicated in the initiation and development of cancer and 
disease progression [7, 8].   
Wnt genes encode a large family of secreted glycoproteins that act as extracellular 
signaling molecules.  Binding of Wnt proteins initiates a signaling cascade, which results in 
activation of β-catenin, the central player in the canonical Wnt pathway.   However, in most 
normal unstimulated adult cells, where the Wnt/β-catenin pathway is inactive, this steady-state 
condition is ensured by the absence of Wnt protein and the degradation of β-catenin.  Free 
cytoplasmic β-catenin is bound in a complex with Axin, adenomatous polyposis coli (APC), 
casein kinase 1 (CK1) and glycogen synthase kinase 3β (GSK3β), which collectively comprise 
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the destruction complex.  β-catenin is phosphorylated by casein kinase 1 (CK1) and GSK-3β at 
specific serine/threonine residues located at the N-terminal region of the protein, which is 
facilitated by the scaffolding proteins Axin and APC [9].  This sequential phosphorylation targets 
β-catenin for ubiquitination and ultimate degradation by the proteasome.   
Binding of Wnt proteins to the seven-pass transmembrane Frizzled (Fz) receptor on the 
surface of cells induces association with the low-density lipoprotein receptor related protein 
(LRP) 5/6.  This coreceptor complex triggers activation of the canonical Wnt pathway. 
Dishevelled (Dvl) is recruited to the Frizzled receptor [10], and the Fz/Dvl complex in turn 
relocates Axin to LRP5/6 [11].   Axin-bound GSK-3β and CK1 then phosphorylate LRP5/6 [12, 
13], which leads to inactivation of GSK-3β [14].  The absence of β-catenin phosphorylation 
releases it from the Axin/APC/GSK3 complex, resulting in accumulation of cytoplasmic and 
active β-catenin.  Although β-catenin lacks a nuclear localization sequence, it then translocates to 
the nucleus through an unknown mechanism which may involve interaction with either 
components of the nuclear pore complex [15] or LEF/TCF [16], its nuclear binding partner.  
Once in the nucleus, β-catenin binds to lymphoid enhancer-binding factor/T cell-specific 
transcription factor (LEF/TCF), displacing the transcriptional inhibitor Groucho, and in complex 
with TCF initiates transcription of target genes [4]. 
The number and variety of target genes activated by Wnt/β-catenin signaling are diverse 
and include target genes such as Met, Jagged, gastrin, MMP7, survivin, and various FGFs [17-
24].  β-catenin also controls expression of cell-cycle regulators important in proliferation such as 
cyclin-D1 [25, 26], as well as oncogenes such as c-myc [27].  Interestingly, some of the target 
genes of the pathway are components of the Wnt signaling pathway itself.  For example, β-
catenin can activate expression of repressors such as Axin2, Tcf1, and Dkk1 [23, 28, 29], or 
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suppress positive pathway components such as Frizzled and LPR6 [30, 31], indicating the 
presence of a negative feedback loop to dampen or suppress Wnt signaling.  Intriguingly, Wnt/β-
catenin signaling can induce expression of genes such as LEF1, which enhances and prolongs the 
signal, indicating the presence of a feed-forward mechanism which can be exploited by 
carcinoma cells [32, 33].  The majority of Wnt target genes, however, appear to be cell-type 
specific and are thus regulated both temporally and contextually.  In the liver, these genes 
include glutamine synthetase, several cytochrome P450s, glutathione-S-tramsferases (GSTs), and 
leukocyte cell-derived chemotaxin 2 (LECT2) [34-37], as well as our recently discovered target 
regucalcin [38]. 
1.1.2 Interaction of β-catenin with other pathways  
In addition to the above-mentioned participants involved in the canonical Wnt signaling 
pathway, several other proteins are known to interact with β-catenin in liver (Figure 1).  β-
catenin forms a bridge between the actin cytoskeleton and E-cadherin present at the surface of 
hepatocytes [39-41].  The β-catenin/E-cadherin interaction mediates cell-cell adhesion and is 
regulated by the phosphorylation of β-catenin at a specific tyrosine residue (Y654) [42, 43].  
Specifically in liver, this causes dissociation of the complex and subsequent degradation of E-
cadherin, resulting in a loss of adherens junctions and impaired apical trafficking in hepatocytes 
[44].  Loss of adhesion may also contribute to motility, which is an important component of the 
cellular response in processes such as development, regeneration, and cancer growth.   
TGF-β, a known regulator of self-renewal which has also been implicated in the 
modulation of hepatocellular carcinoma [45], plays an important role in E-cadherin/β-catenin 
interactions as well.  TGF-β-mediated loss of E-cadherin results in the release of β-catenin from 
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cell-cell contacts and its subsequent translocation to the cytoplasm.  Active β-catenin thus leads 
to the increased cell motility and invasive phenotype seen in gastrointestinal and liver cancers 
[46, 47]. 
Another important interaction involving β-catenin in hepatocytes is the β-catenin/Met 
complex.  Met is the receptor for hepatocyte growth factor (HGF), a known mitogen, motogen, 
and morphogen for the liver [48].  Our laboratory has previously shown that Met and β-catenin 
associate on the inner surface of hepatocytes [49, 50].  Binding of HGF to its receptor induces 
phosphorylated Met to phosphorylate β-catenin at tyrosine residues 654 and 670, which results in 
its translocation to the nucleus and subsequent upregulation of target genes [51, 52].  Another 
study by our lab found that injecting the human HGF gene into mice leads to hepatomegaly via 
dissociation of the Met/β-catenin complex and induction of the β-catenin pathway [53].  β-
catenin also regulates HGF-induced cell morphogenesis [54], and interactions between Met and a 
mutated active form of β-catenin have been found to facilitate hepatocellular carcinoma [55].  
The Met/β-catenin pathways thus cooperate to induce hepatocyte proliferation both in vitro and 
in vivo.   
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 Figure 1: The three major roles of β-catenin in liver physiology.  Left: in the presence of Wnt, β-catenin is 
released from its inactivating complex and translocates to the nucleus, where it activates genes essential for 
proliferation, growth, and regeneration of the liver.  Middle: β-catenin mediates cell-cell adhesion through its 
interaction with e-cadherin on the hepatocyte membrane.  Right: in the presence of HGF, β-catenin, which associates 
with Met at the surface of hepatocytes, is phosphorylated and translocates to the nucleus to turn on genes important 
in proliferation and morphogenesis. 
 
1.2 BETA-CATENIN IN LIVER DEVELOPMENT  
1.2.1 Embryonic Liver Development 
The induction of embryonic liver is a complex process that requires a series of tightly 
regulated localized signals from multiple cell types.  Liver in mouse begins to arise from the 
definitive gut endoderm at E8.5, or the 7-8 somite stage [56-58].   It is at this time that a family 
of transcription factors, Foxa, specifies the endoderm to express hepatic genes [59, 60].  The 
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fibroblast growth factors FGF1 and FGF2, which are expressed in the cardiac mesoderm at this 
time, are responsible for initiating the expression of these liver-specific genes in the endoderm 
[61].   FGF8, which is important for morphogenetic outgrowth of the liver, is also expressed 
during this stage [61].  Endothelial cells also interact with the hepatic endoderm shortly after 
specification to promote morphogenesis and liver bud formation [62].  The resulting bud 
migrates into the septum transversum mesenchyme upon bone morphogenic protein 4 (BMP4) 
signaling, which is also required for hepatogenesis [63].  One of the most critical genes at this 
stage is Hex, which is maintained by FGF and BMP4 signaling in the commitment phase [64]; 
expression of this transcription factor is essential for hepatoblast differentiation and liver bud 
formation [65-67].   
The second phase of embryonic liver growth is characterized by expansion and 
proliferation.  The cells are now considered hepatoblasts, which means that they are capable of 
giving rise to both major lineages of the liver, hepatocytes and biliary epithelial cells [68].  
Hepatoblasts or hepatic progenitors are the bipotential stem cells that will be undergoing 
expansion while maintaining their de-differentiated state during this stage. This event is 
comparable to the expansion of a lineage-restricted progenitor population in stem cell biology.  
HGF, expressed in the septum transversum mesenchyme which now surrounds the liver bud, is 
critical for this stage of liver growth [69].  Transcription factors required for liver development at 
this stage include Hlx [70] and Prox1 [71].  Albumin and α-fetoprotein mRNA is also being 
produced at this time, indicating commitment to a hepatic fate [72].  There is significant 
proliferation of hepatoblasts leading to expansion of the hepatic bud.  Finally, the general 
architecture of the liver is beginning to be established, including the formation of sinusoids and 
the development of hepatic vasculature [59, 73]. 
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The final stage is characterized by the differentiation of hepatoblasts to mature, fully-
functional cell types.  At the center of the differentiation process are the liver-enriched 
transcription factors such as hepatocyte nuclear factor (HNF) transcription factors and C/EBPα, 
which regulate cell fate decisions in the liver [74, 75].  HNF-4α is essential for differentiation 
toward a hepatocyte phenotype, as well as formation of the parenchyma [76]; GATA6, which 
regulates HFN-4α, is also required for hepatocyte differentiation [77].  HNF-6, HNF-1β, and the 
Notch signaling pathway are required for normal development of biliary epithelia and resulting 
bile duct structures [78-80].  Finally, the expression of transcription factors NF-κB, c-Jun, and 
XBP-1 is necessary for growth and morphogenesis [68], which continues until birth. 
1.2.2 The Role of Wnt/β-catenin in Embryonic Liver Development 
In recent years, a plethora of evidence has emerged identifying regulation of Wnt/β-
catenin signaling as a requirement for embryonic liver development.  In fact, in Xenopus, the 
impact of Wnt/β-catenin signaling on liver development can be seen as early as the maternal 
phase, which occurs before gastrulation.  Maternal Wnt/β-catenin, in conjunction with 
endodermally-derived TGF-β, can induce anterior endomesoderm (AE), a subset of endoderm 
cells fated to form the liver [81].  Thereafter, repression of this pathway becomes necessary 
during the competency and commitment stage of liver development [82].  In Xenopus, β-catenin 
expression after gastrulation is necessary for intestinal formation in the posterior endoderm, 
while repression in the anterior endoderm allows for expression of Hex, which is required for 
liver and pancreas development.  Repressing β-catenin in the posterior endoderm causes organ 
buds expressing liver markers to form [83].  Sfrp5, an antagonist of Wnt, is expressed in the 
ventral foregut endoderm that gives rise to the liver at mouse E8.5 [84], resembling the 
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expression pattern of Hex.  The expression of this inhibitor functions to modulate Wnt-11 
activity by delineating borders between organs in the developing gut [85, 86].  Further, 
calcineurin, a member of the Wnt/calcium signaling pathway, is involved in dorsal-side signaling 
that leads to the formation of liver during Xenopus embryogenesis through its interference with 
canonical Wnt/β-catenin signaling [87].  However, a recent study has shown that as soon as 
foregut endoderm is formed, hepatic specification requires activation of Wnt signaling brought 
about by Wnt2bb [88].  Additional studies, perhaps using conditional knockout mice in which β-
catenin is deleted around E8.5, will be needed to definitively determine whether Wnt/β-catenin 
signaling is activated or repressed during liver specification. 
Our laboratory was the first to demonstrate a mechanistic role for the Wnt/β-catenin 
pathway in developing liver.  Livers from mouse embryos cultured in the presence of a β-catenin 
antisense oligonucleotide showed a decrease in proliferation and a simultaneous increase in 
apoptosis, two processes vital to liver development [89].  This correlated well with a subsequent 
study that found overexpression of β-catenin in developing chicken livers leads to a three-fold 
increase in liver size, which is due at least in part to an expanded hepatoblast population.  
Conversely, blocking β-catenin expression through overexpression of pathway inhibitors resulted 
in decreased liver size and altered liver shape [90].  The effect on cell proliferation noted in both 
cases may be due to cell cycle mediators such as cyclin-D1.  We and others have shown that β-
catenin protein expression peaks at E10-12, during which time it is localized throughout the cell 
including the nucleus, cytoplasm and membrane. Subsequent decreases in β-catenin gene 
expression and increased protein degradation coincide with a dramatic decrease in total β-catenin 
protein levels after E16, at which time it is also localized to the membrane of maturing 
hepatoblasts and hepatocytes [91, 92].  While the early stages coincide with ongoing hepatoblast 
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expansion which is mediated via increased proliferation and survival, the later stages represent 
hepatoblast maturation to hepatocytes, and these maturing cells begin to express genes that are 
associated with measures of hepatic function such as transferrin, cyochrome P450s, coagulation 
factors, haptoglobin and many others [93]. 
As found in our previous studies with ex vivo embryonic liver cultures, there was a 
positive correlation between β-catenin and cell proliferation, which has also been supported by 
additional studies in chicken, zebrafish and Xenopus [83, 88-90, 94].  Thus, these studies have 
established an important physiological role for β-catenin during early liver development in 
expansion of hepatoblasts or the hepatic progenitors.  β-catenin also plays an important role in 
the differentiation of hepatoblasts into the two major liver lineage cell types: biliary epithelial 
cells and hepatocytes.  The addition of Wnt3a to embryonic liver cultures induced a biliary 
phenotype and duct-like arrangement in the developing liver, while lack of Wnt3a causes loss of 
architecture, proliferation, and increased apoptosis [95].   We also observed a lack of mature 
hepatocytes in the absence of β-catenin in the explanted mouse livers. This phenotype was 
confirmed by the concomitant presence of stem cell markers and mature hepatocyte markers in 
the organ culture [89].  Using another in vitro model that recapitulates hepatocyte differentiation, 
we found an increase in total β-catenin protein as early as 24 hours after the induction of 
differentiation [49].  This increase was a result of decreased protein degradation and resulted in 
membranous localization of β-catenin rather than the nuclear localization that is the hallmark of 
proliferating undifferentiated cells.  Finally, deletion of β-catenin from hepatoblasts in vivo using 
β-catenin transgenic mice under the Foxa3 promoter resulted in the decrease of liver-specific 
transcription factors C/EBPα and HNF4α and an overall hepatic deficiency [96].  These studies 
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imply that the presence of β-catenin, as well as its location inside the cell, might be a critical 
event dictating differentiation.   
Although the picture not complete, the data thus far suggests that β-catenin levels vary 
during prenatal hepatic development, and that the temporal expression of β-catenin regulates 
liver formation.  However, spatiotemporal expression of β-catenin is not unique to the liver; the 
Wnt/β-catenin pathway also shows distinct stage specific effects during cardiac [97, 98], gut 
[99], and lens development [100].  For example, activating β-catenin expression during 
embryogenesis enhances cardiomyocyte differentiation, while activation of this pathway later in 
development causes inhibition of differentiation [101].  In the gut, Wnt expression is present in 
developing intestines after the appearance of villi, disappears during villi morphogenesis, and 
then reappears in differentiated postmitotic villus epithelium [102].  Thus, data from 
organogenesis studies demonstrates that turning β-catenin expression on and off at various stages 
of development can cause opposing results depending on the timing of induction. 
1.3 BETA-CATENIN IN LIVER GROWTH AND REGENERATION  
1.3.1 Liver Regeneration 
Adult liver has the unique capacity to regenerate after insult and loss of liver mass, and 
has thus become a useful model to study organ regeneration and controlled growth.  A 
phenomenon unique to liver regeneration is that rather than utilizing progenitor or stem cells, 
repopulation of the liver occurs almost exclusively through proliferation of mature cell 
populations, including hepatocytes, biliary epithelial cells, endothelial cells, and stellate cells 
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[103].  Remarkably, liver regeneration occurs without loss of function; that is, throughout the 
regenerative process, the liver still performs all the essential functions needed for organism 
homeostasis.  Another property that makes liver regeneration unique is that it can be triggered 
without causing inflammation or damage to surrounding tissues.  The most common method of 
inducing regeneration experimentally is surgical removal of three of five lobes from the rodent 
liver, commonly referred to as a 2/3 partial hepatectomy (PHx) [104].  The remaining two lobes 
grow in size until the liver mass is completely restored, which usually occurs after approximately 
7 days in the rat [105].  Because these lobes can be resected within minutes, the entire 
regenerative process can be precisely timed.   
Partial hepatectomy triggers a series of cell signaling pathways and cascades that are very 
tightly regulated.  Many of these pathways are the same as those activated in wound healing and 
innate immunity, although liver resection itself does not generate an immune response.  For 
example, within minutes after PHx in the rat, urokinase plasminogen activator (uPA) activity 
increases [106].  uPA is responsible for several critical functions in liver regeneration, such as 
cleavage of latent hepatocyte growth factor (HGF) to its active form, activation of plasminogen 
to plasmin, and induction of matrix remodeling [105].  Matrix remodeling is a very important 
component of regeneration, and is a complex process involving release of bound growth factors, 
including HGF, by matrix metalloproteinases.  HGF has been shown to be indispensible for liver 
regeneration because it serves as the main mitogenic stimulus driving hepatocytes toward 
proliferation [107].  Once cleaved and activated, HGF then activates its receptor, Met, within 30-
60 minutes after PHx [108], initiating a signaling cascade that results in activation of STAT3, 
PI3K, and Akt [109, 110].  Pre-existing stores of HGF are rapidly consumed within the first 3 
hours [111], causing a 17-fold increase in circulating levels of HGF as early as 2 hours after PHx 
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[112].  To replenish the stores of HGF depleted by activation and utilization, stellate cells begin 
to synthesize new HGF.  Coinciding with the peak of HGF consumption, levels of HGF mRNA 
increases dramatically between 3 and 6 hours after PHx, peaking at 12 hours [113].  Thus, the 
kinetics of HGF consumption and resynthesis are crucial events for liver regeneration and 
provide an example of the coordinated regulation of liver regeneration.   
Another event that occurs within 30 minutes after PHx is the induction of “immediate 
early genes”, including members of the jun, c-fos, and myc families.  Transcription of these 
genes are the result of rapidly activated transcription factors such as Stat3 and NF-κB, which are 
in turn activated by cytokines such as TNF-α and IL-6 [114].  Genes important for regulation of 
cell cycle entry are also transcribed either concurrently with cytokine stimulation or immediately 
following this period in response to growth factors such as HGF and EGF [115, 116].  
Interestingly, fetal markers such as alpha-fetoprotein are also upregulated during this time [117], 
and suggests that regeneration may recapitulate development to some extent.   
The hallmark of liver regeneration is proliferation of adult hepatic cell types.  The first 
peak of DNA synthesis happens in hepatoytes and occurs around 24 hours in the rat and 
approximately 36 hours in the mice [105].  Hepatocyte DNA synthesis and proliferation proceed 
in a zonal manner through the hepatic lobules, from periportal to pericentral areas [118].   Since 
1/3 of the original hepatocytes remain after PHx, they only need to undergo 1.66 rounds of 
replication before the original number of hepatocytes is fully restored [119].  In fact, hepatocytes 
are capable of clonal expansion and have an almost unlimited capacity to proliferate in vivo.  Rat 
liver was able to continue regenerating even after 12 sequential hepatectomies [120], which 
suggests that unlike other mature cells in the body, hepatocytes are not terminally differentiated 
and can divide continuously when presented with appropriate stimuli [103].  Proliferating 
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hepatocytes also produce growth factors for other cell types, including stellate cells and 
endothelial cells, in a paracrine fashion.    These cells undergo DNA synthesis 24 hours after 
hepatocytes, peaking at 48 hours after PHx [121].  A key cell-cycle associated gene critical for 
initiation of cell proliferation is cyclin-D1, which is expressed as early as 6 hours after PHx 
[122].  As β-catenin is a key driver of cyclin-D1 expression and cell proliferation, it is logical to 
assume that β-catenin plays a role in liver regeneration after PHx.  Indeed, work by our lab and 
others have described the function of β-catenin in regeneration and postnatal liver growth, which 
emphasizes its vital role in liver health and repair.   
1.3.2 Wnt/β-catenin signaling in liver growth and regeneration  
In adult resting liver, the Wnt/β-catenin pathway is mostly quiescent.  This steady-state 
condition is characterized by the phosphorylation and subsequent degradation that is the 
hallmark of β-catenin turnover; hence, β-catenin is localized at the cell membrane and is largely 
absent from the cytoplasm and nucleus [123].  In the centrizonal hepatocytes, however, active β-
catenin is evident and regulates expression of genes such as glutamine synthetase, CYP2E1, and 
CYP1A2 [124].  Therefore, when liver is not being challenged by chemical, metabolic, or dietary 
stress, β-catenin is not required for normal physiologic function [125].  However, during liver 
regeneration, levels of β-catenin are dramatically increased.  In a rat model, an increase in β-
catenin protein expression was seen as early as 1-5 minutes post-PHx [126]; this increase was 
not due to an increase in mRNA expression, but rather to a decrease in protein degradation, the 
result of a change in steady-state kinetics.  This expression was transient, and β-catenin levels 
returned to normal at 48 hours.  Translocation of β-catenin to the nucleus, starting at 5 minutes 
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after PHx and continuing until 48 hours post-PHx, contributes to the increase in cyclin-D1 and c-
myc and the concomitant increase in cellular proliferation [126].  
The importance of β-catenin to liver regeneration is highlighted by three studies in which β-
catenin is removed or absent from the liver.  When a β-catenin antisense oligonucleotide was 
administered to rats after 2/3 PHx, total β-catenin decreased significantly at 24 hours [127].  Also 
of note was the decrease in liver weight/body weight ratio as a function of decreased 
proliferation in these animals.  Further, β-catenin conditional knockout mice showed a sick and 
lethargic phenotype after PHx as opposed to their wild-type counterparts.  Additionally, these 
mice displayed suboptimal regeneration, with delayed regenerative onset and a biphasic trend in 
proliferation that peaked at day 3 and increased slightly again at day 14 [94].  These results were 
confirmed by another laboratory that demonstrated a lack of cyclin-D1 induction and a resultant 
delay in DNA synthesis in liver-specific β-catenin knockout mice [128]. 
The Wnt/β-catenin pathway also plays a key role in controlling postnatal liver growth.  Our 
laboratory found an increase in β-catenin levels in wild-type mice shortly after birth [91], which 
serves to promote hepatic growth during postnatal development.  Indeed, increased β-catenin 
translocation to the nucleus correlates with an increase in cell proliferation between 5-20 
postnatal days [129].  Further, mice expressing a conditional deletion of β-catenin generated by 
our laboratory and others showed a significant decrease in the liver weight/body weight ratio 
(15-25%) in mice older than two months [94, 125].  This decrease is correlated with a basal 
decrease in cellular proliferation, which is due to a deficient cyclin-D1 response. 
Several studies have addressed the role of constitutively active β-catenin on postnatal growth.  
Mice expressing an oncogenic form of β-catenin demonstrated hyperplasia and resulting 
hepatomegaly as young as 3-4 weeks after birth [130].  Other reports have described 
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hepatomegaly soon after birth in mouse strains where a dominant stable form of β-catenin was 
activated by adenoviral inoculation [131].  Finally, we have recently generated transgenic mice 
overexpressing wild-type β-catenin and observed a 15% increase in liver size in these mice 
compared to normal wild-type aged-matched controls [132].  This study also identified EGFR, a 
receptor for a known hepatocyte mitogen, EGF, as a transcriptional target of Wnt/β-catenin 
signaling. 
1.4 BETA-CATENIN IN REDOX REACTIONS AND OXIDATIVE STRESS 
1.4.1 Oxidative stress in the liver 
Reactive oxygen species (ROS), reactive nitrogen species (RNS), and free radicals are 
critical for physiology.  They are a normal byproduct of aerobic metabolism and also serve 
important functions as messenger molecules both inside and outside the cell.  Nitric oxide (NO), 
for example, is important in neural signaling, cardiac and vascular function, and platelet 
regulation [133].  Reactive oxygen species generated by growth factors and cytokines are 
implicated in mediating cellular responses through signal transduction [134].  However, when 
the balance between ROS generation and anti-oxidant protection is disrupted, cells undergo 
oxidative stress [135].  Oxidative stress can cause damage through inflammation, ischemia, 
apoptosis, and necrosis. 
Radicals from ROS and RNS are generated by neutrophils, Kupffer cells, cytochrome 
P450s, and mitochondria [136].  Free radicals have an unpaired electron and are either nitrogen-
or oxygen-based.  Examples of some biologically relevant free radicals include NO (nitric 
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oxide), O2- (superoxide), and HO (hydroxyl radical).  They are produced as by-products of 
biochemical reactions such as oxidative phosphorylation, which generates energy through the 
electron transport chain.  During this process, a small percentage of electrons prematurely leak to 
oxygen and are released from the mitochondria as superoxide [137, 138].  Hydrogen peroxide, 
another free radical, is produced from the dismutation or reduction of superoxide.  ROS are also 
formed from the Fenton reaction, in which a transition metal (usually iron) is recycled by 
superoxide and in the process converts hydrogen peroxide into oxygen and hydroxyl radicals 
[139].  NO is created from nitric oxide synthetases (NOS), the most well-known being inducible 
NOS (iNOS).  NOS creates NO from arginine, oxygen, and electrons and releases small amounts 
based on calcium levels.  However, iNOS is capable of producing NO independent of calcium, 
resulting in large amounts of NO which can be either protective or damaging to the cell [133].  
Free radicals are implicated in the pathophysiology of many different liver diseases.  
Free-radical by-products of ethanol metabolism can exacerbate alcohol-induced hepatitis through 
lipid peroxidation and induction of the cytochrome P450 isoform CYP2E1, which in turn creates 
more ROS [140, 141].  Acetaminophen-induced liver injury is caused by production of a reactive 
CYP2E1 metabolite, which binds to and depletes glutathione in the cell [142].  Viral hepatitis 
infections result in increased inflammation leading to oxidative stress through several 
mechanisms, including decreased anti-oxidants, increased ROS and cytokines, and iron overload 
[143, 144].  In fibrosis, activation of stellate cells by ROS results in increased collagen 
deposition [145].  ROS and RNS are generated during periods of hypoxia in hepatic 
ischemia/reperfusion injury concomitant with a decrease in anti-oxidants, reduction of 
mitochondria, and an increase in cytokines [146].  Free radicals are produced in several other 
diseases that invoke an inflammatory response, such as nonalcoholic steatohepatitis and sepsis.  
 16 
In sepsis, however, NO has been shown to be protective, perhaps by invading and damaging 
infecting pathogens or by increasing blood flow to injured tissue [147, 148]   
Reactive oxygen species have also been shown to play an important role in hepatocyte 
apoptosis.  In the setting of liver injury, macrophages or neutrophils release superoxide or 
hydrogen peroxide, which can trigger apoptosis [149].  Toxins such as alcohol, acetaminophen, 
or chemotherapeutic drugs can also release intracellular free radicals, which induce expression of 
the Fas ligand [150].  Reactive oxygen species can stimulate apoptosis through several other 
mechanisms as well, including lipid peroxidation [151], intracellular oxidant stress [152], and 
enhancement of pro-inflammatory gene transcription such as TNF-α [153].  In turn, TNF-α 
signaling can increase reactive oxygen formation in hepatocytes [154].  Free radicals have also 
been implicated in activation of caspases [155] and mitochondrial membrane permeability [156].  
High concentrations of TGF-β can also stimulate apoptosis through production of reactive 
oxygen species, although the mechanism is not well-understood [157]. 
In the cell, ROS and RNS are neutralized by anti-oxidants, which are small molecular 
weight molecules that can prevent oxidative damage by detoxifying free radicals [158].  
Glutathione (GSH) is a peptide whose main function is to reduce peroxidases, although it also 
acts as a general free-radical scavenger [159, 160].  Catalases and peroxidases also neutralize 
hydrogen peroxide [161].  Superoxide dismutases (SODs) are a family of intracellular and 
extracellular enzymes that catalyze the breakdown of superoxide to hydrogen peroxide and water 
[162].  Metal-binding proteins such as transferrin, albumin, and hemoglobin can also serve as 
anti-oxidants [133]. Because they contain high concentrations of GSH, SOD, and catalase, 
hepatocytes are generally resistant to oxidative stress [158].  However, in some pathological 
conditions, such as those mentioned above, the endogenous cellular machinery is insufficient to 
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suppress or prevent oxidative stress.  In these cases, exogenous anti-oxidants, like carotenoids or 
plant phenols, may be therapeutically beneficial.  The most commonly utilized dietary anti-
oxidant is vitamin C, whose potent free radical scavenging ability has been well-documented. 
1.4.2 Regucalcin and oxidative stress 
Regucalcin, also known as SMP30, was first identified as a calcium-binding protein 
located in the cytoplasm of hepatocytes.  As such, it plays a critical role in calcium (Ca2+) 
homeostasis in the liver [163].  Regucalcin activates the Ca2+/Mg2+-ATPase plasma membrane 
pump, thus allowing for influx of Ca2+ and maintenance of intracellular calcium levels [164, 
165].  It also stimulates uptake of calcium from the cytoplasm into the mitochondria and 
microsomes to maintain cytoplasmic Ca2+ levels [166, 167].  Moreover, regucalcin acts to 
exclude Ca2+ from the nucleus by suppressing uptake and stimulating its release [168, 169].  In 
turn, injection of calcium chloride in rats in vivo stimulates regucalcin mRNA expression [170, 
171].  Regucalcin can also translocate to the nucleus, where it inhibits both protein tyrosine 
phosphatase and protein kinase activity [172]. 
Regucalcin is expressed in large amounts in the liver [173], and therefore much of the 
characterization of this protein has occured in the context of liver physiology and 
pathophysiology.  Regucalcin has been shown to be inhibitory for calcium-calmodulin dependent 
enzyme activity, including fructose 1,6-diphosphatase, which is involved in gluconeogenesis 
[174].  It also inhibits cAMP degradation and therefore plays a role in regulating signal 
transduction [175]. In regenerating rat liver, regucalcin plays an important role in the regulation 
of Ca2+ signaling from the cytoplasm to nuclei in proliferating cells [163, 176], which may 
partially account for the increased levels of regucalcin mRNA observed in the first 5 days after 
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PHx [177].  Interestingly, unlike other proteins that are upregulated during this time, regucalcin 
appears to have a suppressive rather than a stimulatory effect on regeneration.  Regucalcin 
inhibits DNA [178], RNA [179], and protein synthesis [180] in rat nuclei isolated from 
regenerating rat liver.  Therefore, because regucalcin functions as an inhibitor of several critical 
cellular processes, it is thought to have an important role in preventing hyper-proliferation of 
hepatocytes during regeneration [176].  This anti-proliferative effect was reported in hepatoma 
cells as well, where overexpression of regucalcin suppressed cell proliferation, possibly through 
decreased c-myc expression [181].   
Regucalcin also plays an important role in preventing oxidative stress and apoptosis.  
Regucalcin increases superoxide dismutase activity in hepatocytes [182] and decreases NO 
synthetase activity [183], thus reducing the production of reactive oxygen species in the cell.  
Transfection of SMP30 decreases the formation of reactive oxygen species in HepG2 cells [184].  
Conversely, loss of SMP30/regucalcin leads to production of reactive oxygen species in the 
brains and lungs of deficient mice [185-187].  DNA fragmentation, a hallmark of apoptosis, is 
inhibited by regucalcin through prevention of cytosolic calcium influx [188].  Overexpression of 
regucalcin in rat hepatoma cells protects them from LPS- or TNF-α induced apoptosis, although 
the mechanisms are not well-understood [189, 190].  Transfection of HepG2 cells with SMP30 
suppresses cell death after TNF-α treatment through regulation of Akt activity [191].  The role of 
regucalcin in preventing apoptosis was confirmed in vivo in SMP30 knockout mice, which show 
enhanced susceptibility to TNF-α and Fas-mediated apoptosis [192].  Regucalcin/SMP30 was 
also recently discovered to function as a gluconolactonase, which is essential to vitamin C 
biosynthesis [193].  Therefore, many of its anti-oxidant and apoptotic effects may be derived 
from its ability to synthesize vitamin C to prevent cellular damage. 
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1.4.3 Regucalcin expression and the Wnt/β-catenin pathway 
Our laboratory has previously reported the characterization of the β-catenin conditional 
knockout (KO) animals, which is an excellent resource for identification of novel targets of β-
catenin in the liver [94].  Regucalcin was identified as one of the genes most affected by the loss 
of β-catenin.   Gene array analysis of β-catenin KO mice generated using three different Cre lines 
reveals a 38-fold decrease in gene expression for regucalcin in KOs as compared to their wild-
type (WT) counterparts (Table 1) [53, 94, 96].  To confirm the results of our gene array analysis, 
we isolated mRNA from 1, 3, and 6 month WT and KO livers.  Figure 2 shows that regucalcin 
mRNA is present in WT animals but absent in the KOs; thus regucalcin expression is directly 
dependent upon the presence or absence of β-catenin.  Based on this information, we 
hypothesized that regucalcin is a downstream target of β-catenin in the liver.   
 
Table 1: Absolute expression of regucalcin and L-gulonolactone oxidase in β-catenin knockout mice 
generated using three different Cre lines. 
 
Conditional β-catenin KO 
 
Stage 
(age) 
RGN Gene 
Expression 
WT 
RGN Gene 
Expression 
    KO 
Ctnnb1loxp/loxp; FoxA3-Cre E16 5362 289 
Ctnnb1loxp/loxp; Alb-Cre 3 months 25218 4418 
Ctnnb1loxp/loxp; Afp-Alb-Cre 3 months 41038 1366 
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Conditional β-catenin KO 
 
Stage 
(age) 
L-gulonolactone 
oxidase Expression 
WT 
L-gulonolactone 
oxidase Expression 
  KO 
Ctnnb1loxp/loxp; FoxA3-Cre E16 1214 595 
Ctnnb1loxp/loxp; Alb-Cre 3 months 4761 336 
Ctnnb1loxp/loxp; Afp-Alb-Cre 3 months 6698 309 
 
 
 
Figure 2:  Semiquantitative RT-PCR using mRNA from WT and KO livers at 4-7 months of age shows 
regucalcin expression in WT livers only.  
 
 
1.5 BETA-CATENIN IN HEPATOCYTE SURVIVAL  
1.5.1 Apoptosis and cell survival mechanisms 
Apoptosis, also known as programmed cell death, is a critical component in liver injury and 
can occur via two major pathways: the death receptor (extrinsic) pathway or the mitochondrial 
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(intrinsic) pathway [194].  The death receptor pathway is activated by binding of death receptor 
ligands to receptors on the cell surface, while the mitochondrial pathway is initiated by 
intracellular stresses such as DNA damage or changes of intracellular Ca2+.  Of these, the death 
receptor pathway has been extensively studied in hepatocytes, since hepatocytes express an 
abundance of death receptors [195].  This is presumably due to evolutionary pressure which 
favored enhanced death receptor expression in the liver to help eliminate pathogens and cells 
damaged by toxins [196].  Thus, death receptor-mediated apoptosis in the liver is a critical 
component of homeostasis, as it targets damaged or abnormal cells for elimination without 
disrupting liver physiology [196, 197].  Of the six identified death receptors, Fas and TNF-α are 
considered to have pathologic significance in the liver [198].  Activation of the Fas-mediated 
apoptotic pathway has been linked to liver diseases such as hepatic inflammation, viral hepatitis, 
alcoholic hepatitis, non-alcoholic steatosis, cholestasis, and Wilson’s disease [199-203].  
Likewise, TNF-α mediated activation of apoptosis has been implicated in alcoholic hepatitis, 
ischemia/reperfusion, and fulminant hepatic failure [204-207]. 
1.5.2 The Fas pathway 
Fas (also known as CD95) is a member of the TNF receptor family which is primarily 
activated by Fas ligand (FasL), a membrane-spanning protein typically expressed on the surface 
of activated T-cells, although soluble forms of FasL are also present in serum [195, 208].  
Alternatively, the Fas pathway can be induced in mice via intravenous injection of Jo-2 antibody, 
a Fas agonist which causes death of the animal through massive hepatocyte apoptosis [209].  
Activation of the receptor by FasL or Jo-2 causes trimerization of the receptor, which leads to 
formation of the death-inducing signaling complex (DISC) [210-212].  This complex consists of 
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the Fas-associated death domain (FADD), which contains a death effector domain (DED) [213] 
that is required for caspase-8 recruitment.  Caspase-8, also called the initator caspase for its 
ability to activate executioner caspases such as caspase 3, 6, and 7, is activated at the DISC  
[214, 215].  In Type II cells such as hepatocytes, additional activation of the mitochondrial 
pathway by caspase-8 is required for apoptosis [216].  Caspase-8 cleavage of Bid, a proapoptotic 
protein that translocates to the mitochondria, triggers the release of cytochrome c, which 
activates caspase-9 and amplifies the apoptotic signal [217, 218].   
Hepatocytes can be protected from the effects of Fas by the anti-apoptotic Bcl-2 family of 
proteins, including Bcl-2, myeloid cell leukemia factor-1 (Mcl-1), and Bcl-xL, which inhibit the 
mitochrondrial pathway [219-222].  Alternatively, apoptosis can be inhibited at the level of 
caspase-8 by c-FLIP, a structural mimetic of caspase-8 that lacks proteolytic activity and binds 
directly to either caspase-8 or FADD [223-225].  Other inhibitors of Fas-mediated apoptosis 
include X-linked inhibitors of apoptosis (IAPs) and serine protease inhibitors (serpins) such as 
antitrypsin [226, 227]. 
Recently, it has been shown that Met sequestration of the Fas receptor can also prevent Fas-
mediated apoptosis in hepatocytes [228].  Mice lacking Met were hypersensitive to Fas-induced 
apoptosis [229]; similarly, high doses of HGF sensitize apoptosis-resistant bid-deficient 
hepatocytes to Fas-induced cell death through increased dissociation of Fas from Met [230].   
Further, YLGA, a peptide derived from the Met α-chain, inhibits Fas-mediated apoptosis in fatty 
liver disease [228].  The Met/Fas interaction has been demonstrated to regulate apoptosis in 
endothelial cells as well [231].  Therefore, the stoichiometric association of Fas, a death receptor, 
and Met, a growth factor receptor, in regulating cell survival and apoptosis appears to be 
mediated by the amount of Met present at the cell surface.  Interestingly, as mentioned 
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previously, Met also forms a complex with β-catenin on the surface of hepatocytes, allowing for 
cross-talk between the β-catenin- and HGF-mediated signaling pathways and synergistic 
activation of cell proliferation [51, 53].   However, the role of this interaction in cell survival, if 
any, is unknown. 
1.5.3 The TNF-α pathway 
TNF-α is a pleiotropic cytokine that is critical to many diverse cellular processes in the liver, 
including proliferation, inflammation, and cell death [232].  Execution of these functions occurs 
when TNF-α binds to its major receptor TNF-R1, causing a conformational change in the 
receptor which initiates DISC formation similar to that formed during Fas-mediated apoptosis.  
In the case of TNF-α-mediated signaling, this complex is composed of TNF/TNF-R1 trimers and 
the TNFR-associated death domain (TRADD) [233-235].  TRADD then recruits FADD, TNF-
associated factor 2 (Traf-2), and receptor-interacting protein-1 (RIP-1) [236].  If anti-apoptotic 
signals are blocked, FADD activates caspase-8, which cleaves other downstream effector 
caspases like caspase-3 as well as activates pro-apoptotic members of the Bcl-2 family such as 
Bax and Bak [237].  Thus, TNF-α-mediated apoptosis utilizes the same downstream apoptotic 
machinery as the Fas pathway, albeit independently of Bid [238-240].    
Although activation of TNF-α signaling is capable of causing apoptosis, the default pathway 
is survival, due to the robust activation of NF-κB.  NF-κB is a dimeric transcription factor that 
consists of five members: p50, p52, p65 (also known as RelA), c-Rel, and RelB, with the 
prototypical NF-κB complex consisting of a heterodimer between p50 and p65 [241, 242].  
Activation of NF-κB has pleiotropic effects in a wide variety of cellular programs, including 
promoting cell survival and suppressing apoptosis by regulating the transcription of anti-
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apoptotic proteins [243-245].  In the absence of signal, NF-κB is retained in the cytoplasm by 
members of the inhibitory IκB complex [242].  Activation of the NF-κB pathway occurs when 
the IκBs undergo phosphorylation, ubiquitination, and degradation [246].  The kinases 
responsible for this phosphorylation are IκB kinases (IKKs), which are recruited to activated 
TNF-R1 by RIP-1 and Traf-2, which are part of the DISC complex mentioned previously [247].  
Loss of the IκB complex after IKK phosphorylation liberates NF-κB, which then translocates to 
the nucleus [248].  Full activation of NF-κB requires further post-translational modification by 
phosphorylation of its various subunits through the action of kinases such as protein kinase A, 
casein kinase II, PKCζ, and GSK-3β [241, 249-252].  NF-κB is then able to provide survival 
signals to the cell through transcription of anti-apoptotic genes such as IAPs, c-FLIP, TRAFs, 
and Bcl family members [253-255].  
A common means of inducing TNF-α signaling other than administration of TNF-α itself is 
through the use of lipopolysaccharide or LPS, an endotoxin derived from gram-negative bacteria 
[198, 256, 257].  The interaction of LPS with macrophages stimulates the release of TNF-α, 
which induces downstream signaling as described before.  Because of the rapid induction of pro-
survival signals by NF-κB, activation of the TNF-α-mediated apoptotic pathway both in vivo and 
in vitro requires hepatocyte sensitization through administration of transcriptional repressors, 
which suppress NF-κB-dependent gene transcription.  D-galactosamine (GalN), one of the most 
commonly used sensitizing agents, suppresses transcription by depletion of UTP, thus inhibiting 
RNA synthesis and rendering hepatocytes susceptible to the effects of endotoxin [256, 258].  The 
half-life of GalN is approximately 3-4 hours [259, 260], which allows for significant and 
irreversible activation of the apoptotic machinery.  Another type of repressor, actinomycin D 
(ActD), inhibits RNA synthesis by binding DNA duplexes and thus prevents transcription [261].  
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Thus, the toxicity of LPS or TNF-α is manifested as apoptotic injury only upon arrested 
transcription and functional translation of NF-κB-dependent pro-survival targets.  
1.5.4 β-catenin in cell survival and apoptosis 
β-catenin signaling appears to play a positive role in cell survival, as evidenced by 
experiments in which this pathway is either repressed or enhanced.  Deletion of β-catenin or 
inhibition of Wnt signaling has been shown to induce apoptosis in several in vivo and in vitro 
models.  Our laboratory has previously shown an increase in hepatocyte apoptosis in developing 
and adult livers following hepatocyte-specific deletion of β-catenin [89, 94].  Inhibition of β-
catenin in cultured E10 livers by an antisense morpholino oligomer resulted in a higher number 
of apoptotic nuclei [89].  We have also shown that loss of regucalcin, a downstream target of β-
catenin, promotes apoptosis in cultured human hepatoma cell lines [38].  There are several 
examples outside of liver as well.  For example, overexpression of Dkk-1, an inhibitor of the 
Wnt/β-catenin pathway, induces apoptosis in human glioma cells through an altered balance in 
Bcl-2 and Bax protein levels [262].   
Apoptosis can also be suppressed through activation of the Wnt/β-catenin pathway.  
Resistance to cancer therapy-mediated apoptosis in Wnt-1 expressing cells is mediated through 
activation of β-catenin signaling concurrent with inhibition of cytochrome c release [263].  
Treatment of hepatic stellate cells with Wnt3a suppresses TRAIL-induced apoptosis and 
contributes to cell survival [264].  Additionally, constitutively active β-catenin inhibits the pro-
apoptotic protein Bax in renal epithelial cells [265].  Thus the way in which β-catenin may 
impact cell survival may be highly tissue- and context-dependent. 
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The role of β-catenin specifically in hepatocyte survival warrants a comprehensive 
investigation.  As discussed, β-catenin is known to associate with Met and Met in turn is known 
to associate with Fas. It will be critical to address if these interactions represent a functional 
cross-talk and thus may impact or regulate hepatocyte survival.  However, somewhat 
paradoxically, activated β-catenin has also been shown to directly bind to and inhibit NF-κB by 
associating with the p65 subunit, thus preventing its translocation and target gene activation 
[266, 267].  Therefore, although β-catenin appears on the whole to contribute to the anti-
apoptotic phenotype as indicated by an increase in basal hepatocyte apoptosis evident in KO 
livers, its role and regulation in hepatocyte survival remains to be elucidated in-depth, in light of 
diverse interactions at multiple levels within the death pathways.   
1.6 CLINICAL IMPLICATIONS 
1.6.1 Hepatocyte Transplantation 
Orthotopic liver transplantation is currently the most effective and widely used method for 
treating liver insufficiency caused by chronic liver diseases such as fulminant hepatic failure, 
end-stage liver disease, and metabolic liver diseases.  However, the relatively high risk of the 
surgery, combined with a requirement for lifelong immunsuppression and a shortage of healthy 
donor organs, has prompted clinicians to seek out promising alternatives.  One such treatment is 
hepatocellular transplantation (HCT).  HCT offers several advantages over whole-organ 
transplantation.  First, HCT is a less-invasive procedure with fewer complications and lower 
morbidity [268].  Additionally, cells from one donor can be used to treat multiple patients, and 
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are obtained from livers that would be discarded or otherwise deemed unfit for transplantation.  
Finally, these cells can be manipulated by ex vivo gene therapy to incorporate genes that correct 
a metabolic disorder [269] or those that are aimed at preventing immune rejection.  Donor 
hepatocytes are generally infused through the portal vein or the spleen [270], where they migrate 
to the liver and display normal architecture and morphology [271, 272].  HCT has been quite 
effective in human trials, treating inborn errors of metabolism such as Crigler-Najjar syndrome, 
alpha-1 antitrypsin deficiency, factor VII deficiency, ornithine transcarbamylase deficiency, and 
glycogen storage disease [273-278], as well as fulminant hepatic failure [268, 279-281].  
However, issues of engraftment, donor cell viability, loss of function, and availability have 
limited the effectiveness and widespread use of HCT. 
Differentiation of embryonic stem (ES) cells, and more recently induced pluripotent stem 
cells (iPSC), into hepatocytes has been seen by many as a viable source of cells for 
transplantation, as their successful differentiation would supply an unlimited amount of high 
quality hepatocyte-like cells [282-285].  Several groups claimed to have successfully 
differentiated ES cells into hepatocyte-like precursors [286, 287], although their use in transplant 
therapy has yet to be determined.  Indeed, selective and careful differentiation can produce a 
hepatic gene expression profile in a fraction of ES cells [288, 289].  Some of these hepatocyte-
like cells even express cytochrome P450 genes and demonstrate drug metabolic activity, which is 
necessary for proper liver function [290-292].  Other groups have had success in differentiating 
other cell types, such as human umbilical cord cells [293], hematopoietic stem cells [294], cord 
blood cells [295], fetal liver progenitor cells [296], murine oval cells [297], embryonic liver 
explants [298], and hepatoblasts transduced ex vivo with lentiviral vectors [299], into hepatocyte-
like cells.  However, these cells have a limited ability to repopulate the liver due to their 
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relatively immature phenotype [300], and often form teratomas following transplantation, even 
after partial differentiation in culture [301, 302].  Overall, although the use of ES cells and other 
precursor cells in treating hepatic insufficiency is promising, much more work needs to be done 
to determine the safety, functionality, and efficacy of these cells [283]. 
Another potential solution to the shortage of donor hepatocytes for HCT is the use of non-
transformed hepatocyte cell lines.  Conditionally immortalized hepatocytes have been shown to 
provide metabolic support in chronic liver insufficiency [303].  Similarly, successful genetic 
manipulation might also provide a source of hepatocytes with enhanced proliferative, 
engraftment, and/or survival capabilities, thus reducing or eliminating the bottlenecks associated 
with supply and quality of donor hepatocytes.   
The role of β-catenin in hepatic differentiation, proliferation, and survival makes this an ideal 
candidate for gene therapy.  Several studies have described the effects of constitutively active β-
catenin in hematopoietic models.  One group found that introduction of a stable form of β-
catenin restores multipotency to committed hematopoietic progenitors, and promotes expansion 
of these progenitors in culture [304, 305].  Similarly, another group reported that expression of a 
mutant active β-catenin in normal hematopoietic progenitors impairs differentiation [306].  
Finally, Reya et al. found that hematopoietic stem cells transduced with active β-catenin 
displayed more efficient reconstitution, higher levels of chimerism, and increased proliferation 
when transplanted into lethally irradiated mice [307].  Therefore, it is possible that 
overexpression of a mutated non-degradable, non-oncogenic form of β-catenin in hepatocytes, 
such as that seen in our S45D TG mice, will give these cells a growth and engraftment advantage 
in transplantation, similar to that seen in HSCs.  Based on the roles of β-catenin in cell 
 29 
proliferation, survival, and as a master differentiation factor for hepatocytes, it may be a 
desirable candidate to promote transplanted cell engraftment and function. 
1.6.2 Oxidative stress, apoptosis, and liver disease 
Upregulation of Fas-mediated apoptosis has been implicated in the progression of many 
human liver diseases.  For example, apoptosis is increased in patients with alcoholic hepatitis, 
and the number of apoptotic cells correlates with disease severity [308].  As mentioned 
previously, one of the mechanisms contributing to apoptosis in alcoholic hepatitis is oxidative 
stress, which may cause cell death through mitochondrial dysfunction [309].  Additionally, both 
the Fas receptor and FasL are strongly expressed in patients with this disease, which suggests 
that FasL-positive hepatocytes can induce apoptosis in adjacent Fas-expressing hepatocytes [195, 
308, 310].  Another disease in which apoptosis occurs primarily through Fas upregulation is non-
alcoholic steatohepatitis [311].  Toxic bile salt accumulation in cholestatic liver disease results in 
induction of apoptosis in a Fas-dependent manner independent of FasL [312].  Fas signaling is 
also an essential component in hepatocyte injury and apoptosis in Wilson’s disease [313].  In 
viral hepatitis, apoptosis, which is regulated either by the pathogen itself or the host cytotoxic T 
cell-mediated immune response, occurs primarily through the Fas pathway [314].  Fas receptor 
expression has been correlated with areas of inflammation and necrosis in hepatitis B [315], and 
is also present in livers of patients with hepatitis C [316].  
The TNF-α pathway is also dysregulated in a wide range of liver diseases.  In addition to 
Fas, TNF-R1 is upregulated in livers of patients with alcoholic liver disease [196, 317].  Serum 
levels of TNF-α are also increased in alcoholic steatohepatitis patients and correlate with disease 
progression and mortality, suggesting that this pathway plays a role in the pathogenesis of this 
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disease [318].  Oxidative stress caused by glutathione depletion can exacerbate the severity of 
alcoholic steatohepatitis by sensitizing hepatocytes to TNF-α [319].  TNF-R1 and TNF-α are 
upregulated in both hepatitis B and hepatitis C, probably as a result of inflammation due to viral 
infection, and are associated with disease progression and severity [320-323].  TNF-α-mediated 
apoptosis also plays a role in ischemia/reperfusion injury and fulminant hepatic failure, likely 
through overaction of the immune system and generation of reactive oxygen intermediaries 
[324]. 
Because apoptosis is a common feature in the pathology of many different liver diseases, 
therapeutic inhibition of this process has the potential to reduce injury and improve patient 
survival [195].  Several therapies aimed at reducing apoptosis are already being utilized in pre-
clinical and clinical trials in the treatment of liver disease.  Infliximab, a monoclonal antibody 
raised against TNF-α, has been shown to attenuate hepatic injury in a pilot study [325].  
Administration of IDN-6556, a caspase inhibitor, lowered aminotransferase activity and 
decreased liver damage in hepatitis C patients [326-328].  Chronic cholestatic liver disease is 
commonly treated with ursodeoxycholic acid, which is believed to attenuate both oxidative stress 
and apoptosis [329, 330].    Exogenous anti-oxidant therapy has also been utilized to treat liver 
injury and apoptosis related to ROS/RNS; however, the results of these studies have been mixed 
[133].   
Other novel anti-apoptotic therapies may include activators of pro-proliferative pathways, 
which would shift the balance towards cell survival and away from death.  The Wnt/β-catenin 
pathway is one such example of a pro-survival pathway that may be amenable to manipulation.  
Although the precise contribution of β-catenin to cell survival is currently unknown, there is 
some evidence to suggest that β-catenin plays an anti-apoptotic role in liver, as outlined above.  
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However, it remains elusive how components of the Wnt pathway, specifically β-catenin, may 
interact with Fas- or TNF-α-dependent cell death pathways.  Based on such interactions, it may 
become relevant to modulate this pathway for improving outcomes in apoptosis-mediated liver 
injury both experimentally and clinically. 
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2.0  LIVER REGENERATION ADVANTAGE IN MICE OVEREXPRESSING 
SERINE-45 MUTATED BETA-CATENIN 
2.1 ABSTRACT 
An important role for β-catenin in liver regeneration has been observed in mice, rats and more 
recently in zebrafish.  In order to elucidate any impact of β-catenin stimulation on liver 
regeneration, we utilized transgenic (TG) mice that express Ser45 mutated β-catenin under an 
albumin promoter/enhancer. In cell culture, TG hepatocytes exhibit enhanced cell proliferation 
as measured by thymidine incorporation, which was increased almost 2-fold over wild-type 
(WT) mice at D5 in culture. Using the partial hepatectomy (PHx) model of liver regeneration, we 
found a dramatic increase in hepatocytes in S-phase in the TG and WT livers at 40 hours (40H) 
and 72H, respectively. Coincident with the earlier onset of proliferation, cytoplasmic 
stabilization of β-catenin and its nuclear translocation as well as a dramatic increase in total and 
nuclear cyclin-D1 protein is also evident at 40H post-PHx in TG and at 72H in the WT. In order 
to investigate if there is any difference in tyrosine (Y)-phosphorylation, an alternate mechanism 
of β-catenin activation, we examined Y654-β-catenin levels in regenerating livers in WT and TG 
mice. An increase in Y-654-β-catenin was evident at 40H and 72H in TG and WT mice, 
respectively.  Finally, we tested if exogenous stimulation of β-catenin signaling via 
hydrodynamic delivery of Wnt-1 naked DNA could impact regeneration in WT mice. We 
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observed a significant increase in total Wnt-1, β-catenin, glutamine synthetase, cyclin-D1 and 
PCNA in the Wnt-1 and not the control plasmid-injected mice. In conclusion, stimulation of 
Wnt/β-catenin signaling is advantageous for liver regeneration through induction of the 
downstream target cyclin-D1, and thus might have implications in regenerative medicine.   
 
2.2 BACKGROUND 
The Wnt/β-catenin pathway is an evolutionarily conserved pathway that has proven to be 
essential in liver health and repair [331].  In adult resting liver, active β-catenin is limited to 
hepatocytes in the centrizonal area where it regulates expression of target genes such as 
glutamine synthetase (GS) and other genes involved in xenobiotic metabolism, and thus is 
implicated in liver zonation [124, 332]. However, in the rest of the unchallenged adult liver, 
Wnt/β-catenin signaling is essentially quiescent. The overall steady-state condition is 
characterized by the phosphorylation and subsequent degradation at key serine/threonine sites 
that is the hallmark of β-catenin turnover. Hence, β-catenin is localized predominantly at the cell 
membrane and is largely absent from the cytoplasm and nucleus in a mature hepatocyte.   
At the cell membrane, β-catenin plays an important role in cell-cell adhesion, forming a 
bridge between the actin cytoskeleton and E-cadherin [40, 41].  Phosphorylation of β-catenin at 
tyrosine residue 654 decreases its interaction with E-cadherin [42, 43].  β-Catenin also forms a 
complex with HGF receptor Met [49-51]. Upon HGF signaling β-catenin becomes 
phosphorylated at tyrosine residues 654 and 670 and translocates to the nucleus to induce target 
gene expression [52, 53].  
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The partial hepatectomy (PHx) model, in which two-thirds of the rat or mouse liver is 
removed and the remaining lobes enlarge to restore the original liver mass [105], is an ideal 
environment to study the role of β-catenin in controlled growth after injury.  Activation of β-
catenin signaling during liver regeneration and delay in regeneration due to its loss has been 
reported in rat and mouse models [94, 126-128].  The decrease in hepatocyte proliferation due to 
the absence of β-catenin, as well as the role of β-catenin in regulating cell proliferation, has 
motivated us to examine the behavior of hepatocytes that express Ser45 mutated β-catenin.   
Ser45 is a key residue in β-catenin that regulates GSK-3β/Axin/CK1/APC dependent degradation 
of this protein.  The mutation of β-catenin at S45 compromises this process and contributes to its 
overall stabilization [333].  Here, we report a growth advantage both in culture of hepatocytes 
expressing S45-mutated β-catenin and after partial hepatectomy in TG mice due to upregulation 
of cell cycle regulators such as cyclin-D1. We also demonstrate that tyrosine-phosphorylation of 
β-catenin may play an important role during initiation of the regenerative process.  Finally, we 
show that induction of the β-catenin pathway through hydrodynamic delivery of Wnt-1 plasmid 
injection in wild-type mice increases β-catenin stabilization along with downstream targets and 
associated cell proliferation after partial hepatectomy. In conclusion, we demonstrate that 
exogenous activation of β-catenin through Wnt-1 may be a useful strategy to improve liver 
regeneration provided useful positive modulators of the pathway become available.   
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2.3 MATERIALS AND METHODS 
2.3.1 Animals 
Liver-specific transgenic mice overexpressing human β-catenin gene were described 
previously by our group [132].  Briefly, we generated β-catenin transgenic mice in a C57BL/6 
background that express the human β-catenin gene under an albumin promoter/enhancer. Here, 
we utilize transgenic mice that were generated similarly but in FVB background and with the 
exception that the β-catenin gene was engineered to carry a mutation affecting serine-45, a site 
relevant in β-catenin degradation [333]. The transgenic mice express S45D-β-catenin mutant 
under an albumin promoter/enhancer and are henceforth referred to as TG mice. The TG mice 
used in the study (~3 months old males) display an overall increase in β-catenin protein at the 
hepatocyte membrane only and lack nuclear or cytoplasmic localization in the normal state, 
although it was observed temporally in TG mice less than 2 months of age. 
2.3.2 Surgery 
 All animal usage was approved by the Institutional Animal Care and Use committee at 
the University of Pittsburgh. Around 3-month old male FVB WT and TG mice were subjected to 
partial hepatectomy. Briefly, three of the five lobes in a mouse liver are surgically removed 
[104].  The remaining 2 lobes regenerate and the liver mass is completely restored by the 14th 
day after PHx [334].  Three-five WT and TG mice were sacrificed at time 0, 10 hours (H) 20H, 
40H, 72H, 4 days (D4), D5, D9, D14, 1 month (M) and 3M. Livers were processed for paraffin 
embedding and protein isolation as described previously [94]. 
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2.3.3 Primary hepatocyte culture 
Hepatocytes were isolated from 3-month old WT and TG mouse livers (n=3) using a 
modified 2-step collagenase perfusion protocol [335, 336], resuspended in minimal essential 
media (MEM) supplemented with 10% fetal bovine serum (FBS), and seeded at a density of 
200,000 live cells per ml onto either wet or dry collagen-coated plates.  After 2 hours, media 
were replaced with a chemically defined MEM-based growth medium containing 
insulin/transferrin/selenium (ITS; 1g/L), dexamethasone (10-7M), HGF (40ng/ml), and epidermal 
growth factor (EGF; 25ng/ml) as described previously [337].  Plates were incubated at 37°C in 
5% CO2 until harvested for proliferation and viability assays as described below.   
2.3.4 Wnt-1 Plasmid injection  
The recombinant Wnt-1 expression plasmid was purchased from Upstate Biotech 
(Catalogue # 21-121). The plasmid contains HA-tagged mouse Wnt-1 cDNA under the control of 
the CMV promoter. For hydrodynamic delivery of naked DNA, 1 μg/gm of body weight of Wnt-
1 plasmid or pcDNA3 control plasmid (Invitrogen, San Diego CA) was administered via 
hydrostatic tail vein injection to CD-1 mice weighing around 18 grams, as described previously 
[338]. Twenty-four hours after the injection, the mice were subjected to PHx. Mice were 
sacrificed at 30 hours after PHx and livers processed for total and nuclear protein extraction and 
immunohistochemistry. 
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2.3.5 Protein Extraction, Immunoprecipitation, and Western Blots 
Whole-cell lysates from mouse livers were prepared by homogenization using RIPA 
buffer (9.1 mmol/L dibasic sodium phosphate, 1.7 mmol/L monobasic sodium phosphate, 150 
mmol/L sodium chloride, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium 
dodecylsulfate [pH adjusted to 7.4]) containing fresh protease and phosphatase inhibitor 
cocktails (Sigma, St. Louis, MO) [94]. Nuclear extracts were prepared using the NE-PER 
Nuclear and Cytoplasmic Extraction Reagents kit as per the instructions (Thermo Fisher 
Scientific, Rockford, IL).  The concentration of the protein in all lysates was determined by the 
bicinchoninic acid assay using BSA as a standard.  
For immunoprecipitation studies, 500 μg of cell lysate from WT and TG livers harvested 
at T0, 40H, and 72H after PHx (prepared in RIPA buffer in the presence of inhibitors) was 
precleared with goat IgG together with Protein A/G agarose for 30 m at 40C.  After 
centrifugation, the supernatants were incubated with either Met antibody for 1 h at 40C followed 
by overnight incubation with Protein A/G agarose at 40C, or agarose-conjugated β-catenin 
antibody overnight at 40C.  Pellets were collected the next day, washed in PBS containing 
inhibitors, resuspended in loading buffer, and subjected to electrophoresis, as described below.  
Proteins were subjected to SDS-PAGE [126].  Briefly, 50 μg of protein from cell or liver 
lysate or 15-20 μl of eluate from IP studies was resolved on 7.5% or 12% precast SDS-PAGE 
gels (ISC BioExpress, Kaysville, UT) using the mini-PROTEIN 3-electrophoresis module 
assembly (Biorad, Hercules, CA), followed by transfer to either Immobilon-PVDF membranes 
(Millipore, Bedford, MA) or nitrocellulose membranes (Bio-Rad Labs, Hercules, CA).  
Membranes were stained with Ponceau-S solution to confirm equal loading and then blocked in 
either 5% nonfat dry milk in blotto solution (20mM TRIS-HCl pH 7.5, 150 mM NaCl, 0.1% 
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Tween 20), 10% Block Hen (Aves Labs, Inc, Tigard, OR) followed by 5% milk in blotto, or 5% 
BSA in blotto, followed by incubation with primary antibody diluted in either 5% milk/blotto or 
5% BSA/blotto for 1-2 h or overnight.  Membranes were washed and incubated in horseradish-
peroxidase conjugated secondary antibodies (Chemicon, Temecula, CA) for 1h followed by 
washing.  Secondary antibodies were goat anti-mouse (1:50,000), donkey anti-rabbit (1:25,000), 
donkey anti-goat (1:25,000) (Chemicon), and goat anti-chick (1:15,000) (Aves Labs, Inc., 
Tigard, OR).  Proteins were detected by Super-Signal West Pico Chemiluminescent Substrate 
(Pierce, Rockford, IL) and visualized by autoradiography.  Primary antibodies used in this study 
were against β-catenin (1:1000) (BD Biosciences, San Jose, CA), glutamine synthetase (1:500), 
Wnt-1 (1:200), lamin B1 (1:200), Met (1:200), and c-myc (1:200) (all from Santa Cruz 
Biotechnology, Santa Cruz, CA), cyclin-D1 (1:500) (Neomarkers, Fremont, CA), HGF (1:500) 
(R&D Systems, Minneapolis, MN), Y654-Phospho-β-Catenin Antibody [339] (Aves Labs, Inc.), 
and actin (1:5000) (Chemicon).  Blots were stripped with IgG elution buffer (Pierce, Rockford, 
IL) for 30 m before re-probing.  
2.3.6 Immunohistochemistry 
Immunohistochemistry was performed on mouse livers and primary hepatocyte cell 
cultures. Tissues fixed in 10% formalin and embedded in paraffin were sectioned at 4 µm onto 
Superfrost Plus glass slides (Fisher Scientific, Pittsburgh, PA). Sections were stained with 
hematoxylin and eosin (H&E) in order to determine the mitotic index.  Additional sections were 
microwaved in either citrate buffer or 1% ZnSO4, pretreated with 3% H2O2 to eliminate 
endogenous peroxidases, and blocked using protein blocking agent (Thermo Scientific, 
Waltham, MA) or Super Block (Scy Tek, Logan, UT).  Alternatively, cell culture plates 
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containing hepatocyte cultures were fixed with 2% paraformaldehyde for 15 m, permeabilized 
with 2N HCl/1% Triton-X-100, and blocked in Ultra V Block (Lab Vision Products, Fremont, 
CA).  Primary antibodies used for this project were anti-PCNA (1:5000) (Dako, Denmark), anti-
β-catenin (1:50) (BD Biosciences), glutamine synthetase (1:50) (Santa Cruz Biotechnology), 
Y654-Phospho-β-Catenin Antibody (1:100) (Aves Labs, Inc.) and anti-cyclin-D1 (1:50) 
(Neomarkers).  Secondary antibodies were biotinylated donkey anti-mouse (Jackson 
ImmunoResearch Laboratories, Inc., West Grove, PA), donkey anti-goat (Chemicon), or goat 
anti-chick (Aves Labs, Inc.), all used at a 1:500 dilution.  Immunohistochemistry was performed 
using the Vectastain ABC Elite kit and developed using DAB (Vector Laboratories, Inc., 
Burlingame, CA).  The slides and culture plates were counterstained with either Harris or 
Shandon hematoxylin and mounted with cytoseal or crystal mount (Biomeda Corp., Foster City, 
CA). 
2.3.7 Cell Growth and Viability Assays 
A [3H]thymidine uptake assay was utilized as previously described to measure cell 
proliferation [340, 341].  Briefly, WT or TG primary hepatocytes were dosed with 2.5 µCi/ml of 
[3H]thymidine (MP Biomedicals, Solon, OH) 48h before harvesting and incubated at 37°C in 5% 
CO2.  Plates were harvested at two time points – 48 and 120 hours post-plating - and assessed for 
thymidine incorporation as follows.  1.5 ml of cold 5% (w/v) trichloroacetic acid was added to 
each well after removal of media. The plates were placed at 4°C for 2 h and then were washed 
and allowed to air-dry. The precipitate was solubilized by the addition of 1 ml of 0.33 M NaOH, 
and an aliquot was added to Universol (MP Biomedicals). The counts/min of the solubilized 
precipitates were determined with a scintillation counter (Beckman Instruments, Palo Alto, CA).   
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Cell growth and viability was measured using the MTT assay as described previously 
[342].  Briefly, 10% vol/vol of 5 mg/ml (3,4.5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium 
bromide (MTT) was added to cultures of WT or TG primary hepatocytes for 30 m.  The media 
were aspirated after 30 m followed by addition of 1 ml of isopropanol.  After shaking the plate 
gently for 2 m, 200 μl of this solution was examined for conversion to colored formazan by 
spectrophotometric analysis (490 nm).   
2.3.8 Statistical Analysis 
All experiments were performed three or more times. Representative data from 
experiments is presented. Autoradiographs of various western blots were scanned and subjected 
to densitometry using the ImageJ software. Mean integrated optical density (IOD) was compared 
between various groups.  Statistical assessment of significance was made by the Student’s t-test 
(Kaleidagraph, Synergy Software). A P value of less than 0.05 or 0.001 was considered 
significant (*) or extremely significant (**), respectively. 
2.4 RESULTS 
2.4.1 Increased growth of TG hepatocytes in culture 
Hepatocytes from WT and TG mice were isolated and cultured in the presence of HGF 
and EGF.  The cells were examined under phase-contrast microscopy 48 hours and 120 hours 
after plating.  WT and TG hepatocytes appeared morphologically indistinguishable at 48H of 
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culture. However, at 120H, TG hepatocytes appeared more flattened, spread out, and healthy as 
compared to WT suggesting more robust growth (Fig. 3A). Based on this observation, we 
compared the proliferation and viability of TG and WT hepatocytes in culture.  The proliferative 
capacity of these hepatocytes was assayed by adding [3H] thymidine to the cultures as detailed in 
the Methods. TG hepatocytes exhibited around 2-fold (P < 0.05) increase in thymidine 
incorporation over WT after 120H (Fig. 3B), suggesting greater proliferation by the TG cells in 
culture. To confirm this result, we cultured WT and TG cells for 48 and 120 hours and stained 
them with proliferating cell nuclear antigen (PCNA), a marker of DNA synthesis and cell 
proliferation. Figure 3C shows that while the number of PCNA-positive cells is unchanged over 
time in cultures of WT hepatocytes, there is a 27% increase in PCNA positivity from 48 to 120 
hours in TG cultures.  Next, we examined the cell viability of WT and TG hepatocytes grown in 
the presence of HGF and EGF as measured by (3,4.5-dimethylthiazol-2-yl) 2,5-
diphenyltetrazolium bromide (MTT) assay, which also showed significantly greater viability in 
hepatocytes from TG as compared to WT mice (P < 0.05) at 120H (Figure 3D).  Thus, overall 
the TG hepatocytes exhibit in vitro growth advantages over WT hepatocytes in culture. 
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 Figure 3: TG hepatocytes have a growth advantage over WT cells in culture.  (A) WT and TG hepatocytes in 
culture are morphologically distinct at 120H.  (B) Increased [3H] thymidine uptake by TG hepatocytes as compared 
to WT cells.  The counts were normalized to values at 40H after culture for each group and presented as fold change.  
(C) While numbers of PCNA-positive hepatocytes remained constant between 40H and 120H in WT hepatocyte 
culture, a net and significant gain in numbers of PCNA-positive cells was evident between 40H and 120H in the TG 
hepatocytes.   (D) A significant increase in cell viability as determined by MTT assay was observed in TG versus 
WT hepatocytes at 120H in culture. 
2.4.2 β-catenin overexpression provides a regenerative advantage to TG mice over WT 
after partial hepatectomy 
WT and TG mice were subjected to partial hepatectomy (PHx) in order to determine the 
proliferative status of β-catenin overexpressing livers after injury.  Regenerating livers from WT 
and TG mice were harvested at various time points as indicated in the Methods. These time 
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points reflect DNA replication and peak mitosis reported at around 48 hours after PHx in 
C57BL/6 mice [343] and around 48-72 hours in FVB mice [344].  Since we identified an in vitro 
growth advantage of the TG hepatocytes, we also included the early time points for a more 
thorough analysis. Finally, we chose the later time points to determine any effect of excess β-
catenin on termination of regeneration or identify any late consequences such as growth 
dysregulation.  
WT livers at 40 hours after PHx exhibit very little active mitoses upon histological 
examination (average <1 cell per 20X field), suggesting that hepatocytes have not undergone cell 
division at this time. Interestingly, TG livers are undergoing active mitosis at this time (average 9 
per 20X field) (Figure 4A and 4B).  At 72 hours, the WT livers display 11-12 mitotic figures per 
20X field, while the numbers in TG are in excess of 19-20 mitotic figures per 20X field.  
Next, PCNA immunohistochemistry was performed to address the state of cell cycle 
progression in the WT and TG livers after PHx. A highly significant (p<0.001) increase in the 
numbers of PCNA-positive cells representing hepatocytes in S-phase was evident even at 40 
hours in TG mice (448 +/-33.2), which is completely lacking in the corresponding WT livers at 
this stage (1.9 +/- 1.9) (Figure 4C and 4D).  At 72 hours, both WT and TG livers display 
comparable numbers of PCNA-positive hepatocytes (329 +/- 78.6 vs. 323 +/- 45.3, respectively).  
At D4 and D5, the numbers of PCNA-positive cells were greater in WT than TG (P < 0.05) (223 
+/- 106 vs. 64.9 +/- 68.4 for D4 and 43.1 +/- 14.2 vs. 25.5 +/- 8.4 for D5).  By D9 and D14, the 
number of PCNA-positive cells has fallen to less than 20 cells per field in both WT and TG. 
Similarly, insignificant differences in the numbers of PCNA-positive cells are observed in TG 
and WT hepatocytes at 1 and 3 months after hepatectomy. Thus, β-catenin overexpression leads 
to earlier entry of hepatocytes into the cell cycle and more robust hepatocyte proliferation in TG 
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livers as compared to WT livers after partial hepatectomy. However, this increase in proliferation 
is transient and not sustained and thus does not lead to any phenotype of growth dysregulation in 
TG livers up to 3 months after PHx. 
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 Figure 4: There is a dramatic upregulation of proliferation 40 hours after PHx in TG mice.  (A) At 40 hours 
(40H), WT livers are quiescent; however, TG livers are clearly undergoing mitosis.  Both WT and TG livers have 
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approximately the same number of mitotic figures at 72H.  (B) Quantification of the number of mitotic figures in 
representative 10X fields (n=5) show TG livers to have significantly more cells in mitosis at 40H and 72H than 
corresponding WT livers.  (C) At 40H TG livers show massive PCNA-positive hepatocytes in S-phase, while WT 
livers are PCNA-negative.  WT livers show many PCNA-positive hepatocytes at 72H post-PHx.  (D) Quantification 
of the number of PCNA-positive cells in 5 representative 10X fields from three WT and TG livers show 
significantly greater numbers of PCNA-positive hepatocytes in TG livers at 40H (p<0.001). 
2.4.3 Early β-catenin activation in TG mice imparts a regenerative advantage over WT 
after PHx 
Next, we examined β-catenin protein expression through western blot analysis to verify the 
contribution of β-catenin in the regenerative process in WT and TG and to specifically address 
the mechanism of enhanced hepatocyte proliferation in TG livers.  TG livers show an increase in 
nuclear β-catenin at 40 hours, which corresponds to the peak of hepatocytes in S-phase of the 
cell cycle in these mice. Higher nuclear translocation of β-catenin is observed at 72 hours in the 
WT livers (Figure 5B).   
We next investigated the expression of several known downstream targets of β-catenin to 
determine which, if any, were expressed earlier or were upregulated in TG mice after PHx. 
Cyclin-D1 protein, a downstream target of β-catenin [25, 26] that controls the critical G1/S 
transition in the cell cycle [345], is increased in total cell lysate in the TG livers at 40 hours 
(Figure 5A). This mirrored an increase in nuclear cyclin-D1 at 40 hours and also was evident at 
72 hours in TG livers. No increase in total or nuclear cyclin-D1 was observed in WT liver at 40 
hours, however its nuclear levels were increased over all preceding time points at 72 hours after 
PHx. 
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We also examined protein levels of other β-catenin targets, such as glutamine synthetase, 
which is involved in glutamine metabolism [34], and c-myc, a transcription factor best known for 
its oncogenic properties [27]. Interestingly, these remained unchanged between the TG and WT 
groups at all time points during the regenerative process (Figure 5A).  Thus, the regenerative and 
proliferative advantage seen in TG mice is due to an early nuclear translocation of β-catenin in 
TG mice, which led to an upregulation of cyclin-D1, an important cell cycle regulator. 
 
 
Figure 5: β-catenin and cyclin-D1 increase earlier in TG mice during regeneration as compared to WT mice.  
(A) The increase in cyclin-D1 in TG livers at 40H after PHx is seen in whole cell extracts, while levels of glutamine 
synthetase and c-myc remain unchanged.  Actin verifies equal loading.  (B) Nuclear extracts from regenerating 
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livers show an increase in both nuclear β-catenin and cyclin-D1 that begins at 40H in TG and 72H in WT livers.  
Lamin B1 verifies equal loading. 
 
Finally, we investigated β-catenin redistribution by immunohistochemistry in the WT and 
TG livers in pre-hepatectomy and regenerating livers at 40 hours. The TG livers at Time 0 
exhibit higher β-catenin at the hepatocyte membrane than the WT livers as expected. Forty hours 
after PHx, while β-catenin was still predominantly observed at the hepatocyte membrane in the 
WT, a noteworthy cytoplasmic stabilization and nuclear translocation is evident in TG liver 
sections (Figure 6). This is in agreement with the western blot analysis presented above and 
clearly demonstrated an early and robust β-catenin activation in the TG mice during the process 
of liver regeneration.     
 49 
 Figure 6: Immunohistochemistry for β-catenin demonstrates translocation to the nucleus in the TG livers at 
40H as evidenced by an increase in cytoplasmic and nuclear staining.  Arrows indicate cytoplasmic staining; 
arrowheads point to nuclear staining. 
 
2.4.4 Early tyrosine phosphorylation of β-catenin in TG livers after PHx 
Mutation of Ser45 in CTNNB1 is known to affect the degradation of β-catenin protein; 
however in our TG mouse model, this mutated form of β-catenin was deemed as being not 
constitutively active as seen by its predominant membranous localization and lack of nuclear 
staining in livers of TG mice greater than 2 months.  This was an intriguing observation that 
shows an adaptive capability of hepatocytes to regulate a mutant form of β-catenin through its 
membranous sequestration.  To address the mechanism which may have resulted in an increase 
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in the nuclear translocation and activation of β-catenin signaling in TG mice at 40 hours after 
PHx, we investigated the tyrosine phosphorylation status of β-catenin during liver regeneration 
in TG and WT mice.  Phosphorylation at Y654 is a hallmark of HGF- and EGF-mediated β-
catenin activation and translocation [52].  Western blotting for Y654 shows around a 20% 
decrease in Y654-phosphorylated β-catenin in TG livers as compared to WT at baseline (Figure 
7A and 7C).  While the difference is modest, hypophosphorylation of β-catenin at this residue 
may be an important mechanism of regulating S45D mutant β-catenin by enabling its enhanced 
membranous localization with E-cadherin and Met.  However, there is an increase in β-catenin 
phosphorylation at 40 hours after PHx in TG mice and at 72 hours in WT mice (Figure 7A). This 
increase was around 40% at 40 hours in the TG livers as measured by densitometry (Figure 7C). 
Increased levels of total HGF protein were observed in WT and TG mice at 40 hours and 72 
hours after PHx over pre-hepatectomy levels although HGF levels were modestly higher in WT 
compared to TG livers at 72 hours (Figure 7A).  
Since HGF is known to phosphorylate c-Met, which in turn phosphorylates β-catenin and 
results in dissociation of the β-catenin-Met complex and nuclear translocation of β-catenin, we 
sought to determine Met-β-catenin association in TG and WT mice during the regeneration 
process [51].  Coprecipitation studies identified a decrease in β-catenin-Met association at 40 
hours and 72 hours in TG and at 72 hours in WT mice supporting premature HGF/Met activation 
of β-catenin in TG mice after PHx (Figure 7B). Densitometry revealed a decrease of association 
from 37% to around 18% in TG livers at 40 hours after PHx, while it remained unchanged in WT 
mice (Figure 7D). The association dropped to around 9% in both TG and WT mice at 72 hours 
after PHx.  While these changes appear modest, their functional implications would be marked 
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especially in TG livers, where β-catenin is mutated at S45 and hence cannot be degraded by the 
ubiquitin-proteasome pathway. 
To conclusively address the fate of tyrosine-phosphorylated β-catenin, we next determined 
the localization of Y654-β-catenin in WT and TG livers during liver regeneration by 
immunohistochemistry (Figure 7E). Scanty cytoplasmic staining for Y654-β-catenin is observed 
in in pre-hepatectomy WT and TG livers.  However, a robust increase in nuclear and cytoplasmic 
localization of Y654-β-catenin is observed in TG livers at 40 hours and 72 hours. A similar 
increase is observed in WT livers at 72 hours only. Thus, β-catenin activation in TG mice at 40 
hours is at least in part contributed by its tyrosine-phosphorylation, which might be HGF-
dependent and a function of excessive β-catenin at the hepatocyte membrane in TG livers. 
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 Figure 7: Tyrosine-654 (Y654) phosphorylation and dissocation of β-catenin from Met during regeneration 
occurs at 40H in TG mice and 72H in WT mice.  (A) Western blot using total cell lysates detects increased 
phosphorylation of Y654 at 40H and 72H after PHx in TG and WT respectively. Levels of HGF increase in WT and 
TG livers at 40H and beyond.  (B) Immunoprecipitation studies detect dissociation of β-catenin from Met at 40H in 
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TG livers, but at 72H in WT livers.  (C) Denistometry of scanned representative western blots reveals around 40% 
increase in Y654-β-catenin in TG mice at 40H; a similar increase in Y654-β-catenin occurs in WT mice at 72H.  
O.D. was normalized to loading control.  (D) Quantitative changes in c-Met-β-catenin association during liver 
regeneration in WT and TG mice reveal a decrease at 40H in TG and at 72H in both TG and WT.  O.D. was 
normalized to loading control.  (E) Immunohistochemistry for Y654 β-catenin reveals increased cytoplasmic and 
nuclear localization at 40H and 72H after PHx in TG and at 72H in WT livers. 
 
2.4.5 Hydrodynamic injection of Wnt-1 naked DNA induces β-catenin activation and 
regeneration in wild-type mice 
Finally, in order to determine if temporal activation of Wnt/β-catenin signaling could impact 
hepatocyte proliferation during regeneration, we systemically administered pCMV-Wnt-1 
plasmid or empty expression plasmid vector pcDNA3 in wild-type CD-1 mice. Twenty-four 
hours after injection, these mice were subjected to partial hepatectomy and the livers were 
harvested at 30 hours after PHx. This time-point was selected because peak hepatocyte 
proliferation after PHx is reported at 48 hours in CD-1 mice [346] and we wanted to determine 
any premature entry into cell cycle as a sign of cell proliferation and enhanced regeneration in 
the Wnt-1-plasmid-injected group of mice.  Western blot for Wnt-1 protein confirms an increase 
in expression at 30 hours after PHx in the Wnt-1 injected animals compared to the control group 
(Figure 8A).  Concurrent with this increase, β-catenin translocation to the nucleus is also evident 
(Figure 8B). A simultaneous increase in the protein expression of β-catenin downstream targets 
such as glutamine synthetase and cyclin-D1 were observed at 30 hours after PHx in the Wnt-1-
treated group by western blot analysis and/or immunohistochemistry (Figure 8A and 8C).  
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To determine the effect of Wnt-1 injection on cell proliferation, we examined both control 
and Wnt-1 injected livers for PCNA to identify cells in S-phase of cell cycle.  Figures 8C and 8D 
show an almost three-fold increase in the numbers of PCNA-positive hepatocytes at 30 hours in 
the Wnt-1 injected mice than in the controls (p<0.05).  These data suggest that like the TG mice, 
the Wnt-1 injected mice have a proliferative advantage over the pcDNA3-injected controls due 
to enhanced β-catenin activation after PHx, and thus exogenous stimulation of β-catenin 
signaling may be an attractive means to stimulate regeneration. 
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 Figure 8: Hydrodynamic delivery of Wnt-1 plasmid and not pcDNA3 through tail vein induces Wnt/β-catenin 
activation in the liver.  (A) Western blots utilizing livers from Wnt-1 or pcDNA3 plasmid injected mice at 30H 
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after PHx reveal increased protein levels of Wnt-1 and glutamine synthetase in the Wnt-1 injected group over the 
controls.  (B) Western blots using nuclear lysates show increased β-catenin in the Wnt-1 injected livers as compared 
to pcDNA3-injected controls at 30H after PHx.  (C) Downstream targets glutamine synthetase and cyclin-D1 are 
increased in Wnt-1 injected animals at 30H after PHx, as shown by immunohistochemistry. A concomitant increase 
in the number of PCNA stained cells is evident in the livers of Wnt-1 injected animals at 30H after PHx as compared 
to controls.  (D) Quantification of the number of PCNA-positive cells in five representative 10X fields from Wnt-1 
or pcDNA3-injected livers (n=3) show significantly greater numbers of proliferating cells at 30H after PHx in the 
experimental group (p<0.05). 
 
2.5 DISCUSSION 
β-Catenin is the crucial downstream effector of the canonical Wnt pathway, and its 
activation is essential in liver development and regeneration [331].  Mutations in the β-catenin 
gene that render the protein aberrantly active such as mutations affecting serine-45 have been 
commonly implicated in HCC [347].  Phosphorylation of β-catenin at serine-45 is essential for 
proteosomal degradation. Both non-phosphorylatable and phospho-mimetic mutations affecting 
this residue along with others in exon-3 have been shown to retard degradation of β-catenin 
protein [333].  In the current study we employed transgenic mice overexpressing mutant S45D-
β-catenin under an albumin promoter/enhancer in order to investigate the impact on hepatocyte 
proliferation in primary cultures and during liver regeneration. These transgenic mice showed 
temporal activation during early postnatal liver development but at 2 months of age, β-catenin 
was limited predominantly to the hepatocyte membrane. 
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What was the mechanism of membranous sequestration of the oncogenic mutant β-
catenin in the TG hepatocytes?  An approximately 20% decrease in Y654-phosphorylated β-
catenin in TG liver over WT, concomitant with enhanced membranous localization of β-catenin, 
indicates a rather novel means of directing mutant β-catenin to complex with Met at the 
hepatocyte membrane.  This also suggests a role for a tyrosine phosphatase which might in fact 
be a part of this adaptive mechanism and may be potentially exploited for therapeutic benefit.  
Indeed, protein tyrosine phosphatases such as PCP-2 are known to inhibit β-catenin signaling by 
inducing its association with E-cadherin [348].  Despite successful sequestration of β-catenin at 
the hepatocyte membrane, TG hepatocytes show a growth advantage both in vitro and in vivo. 
This indicates that when suitable signals are provided, the excess β-catenin from its membranous 
pool is available for transactivation of target genes (Figure 9). Indeed in primary cultures, the 
growth advantage of TG hepatocytes is due to increased availability of β-catenin from the 
membrane due to the presence of growth factors such as HGF and EGF in the culture media, 
which are known to induce tyrosine phosphorylation-dependent β-catenin nuclear translocation 
and activation [51, 349].  
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 Figure 9:  The growth advantage of S45D TG hepatocytes after PHx may be attributed to acceleration of β-
catenin dissociation, phosphorylation, and nuclear translocation 40 hours after partial hepatectomy.  At 
baseline, excess S45D-mutated β-catenin is sequestered at the cell membrane by complexing with the Met receptor.  
After partial hepatectomy, mutated β-catenin is rapidly tyrosine phosphorylated and translocates to the nucleus, 
where it turns on expression of cyclin-D1, thus inducing accelerated proliferation as early as 40 hours after PHx.  In 
WT livers, this phosphorylation and translocation of β-catenin does not occur until 72 hours after PHx.  
 
The positive role of β-catenin in liver regeneration has been identified in rats, mice, 
zebrafish and humans [94, 126-128, 350, 351].  Along those lines, we identify a regenerative 
advantage after PHx in vivo in the current TG mice, where hepatocyte proliferation was earlier 
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and robust.  It is important to note that despite the earlier initiation of DNA synthesis and 
proliferation in the TGs after PHx, the regeneration process was completed unequivocally and 
without any adverse consequences.  The differences in liver weight to body weight ratios 
between WTs and TGs are unremarkable at all time points after PHx; the number of apoptotic 
nuclei at D9 and D14 also do not differ significantly between WTs and TGs (data not shown).  
Additionally, there is no evidence of either dysplastic nodules, adenomas, or HCC as late as 3 
months after PHx.   
The regeneration advantage seen in our TG model was due to enhanced cyclin-D1 
expression, which is necessary for G1 to S phase transition of the cell cycle [352]. While cyclin-
D1 as the target of β-catenin signaling has been known for quite some time [25, 26], its true 
relationship to β-catenin in the liver has been controversial with precedence given to targets such 
as GS [353]. However, several studies support a key role of β-catenin in regulating cyclin-D1 in 
the liver especially during proliferation. In prenatal and postnatal liver development cyclin-D1 
levels closely follow β-catenin activity in normal and β-catenin-conditional knockouts [96, 354]. 
Similarly, β-catenin regulates cyclin-D1 expression during regeneration after sublethal doses of 
acetaminophen [351].  Finally, conditional hepatic disruption of β-catenin compromises cyclin-
D1 expression during both development and liver regeneration [94, 96].   Thus, it is of relevance 
to emphasize that genetic targets of β-catenin signaling are tissue-and context–dependent and 
while cyclin-D1 may be subject to Wnt-independent regulation, β-catenin is among the chief 
regulators of cyclin-D1 and, in turn, of cell proliferation in liver. 
Our data also suggests that there may be an opportunity to stimulate liver regeneration 
from a therapeutic standpoint, through Wnt/β-catenin activation. Transfection of Wnt-1 plasmid 
was previously shown to induce nuclear localization of β-catenin in NIH3T3 [355] and 
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mammary epithelial cells [50].  Rat fibroblasts infected with Wnt-1 adenovirus or retrovirus 
showed proliferation in the absence of serum [356], which was mediated in part by β-catenin 
activation [357]. In our study, hydrodynamic delivery of Wnt-1 DNA led to β-catenin activation, 
increased cyclin-D1 expression and high hepatocyte proliferation after PHx. Thus our report for 
the first time provides evidence that exogenous canonical Wnt activation might be useful to 
augment liver regeneration, especially in the case of acute liver failure. 
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3.0  BETA-CATENIN REGULATES VITAMIN C BIOSYNTHESIS AND CELL 
SURVIVAL IN MURINE LIVER 
3.1 ABSTRACT 
Since the Wnt/β-catenin pathway plays multiple roles in liver pathobiology such as regulating 
cell proliferation, it is critical to identify additional gene targets that mediate diverse effects.  
Here, we report a novel role for β-catenin in controlling ascorbic acid biosynthesis and in turn 
regulating cell survival in murine liver through regulation of expression of regucalcin or 
senescence marker protein-30 and L-gulonolactone oxidase. RT-PCR, Western blotting and 
immunohistochemistry demonstrate decreased regucalcin expression in β-catenin-null livers and 
greater expression in β-catenin overexpressing transgenic livers, HepG2 hepatoma cells 
(containing constitutively active β-catenin), regenerating livers and in hepatocellular cancer 
tissues that exhibit β-catenin activation.  Interestingly, coprecipitation and immunofluorescence 
studies also demonstrate an association of β-catenin and regucalcin.  Significantly lower serum 
ascorbate levels were observed in β-catenin knockout mice as a consequence of decreased 
expression of regucalcin and also of L-gulonolactone oxidase, the penultimate and last (also rate-
limiting) steps, respectively, in the synthesis of ascorbic acid, a known anti-oxidant.  There was 
also a concomitant increase in basal hepatocyte apoptosis in these mice.  To test if ascorbate 
deficiency secondary to β-catenin loss and regucalcin decrease was indeed contributing to 
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apoptosis, β-catenin-null hepatocytes or regucalcin siRNA- transfected HepG2 cells were 
cultured, and both cell types exhibited significant apoptosis that was alleviated by the addition of 
ascorbic acid. Thus, through regucalcin and L-gulonolactone oxidase expression, β-catenin 
regulates vitamin C biosynthesis in murine liver, which in turn is one of the mechanisms 
contributing to the role of β-catenin in hepatocyte survival. 
3.2 INTRODUCTION 
The Wnt/β-catenin signal transduction pathway, which is essential for normal 
development and tissue regeneration [2, 358], also has a well-characterized role in tumorigenesis 
and is implicated in cancers affecting several tissue types, including the colon, rectum, lung, 
skin, breast, and liver [359-362]. Mutations in β-catenin lead to aberrant signaling, which causes 
stabilization and nuclear translocation of β-catenin, along with subsequent activation of target 
genes such as c-myc and cyclin-D1 [25, 27, 363]. In the liver, mutations in β catenin gene are 
primarily involved in the pathogenesis of HCC [364-367]. Because the Wnt/β-catenin pathway 
plays an essential role in both liver biology and cancer [331], it is critical to identify other 
potential targets of this pathway.    
Regucalcin, also known as SMP30 [165], is a Ca2+-binding protein that has been 
implicated in maintaining cell homeostasis and function [163, 176].  Regucalcin activates plasma 
membrane Ca2+-pumping ATPases and thus regulates the cytosolic calcium ion levels [164, 368].  
Expression of regucalcin can be stimulated by the addition of calcium [170, 369-371].  
Moreover, regucalcin may regulate the transcriptional process by binding protein and DNA in 
the nucleus [372].  Much of the characterization of regucalcin has occurred in the context of the 
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liver.  Regucalcin plays an important role in the regulation of Ca2+ signaling from the cytoplasm 
to nuclei in the proliferative cells of regenerating rat liver [163, 176].  During regeneration, 
regucalcin has been suggested to suppress protein synthesis [180] and DNA synthesis [178, 373]. 
Regucalcin has also been implicated in the suppression of RNA synthesis in the nucleus [172, 
374], NO synthase activity [183, 375], and protein phosphatase activity [376, 377].  The 
overexpression of regucalcin in hepatoma cells suppresses cell proliferation and the expression 
of several known oncogenes, such as c-myc [181].  Regucalcin overexpression also has a 
suppressive effect on apoptosis induced by TNF-α or thapsigargin [189].  Because regucalcin 
functions as an inhibitor of several cellular processes, it is thought to have an important role in 
suppressing the differentiation and proliferation of hepatocytes after liver injury [176]. 
Regucalcin may play a role in liver tumorigenesis as well.  Regucalcin mRNA is 
decreased in chemically-induced rat hepatomas [378], as well as in the rat hepatoma cell line H4-
II-E [377].  These data suggest that regucalcin may be implicated in the formation of some 
hepatomas through a decrease in expression, which can lead to an overabundance of hepatocyte 
proliferation.  Interestingly, the human hepatoma cell line HepG2 also expresses regucalcin, and 
its expression could be further stimulated by insulin [379, 380], suggesting that glucose 
metabolism and homeostasis may play a role in regulating regucalcin expression.   
More recently, regucalcin/SMP30 was reported to be a gluconolactonase [193]. 
Conversion of L-gulonate to L-gulonolactone is the penultimate step in the biosynthesis of L-
ascorbic acid, the final step being oxidation to ascorbic acid by L-gulonolactone oxidase [381]. It 
should be noted that the inactivity of the latter enzyme due to mutations that has led to inability 
of humans, guinea pigs and other species to synthesize vitamin C. In summary, regucalcin is 
thought to have a diverse role in proliferation, survival and differentiation of cells [176].  
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In a previous study, our laboratory found that β-catenin conditional knockout animals 
exhibited altered gene expression for many potential and known targets of β-catenin [94].  
Regucalcin was one of the genes that was most affected by the loss of β-catenin.   Based on this 
information, we hypothesized that regucalcin is a downstream target of β-catenin in the liver.  In 
order to establish the relationship between β-catenin and regucalcin in normal liver, we analyzed 
regucalcin expression in β-catenin conditional knockout mice, and in rats subjected to two-thirds 
partial hepatectomy.  We then expanded this initial characterization by examining human 
hepatocellular carcinoma tissues to determine the clinical significance of this relationship.  We 
also performed siRNA studies and immunoprecipitations to determine the biological function of 
regucalcin in liver.  Lastly, we addressed the role of regucalcin as a target of Wnt/β-catenin 
signaling in hepatocytes, which along with L-gulonolactone oxidase, plays an important role in 
vitamin C biosynthesis and also regulates cell survival. Thus, through these approaches, we 
demonstrate that regulation of SMP30 and L-gulonolactone oxidase expression by β-catenin 
contributes to a broader role of Wnt/β-catenin in liver homeostasis.  
3.3 MATERIALS AND METHODS 
3.3.1 Tissues, Animals, and Cell Lines 
A total of 19 human hepatocellular carcinomas from two different groups were used for 
this study.  The first group (Group 1), containing nine samples, was obtained from HCCs that 
had known β-catenin mutations; the second group (Group 2), containing ten samples, was 
obtained from HCCs where the β-catenin status is unknown.  Normal livers (from donor liver 
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tissue) were obtained from 4 cases.  Tissues from the first group were processed for mRNA 
analysis, whereas samples from the second group were processed for protein and 
immunohistochemistry. 
 Mouse models used in this study include a conditional β-catenin knockout described 
previously [94], and a stable β-catenin overexpressing transgenic mouse similar to one described 
previously [132].  For the conditional knockout, homozygous floxed β-catenin mice were bred to 
albumin-cre mice (both on a C57BL/6 background); the resulting mice, after another 
backcrossing to homozygous floxed β-catenin mice resulted in conditional null mice with the 
genotype Ctnnb1loxp/loxp; Alb-Cre+/− (referred to in this paper as knockout or KO mice) and 
controls with the genotype Ctnnb1loxp/loxp; Alb-Cre−/− or Ctnnb1loxp/Wt; Alb-Cre−/− (referred to in 
this paper as wild-type or WT mice).  The mice were sacrificed at 1, 3, and 6 months time points, 
and the livers were harvested for protein and immunohistochemistry.  The β-catenin TG mice 
(generated in an FVB background) show significantly elevated total β-catenin as compared to 
their wild-type littermates and were generated similar to the albumin/β-catenin transgenic mice 
characterized previously [132], except in this strain, β-catenin carries a point mutation at serine-
45 rendering it more stable overall, as discussed in the preceding chapter. 
 Rat liver tissue was obtained from partial hepatectomy studies, as previously described 
[94].  Frozen livers from partial hepatectomy studies were harvested for protein.   
For hydrodynamic delivery of naked DNA, 1 μg/gm of body weight of Wnt-1 plasmid 
(Millipore, Billerica, MA) or pcDNA3 control plasmid (Invitrogen, San Diego CA) was 
administered via hydrostatic tail vein injection to CD-1 mice weighing around 18 grams, as 
described previously and in the preceding chapter [53, 338]. Twenty-four hours after the 
injection, the mice were subjected to PHx. Mice were sacrificed at 30 hours after PHx and livers 
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were processed for total and nuclear protein.  Cytoplasmic and nuclear extracts were prepared 
using the NE-PER Nuclear and Cytoplasmic Extraction Reagents kit as per the instructions 
(Thermo Fisher Scientific, Rockford, IL).   
Hep3B and HepG2 human hepatoma cell lines described previously [382] were obtained 
from American Type Culture Collection (Manassas, VA) and cultured in EMEM (Cambrex, East 
Rutherford, NJ) with 10% FBS (Mediatech, Herndon, VA) in a humidity-saturated incubator 
with 5% CO2 maintained at 370C. 
3.3.2 mRNA Isolation and Real-Time PCR 
mRNA was isolated and purified from frozen livers using TRIzol (Invitrogen, Carlsbad, 
CA).   For RT-PCR, the RNA (from 4-7 month old WT and AFP/Alb/Ctnnb1 KO mice) was 
diluted to a working concentration of 1 μg/μl in nuclease-free water with the addition of RNase 
inhibitor followed by removal of potential contaminating DNA by treatment with DNase I 
(Promega, Madison, WI). Two μg total RNA was used for reverse transcription in a 20 μl 
reaction buffer with random primers and Superscript III (Invitrogen) to generate first-strand 
cDNA.  PCR was carried out using a standard PCR kit including Taq DNA polymerase 
(Invitrogen) with specific primer pairs and 1 μl cDNA.  The forward (F) and reverse (R) primers 
for mouse regucalcin and L-gulonolactone oxidase were selected using Primer Express software 
(PE Applied Biosystems) and produce a 413-bp product and a 681-bp product, respectively.  
Regucalcin (F): 5’-GAT GCC CCA GTC AGT TCA GT-3’; Regucalcin (R): 5’-ATT CTG CGG 
TTG GAA ATC TG-3’. L-gulonolactone oxidase (F): 5'-AAA ACT GGG CGA AGA CCT 
ATG-3'; (R): 5'-CCT TGT TGG TGT GAT CTT GGT-3'. β-actin primers were used as an 
internal control, (F): 5’- CAG CTG AGA GGG AAA TCG TG -3’; (R): 5’- CGT TGC CAA 
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TAG TGA TGA CC -3’ and produce a 150- bp product.  PCR amplification was carried out as 
follows: initial denaturation at 94°C for 2 m, followed by 35 cycles or 28 cycles of denaturation 
at 94°C for 1 m, annealing 55°C for 1 m; 72°C for 1 m, and 10 m of final extension at 72°C 
[383].  
For real-time PCR, following DNase treatment, mRNA was converted to cDNA using M-
MuLV reverse transcriptase enzyme (Invitrogen, Carlsbad, CA) in a reverse-transcription (RT) 
master mix containing random primers, 5× RT buffer, dNTP mix, RiboLock, and M-MuLV 
reverse transcriptase enzyme [53].   
Real-time PCR was performed as described previously [384].  TaqMan Gene Expression 
Assays for human regucalcin and β-actin were obtained from Applied Biosystems (Foster City, 
CA). The standard conditions used for real-time PCR were as follows: 50°C for 2 m and 95°C 
for 10 m followed by 40 cycles of 15 s denaturation at 95°C and 1 m annealing/elongation at 
60°C. TaqMan signal (Applied Biosystems, Foster City, CA) was measured in each step. The 96-
well plate contained a standard curve using normal human liver samples and β-actin primers. 
Changes in regucalcin mRNA were normalized to actin mRNA and presented as fold-change 
over the average from four normal livers.  Mean fold gene expression was calculated with 
Applied Biosystems software.  In hepatoma cell lines, the expression of regucalcin gene was 
calculated using the delta-delta CT method [385].  Each sample was run in duplicate.      
3.3.3 Protein Extraction, Immunoprecipitation, and Western Blots 
Whole-cell lysates from mouse livers, cell cultures, and human tumor tissues were 
prepared by homogenization using RIPA buffer (9.1 mmol/L dibasic sodium phosphate, 1.7 
mmol/L monobasic sodium phosphate, 150 mmol/L sodium chloride, 1% Nonidet P-40, 0.5% 
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sodium deoxycholate, 0.1% sodium dodecylsulfate [pH adjusted to 7.4]) containing fresh 
protease and phosphatase inhibitor cocktails (Sigma, St. Louis, MO) [386].  The concentation of 
the protein in the lysates was determined by the bicinchoninic acid assay using BSA as a 
standard. 
For immunoprecipitation studies, one thousand micrograms of cell lysate from HepG2 
and Hep3B cell lines (prepared in RIPA buffer in the presence of inhibitors) was precleared with 
the appropriate control IgG (either mouse or goat) together with Protein A/G agarose for 30 m at 
40C.  After centrifugation, the supernatants were incubated with either regucalcin/SMP30 
antibody or β-catenin antibody for 1 h at 40C, followed by overnight incubation with Protein A/G 
agarose at 40C.  Pellets were collected the next day, washed in PBS containing inhibitors, 
resuspended in loading buffer, and subjected to electrophoresis.  
Proteins were electrophoresed and blotted as described previously [49, 126].  Briefly, 50 
μg of protein from cell or liver lysate or 15-20 μl of eluate from IP studies was resolved on 7.5% 
or 12% precast SDS-PAGE gels (ISC BioExpress, Kaysville, UT) using the mini-PROTEIN 3-
electrophoresis module assembly (Biorad, Hercules, CA), followed by transfer to Immobilon-
PVDF membranes (Millipore, Bedford, MA).  Membranes were stained with Ponceau-S solution 
to confirm equal loading, then blocked in 5% nonfat dry milk in blotto solution (20mM TRIS-
HCl pH 7.5, 150 mM NaCl, 0.1% Tween 20), followed by incubation with primary antibody 
diluted in 5% milk/blotto for 1-2 h or overnight.  Membranes were washed and incubated in 
horseradish-peroxidase conjugated secondary antibodies (Chemicon, Temecula, CA) for 1 h 
followed by washing.  Proteins were detected by Super-Signal West Pico Chemiluminescent 
Substrate (Pierce, Rockford, IL) and visualized by autoradiography.  Primary antibodies used in 
this study were against regucalcin/SMP30 (K-18 used at 1:500; C-16 used at 1:150), β-catenin 
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(1:200), glutamine synthetase (1:500) (Santa Cruz Biotechnology, Santa Cruz, CA) and actin 
(1:5000) (Chemicon, Temecula, CA).  Secondary antibodies were goat anti-mouse (1:10,000), 
donkey anti-rabbit (1:10,000), and donkey anti-goat (1:2500) (Chemicon, Temecula, CA).  Blots 
were stripped with IgG elution buffer (Pierce, Pierce, Rockford, IL) for 30 m at room 
temperature before re-probing.  Densitometry analysis was performed using Image J version 
1.38. All experiments were performed in triplicates and representative results are shown. 
3.3.4 Immunohistochemistry and Immunofluorescence 
Immunohistochemistry on paraffin-embedded sections was performed on mouse livers 
and human tumors [387].  Tissues fixed in 10% formalin and embedded in paraffin were 
sectioned at 4 µm onto Superfrost Plus glass slides (Fisher Scientific, Pittsburgh, PA) and heat-
fixed overnight at 37°C.  Sections were microwaved in citrate buffer, pretreated with 3% H2O2 to 
eliminate endogenous peroxidases, and blocked using protein blocking agent (Thermo Scientific, 
Waltham, MA).  Primary antibodies used for this project were anti-β-catenin (1:200), anti-
SMP30 aka regucalcin (1:100), anti-glutamine synthetase (1:200) (Santa Cruz Biotechnology, 
Santa Cruz, CA), and anti-β-catenin (1:50) (BD Biosciences, San Diego, CA).  Secondary 
antibodies were biotinylated horse anti-mouse (Vector Laboratories, Inc., Burlingame, CA), goat 
anti-rabbit, and donkey anti-goat (Chemicon, Temecula, CA), all used at a 1:500 dilution.  
Immunohistochemistry was performed using the Vectastain ABC Elite kit (Vector Laboratories, 
Inc., Burlingame, CA) and developed using either DAB (Vector Laboratories, Inc., Burlingame, 
CA) or AEC substrate (Scytek Laboratories, Logan, UT).  The slides were counterstained with 
aqueous Gill’s hematoxylin and mounted with either crystal mount or cytoseal (Biomeda Corp., 
Foster City, CA).  For β-catenin, GS and regucalcin expression in HCCs, each sample was 
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allocated an arbitrary IHC score on the basis of the intensity of the expression of β-catenin, GS 
and regucalcin in the nucleus and/or cytosol as compared to the normal liver samples. Each stain 
was scored as – (absent staining), + (positive, similar to normal) and ++ (strongly positive or 
greater than normal).  For β-catenin IHC, even a subset of HCC cells showing nuclear and/or 
cytoplasmic localization were assigned a positive score. 
Coverslips plated with either HepG2 or Hep3B hepatoma cell lines were processed for 
immunofluorescence as previously described [388].  Cells were washed with PBS, fixed in cold 
2% paraformaldehyde in PBS for 15 m, and permeabilized in 0.1% Triton-X-100 in PBS for 10 
m.  Coverslips were then washed five times each in PBS and 1% BSA in PBS, and blocked for 1 
h in 5% normal donkey serum in 1% BSA/PBS.   Primary antibodies against β-catenin (1:100) 
and anti-SMP30 aka regucalcin (1:100) (Santa Cruz Biotechnology, Santa Cruz, CA) were 
diluted in 1% BSA/PBS, added to the coverslips, and incubated overnight.  Cells were washed 
five times in 1% BSA/PBS, then incubated for 1 h with secondary antibodies diluted in 1% 
BSA/PBS.  Secondaries used for this project were donkey anti-goat Alexa 488 and donkey anti-
mouse Cy3 at either a 1:500 or a 1:1000 dilution (Molecular Probes, Eugene, OR).  Following 
five washes in 1% BSA/PBS and then PBS, coverslips were incubated with Hoescht counterstain 
(30 s), washed with PBS, and mounted on slides.  All fluorescence labeling was imaged under 
Zeiss Axiovert 40 CFL microscopy (Carl Zeiss, Thornwood, NY) and photographs obtained 
using a Zeiss Axiocam MRC5 digital camera. 
3.3.5 Primary Hepatocyte Culture  
 
 71 
Hepatocytes from β-catenin KO mice were isolated using a modified 2-step collagenase 
perfusion protocol as previously described and seeded on chamber slides wet-coated with 
collagen at a density of 100,000 cells per ml in minimal essential media (MEM) supplemented 
with 10% fetal bovine serum (FBS) [335].  After 2 hours, media were changed to a chemically 
defined MEM-based growth medium containing insulin/transferrin/selenium (ITS; 1g/L), 
dexamethasone (10-7M), HGF (40ng/ml), and epidermal growth factor (EGF; 25ng/ml) as 
described elsewhere [337]. The cells were cultured for 48 h in the presence or absence of 
ascorbic acid at a final concentration of 0.2 mM [389]. The apoptotic nuclei were detected by 
terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining using 
the ApopTag Peroxidase kit (Intergen Company, Purchase, NY) as previously described [89]. 
The numbers of positive cells per field were counted, for a total of 5 fields per condition. 
Rat hepatocytes were isolated and plated as discussed elsewhere [337].  After 2 hours, 
plating media were replaced with basal medium, and either 5ng/ml recombinant mouse Wnt3a 
(R&D Systems, Minneapolis, MN) or PBS.  Plates were harvested for nuclear protein 24 h after 
treatment.  Nuclear extracts were prepared using the NE-PER Nuclear and Cytoplasmic 
Extraction Reagents kit as per the instructions (Thermo Fisher Scientific, Rockford, IL).   
3.3.6 Transfection of siRNA  
 Hep3B and HepG2 human hepatoma cell lines were seeded onto either 100-mm 
dishes or 6-well plates and maintained until the cells reached 50-60% confluence in EMEM 
(ATCC, Manassas, VA) with 10% FBS.  Two independent siRNA’s were utilized for 
transfection. Cells were transfected with siRNA purchased from either Dharmacon (Lafayette, 
CO) or Applied Biosystems (Foster City, CA).  100nM of control siRNA or siRNA against 
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human regucalcin mRNA from Dharmacon was transfected into cells using Oligofectamine 
transfection reagent (Invitrogen, Carlsbad, CA) in the absence of serum for 4 h.  After incubation 
with siRNA, EMEM with 10% FBS was added to the cells without removal of the siRNA 
mixture.  Media were changed 24 h after transfection, and fresh EMEM with 10% FBS was 
added.  Plates were harvested for protein 48 h after addition of siRNA.  Cells were transfected 
with 5nM of either control siRNA or siRNA against human regucalcin mRNA from Applied 
Biosystems using Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA) in the 
presence of serum.  Media were changed 24 h after transfection, and fresh EMEM with 10% FBS 
was added.  Plates were harvested for protein and RNA 48 h after addition of siRNA.   
3.3.7 Cell Growth and Viability Assays  
A [3H]thymidine uptake assay was utilized as previously described to measure cell 
proliferation [340, 341].  Briefly, Hep3B and HepG2 human hepatoma cell lines transfected with 
control or human regucalcin siRNA were dosed with 2.5 µCi/ml of [3H]thymidine (MP 
Biomedicals, Solon, OH) 24 h before harvesting and incubated at 37°C in 5% CO2. The cells 
were harvested by adding 1.5 ml of cold 5% (w/v) trichloroacetic acid to each well. The plates 
were placed at 4°C for 2 h and then were washed and allowed to air-dry. The precipitate was 
solubilized by the addition of 1 ml of 0.33 M NaOH, and an aliquot was added to Universol (MP 
Biomedicals, Solon, OH). The counts/min of the solubilized precipitates were determined with a 
scintillation counter (Beckman Instruments, Palo Alto, CA).  Plates were harvested 48 h after 
addition of siRNA.   
HepG2 cells cultured on chamber slides were dosed with either control or human 
regucalcin siRNA in the presence or absence of ascorbic acid at 0.2 mM final concentration or in 
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the presence or absence of N-acetylcysteine (NAC) at 20mM final concentration in 10XPBS as 
reported elsewhere [389, 390].   48 h after treatment, slides were fixed in a 3:1 solution of 
methanol/glacial acetic acid for 5 m and allowed to air-dry.  Slides were processed for TUNEL 
analysis as described in the previous section. 
Assays were done in triplicates and statistical assessment for significance was performed 
by the Student’s t-test.  A P value of less than 0.05 was considered significant. 
3.3.8 Ascorbate and Lipid Peroxidation Assays 
Fresh whole blood from age- and sex-matched WT and β-catenin KO mice (n=3) was 
obtained through retro-orbital bleeding and centrifuged at 4,000 rpm for 10 minutes to obtain 
serum.  Serum was utilized to determine ascorbate levels with the Ascorbic Acid Assay Kit II 
(FRASC) Kit (Bio-Vision, Mountain View, CA) according to the manufacturer’s instructions. 
 
3.4 RESULTS 
3.4.1 Regucalcin protein expression correlates with β-catenin expression  
Livers from 1, 3, and 6 months old wild-type (WT) and β-catenin conditional knockout 
(KO) mice were used for isolation of protein and IHC.  Deletion of β-catenin leads to a decreased 
expression of regucalcin protein in the KO livers at 3 and 6 months as compared to the WT and 
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coincides with loxP recombination driven by albumin-cre recombinase [391] (Figure 10A).  This 
result correlates with the absence of regucalcin mRNA in the KOs as shown in Figure 2. 
 
Figure 10: Regucalcin expression is regulated by β-catenin in the liver. (A) Western blot using whole cell lysates 
from WT and KO livers show regucalcin is present in all WT samples but is decreased at 3 and 6 months in the KO 
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mice. (B) Representative immunohistochemistry for regucalcin on 3-month old WT and KO livers (top four panels) 
shows cytoplasmic and nuclear expression of regucalcin protein in WT hepatocytes; in contrast, regucalcin 
expression was dramatically decreased in KO livers. PT-portal triad; CV-central vein.  (C) Immunohistochemistry 
for regucalcin on 3-month old WT and stable-β-catenin overexpressing transgenic mice (bottom four panels) shows 
centrizonal regucalcin staining in WT FVB livers, whereas the transgenic livers show widespread nuclear and 
cytoplasmic regucalcin. PT-portal triad; CV-central vein. 
 
IHC detected regucalcin protein in the nucleus and cytosol of WT hepatocytes (C57BL/6) 
in all zones, with a clear accentuation in centrizonal and sometimes midzonal areas (Figure 10B). 
However this expression was markedly diminished in the KO livers with only a few cells around 
the central vein showing leftover positivity for regucalcin (Figure 10B).  Conversely, low levels 
of nuclear and cytoplasmic regucalcin were observed in normal FVB hepatocytes, and where 
regucalcin was clearly less pronounced than normal WT livers of C57BL/6 mice, it was mostly 
localized to centrizonal areas only and absent periportally (Figure 10C). However a noteworthy 
widening of regucalcin localization was observed around the centrizonal areas in β-catenin 
overexpressing transgenic (TG) livers with continued periportal sparing (Figure 10C). Thus 
regucalcin expression mimicked β-catenin levels in murine livers. 
3.4.2 Regucalcin levels correlate with β-catenin target glutamine synthetase in the rat 
partial hepatectomy model  
Previously, our lab has shown temporal changes in β-catenin expression during liver 
regeneration in rats after partial hepatectomy (PHx) [126]. A transient increase in β-catenin 
protein was accompanied by its nuclear translocation for up to 48 hrs after partial hepatectomy. 
We used this model of liver regeneration to determine if regucalcin expression correlated with 
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levels of glutamine synthetase, a known target of β-catenin [34]. Figure 11A shows an increase 
in regucalcin protein expression in the rat as early as 1 h following partial hepatectomy.  
Regucalcin then decreases at 12 h, but rises again at D1 post-PHx, suggesting a cyclic regulation 
of expression. This pattern coincides with glutamine synthetase during liver regeneration, 
although the protein levels of GS changed only marginally, and thus supports regulation of 
regucalcin by β-catenin in this model of liver growth.     
3.4.3 Human hepatocellular carcinomas have increased levels of regucalcin compared to 
normal liver 
Next, we examined human hepatocellular carcinomas for regucalcin expression in 
relation to β-catenin status.  The two different groups used in the study are described in the 
Methods. We hypothesized that the samples containing known β-catenin mutations would have 
higher levels of regucalcin mRNA expression.  Figure 11B shows the results of a representative 
real-time PCR reaction using mRNA from HCCs with mutations in exon-3 of β-catenin gene. 
Group 1 HCC samples with known activating mutations in β-catenin gene [339] showed a 40-
1000-fold increase in regucalcin gene expression as compared to the normal livers (Figure 11B).  
Next, paraffin tissues from group 2 HCC patients, where the β-catenin mutational status 
was unknown, were assessed for β-catenin, glutamine synthetase and regucalcin expression by 
IHC. We hypothesized that if we could determine the relative expression of β-catenin in these 
samples, we could establish a correlation between increases in β-catenin expression and an 
increase in regucalcin expression.  Each tumor sample was allocated an arbitrary 
immunohistochemical score on the basis of the expression of β-catenin, GS and regucalcin in the 
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nucleus and/or cytosol (Figure 11C).   Based on the IHC, normal human liver received a score of 
(-) for β-catenin in the nucleus and cytosol, and + for GS and regucalcin. As shown in 
representative HCC samples, increased cytoplasmic and nuclear β-catenin coincided with 
elevated GS and regucalcin staining in adjacent serial sections (Figure 11C). Overall, 9/10 HCC 
tissues exhibited some nuclear/cytoplasmic β-catenin in additional to its membranous 
localization, and 7/9 of these samples showed increased regucalcin, of which 6 also showed a 
concomitant increase in GS (Figure 11D). A small subset (T5 and T8) showed no evidence of 
increased GS or regucalcin despite exhibiting intense nuclear β-catenin staining.  
3.4.4 Exogenous Wnt stimulation induces regucalcin expression in vitro and in vivo 
Next, we investigated if exogenous Wnt stimulation had an effect on regucalcin protein 
expression.  Rat primary hepatocytes were cultured in the presence of recombinant Wnt3a 
protein as described in the Methods.  As expected, there was a significant increase in nuclear β-
catenin in response to 24 h of Wnt3a treatment. There was also a corresponding increase in 
nuclear regucalcin levels after Wnt3a treatment (Figure 11E). 
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 Figure 11: Regucalcin protein expression correlates with β-catenin activation during liver regeneration, in 
HCC and after exogenous Wnt administration.  (A) Western blot with lysates from rat livers harvested at various 
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time points after partial hepatectomy display concomitant increase in regucalcin and known β-catenin target-GS 
expression at 1h, 6h and D1 during regeneration.  (B) Real-time PCR analysis of mRNA harvested from human 
HCCs with known β-catenin mutations (Group 1) shows many fold increase in regucalcin mRNA expression, which 
was plotted for each tumor. Regucalcin mRNA expression was standardized to actin expression in each sample and 
normalized to average signal in four normal livers.  (C) Immunohistochemistry for β-catenin, regucalcin, and GS on 
representative human HCCs where the mutational status of β-catenin is unknown (Group 2).  Areas of increased β-
catenin staining in the nucleus and cytoplasm often correlated to areas of high regucalcin and GS expression. (D) 
Arbitrary scoring of relative amounts of β-catenin, regucalcin, and GS in human HCCs with unknown mutational 
status of β-catenin (Group 2).  Each tumor sample was given arbitrary immunohistochemical scores of (+) or (-) for 
presence or absence of nuclear and/or cytoplasmic β-catenin in hepatocytes.  Regucalcin and GS samples were 
scored based on a comparison to the normal liver tissue; an increase above normal scored (++) or a level of 
expression similar to normal (+).  Most biopsies that showed nuclear/cytoplasmic β-catenin also showed elevated 
levels of regucalcin and/or GS.  (E) Western blot analysis utilizing nuclear fractions from rat hepatocytes cultured in 
the presence of Wnt3a or PBS for 24 hours shows an increase in β-catenin and regucalcin expression in Wnt3a-
treated cultures only. Lamin B1 represents the loading control.  (F) Western blot utilizing nuclear and cytoplasmic 
extracts from livers of two representative Wnt-1- or pcDNA3 (Con)-injected mice shows an increase in nuclear β-
catenin and nuclear and cytoplasmic regucalcin expression in the experimental group.  
 
As described in the previous chapter, we have previously employed hydrodynamic 
delivery of naked DNA as a means to induce expression of a gene in the liver [53]. Here, we 
utilized this approach to induce Wnt-1 expression in the liver after partial hepatectomy, as 
outlined in the Methods. An increase in the hepatic nuclear β-catenin level was observed in the 
Wnt-1- and not pcDNA3-injected mice (Figure 11F). A modest increase in levels of hepatic 
nuclear and cytosolic regucalcin accompanied the increased β-catenin expression in the Wnt-1-
injected group as well (Figure 11F). Thus, Wnt/β-catenin activation induces regucalcin 
expression in vitro and in vivo, in both rat and mouse hepatocytes.  
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3.4.5 Association of regucalcin and β-catenin in human hepatoma cell lines 
We next examined the human hepatoma cell lines Hep3B, which contains the wild-type 
β-catenin gene, and HepG2, which contains the β-catenin gene with a deletion in exon-3 
rendering it non-degradable, for expression and functional analysis of regucalcin in liver biology 
[366].  Western blots demonstrate higher levels of regucalcin protein in HepG2 cells as 
compared to Hep3B cells (Figure 12A).  This result was also confirmed by real-time PCR, which 
showed higher mRNA expression of regucalcin in HepG2 cells than in Hep3B cells (Figure 
12B).  Finally, immunofluorescence studies were concordant with the above results, with HepG2 
cells displaying higher levels of regucalcin in the cytosol than Hep3B cells (Figure 12C). 
Interestingly, when cells were stained with both regucalcin and β-catenin, there appeared to be 
areas of signal co-localization in both cell lines, which was greater in HepG2 than in Hep3B cells 
(Figure 12C). 
To determine whether this colocalization of β-catenin and regucalcin in HepG2 
represented a physical association between the two proteins, we immunoprecipitated protein 
lysates from both HepG2 and Hep3B cells with regucalcin/SMP30 antibody and probed the blots 
for β-catenin and vice versa.  Figure 12D shows coprecipitation of β-catenin and regucalcin in 
both HepG2 and Hep3B cells, although HepG2 cells show a stronger association. Also, 
following immunoprecipitation utilizing HepG2 cells, it was apparent that regucalcin associates 
with both the truncated (predominant species) and full-length form of β-catenin (minor species). 
Lysates incubated with normal IgGs instead of β-catenin or regucalcin antibodies did not pull 
down protein in either preparation (Figure 12D and data not shown).  Thus, in addition to 
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regucalcin being a direct target of β-catenin signaling, these data demonstrate physical 
interactions between β-catenin and regucalcin. 
 
Figure 12: Regucalcin, which is expressed in both Hep3B cells and HepG2 cells, also associates with β-catenin 
in the cell. (A) Western blot of proteins harvested from HepG2 and Hep3B human hepatoma cell lines shows that 
HepG2 cells express higher levels of regucalcin than Hep3B cells. Western blot for actin serves as the loading 
control.  (B) Real-time PCR analysis of mRNA harvested from HepG2 and Hep3B human hepatoma cell lines.  
Regucalcin mRNA expression was 6-fold higher in Hep3B cells but more than 200-fold higher in HepG2 cells as 
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compared to average of normal human livers. Regucalcin mRNA expression was standardized to actin expression.  
(C) Immunofluorescence on cultured HepG2 and Hep3B cells demonstrates higher regucalcin (green) and β-catenin 
(red) in HepG2 cells than Hep3B cells. Also, as seen in bottom panels, colocalization (white arrows) of β-catenin 
and regucalcin was evident especially in HepG2 cells. Images were taken at 600X magnification.  (D) HepG2 and 
Hep3B cell lysates immunoprecipitated with β-catenin antibody and probed for regucalcin (top) show association of 
the two proteins. Non-specific IgG (N) did not pull down regucalcin. Similar lysates immunoprecipitated with 
regucalcin (SMP30) antibody and probed for β-catenin also show association of full length β-catenin with regucalcin 
in both cell types and truncated β-catenin-regucalcin association in HepG2 cells. Successful pulldown of β-catenin 
and regucalcin by their antibodies is verified in respective lower panels. 
3.4.6 Regucalcin exerts a prominent effect on cell survival  
Next, we attempted to address the biological role of regucalcin in liver.  Since HepG2 
cells exhibit higher levels of regucalcin, we investigated the effect of regucalcin inhibition on 
cell proliferation and survival in this cell line.  HepG2 cells were cultured and treated with 
control and regucalcin siRNA constructs as outlined in the Methods.  We found a 50-80% 
decrease in regucalcin mRNA expression over multiple experiments as shown in a representative 
real-time PCR, at 48 h after regucalcin siRNA-transfection (Figure 13A). This also coincided 
with decreased regucalcin protein production (Figure 13B).   
Next, we measured the impact of regucalcin knockdown on cell proliferation by 
[3H]thymidine incorporation.  No significant difference in [3H]thymidine incorporation was 
observed in HepG2 cells following regucalcin siRNA-transfection (Figure 13C).  Although we 
were aware of the lower expression of regucalcin in Hep3B cells, we also examined the impact 
of regucalcin siRNA on proliferation in this cell line.  Interestingly a marginal but significant and 
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consistent reduction in thymidine incorporation was observed following regucalcin siRNA 
transfection in Hep3B cells (Figure 13D).  
 
Figure 13: Regucalcin knockdown using siRNA affects survival of hepatoma cells.  (A) Regucalcin siRNA 
decreases mRNA expression in hepatoma cells as shown in representative real-time PCR analysis of mRNA 
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harvested from HepG2 cells.  The 2deltaCt of regucalcin mRNA was plotted for each cell line.  In this representative 
plot, siRNA decreases regucalcin expression in HepG2 cells by 60% as compared to cells transfected with control 
siRNA.  Regucalcin mRNA expression was standardized to actin expression.  (B) A comparable decrease in 
regucalcin protein was also observed as shown in a representative western blot using lysates from Hep3B cells. 
Ponceau red staining verifies comparable loading in the western blot. Bottom panel is the plot for normalized 
integrated optical density from densitometric analysis of a representative western blot.  (C) Unremarkable 
differences in thymidine uptake assay by control or regucalcin siRNA-transfected HepG2 cells. (D) A small but 
significant (p<0.05) decrease in thymidine uptake by regucalcin-transfected Hep3B cells as compared to control 
siRNA-transfected cells. (E) A greater than 2-fold increase in the numbers of TUNEL-positive apoptotic nuclei in 
regucalcin siRNA-transfected HepG2 cells as compared to control siRNA-transfected HepG2 cells.  (F) Increased 
numbers of TUNEL positive apoptotic nuclei (arrowhead) are observed after regucalcin (right panel) and not control 
(left panel) siRNA transfection of HepG2 cells by representative immunohistochemistry.  Images were taken at 
200X magnification. 
 
We then examined the effect of regucalcin suppression on cell survival in the HepG2 
cells by TUNEL analysis. Transfection with regucalcin siRNA and not control siRNA led to a 
significant increase in the numbers of apoptotic nuclei in these cells (Figure 13E-F).  Thus 
regucalcin seems to play an important role in cell survival in hepatoma cells. 
3.4.7 β-Catenin regulates vitamin C synthesis through regulation of regucalcin expression 
 Regucalcin/SMP30 is an essential gluconolactonase in the liver and plays a pivotal role 
in regulating ascorbate biosynthesis [193].  Since SMP30 knockout mice fed a vitamin C-
deficient diet have been shown to develop scurvy due to decreased levels of ascorbate, we 
investigated whether the β-catenin KO mice, which have decreased expression of 
regucalcin/SMP30, are also deficient in ascorbate production since these mice were being fed 
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normal mouse chow (Prolab Isopro RMH 3000), which lacks vitamin C.  This became more 
relevant when gene array analysis of β-catenin-deficient livers also identified a significant 
decrease in the expression of L-gulonolactone oxidase, which is the final and rate-limiting step in 
ascorbic acid biosynthesis (Table 2).  This decrease was also verified by RT-PCR (Figure 14A). 
Next, serum from WT and β-catenin KO animals was tested for ascorbate content (n=3).  A 3.5-
fold reduction in serum ascorbate levels was observed in β-catenin KO mice as compared to the 
WT littermates (Figure 14B).  Therefore, β-catenin, through its role as a mediator of regucalcin 
and L-gulonolactone oxidase expression, plays an important role in regulating ascorbate levels. 
3.4.8 Enhanced apoptosis of β-catenin-deficient hepatocytes is rescued by vitamin C 
supplementation 
Since we previously reported a basal increase in the hepatocyte apoptotic index in β-
catenin-conditional null mice, and an even greater increase in apoptosis during liver 
regeneration, we were interested to investigate if this could be contributed by regucalcin loss 
[94]. We cultured primary hepatocytes from β-catenin conditional null mice for 48 h. Greater 
than 90% of hepatocytes showed significant loss of viability resulting from apoptosis as shown 
by phase-contrast microscopy and TUNEL immunohistochemistry (Figure 14C-D). When β-
catenin null hepatocytes were cultured in the presence of ascorbate, a dramatic and almost 100% 
rescue of cell viability was evident as reflected by negligible apoptosis assayed by TUNEL 
staining (Figure 14C-D).  
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3.4.9 Apoptosis in HepG2 cells due to regucalcin knockdown is rescued by vitamin C and 
NAC 
Next, we wanted to explore if similar to mouse hepatocytes, apoptosis of HepG2 cells 
following regucalcin knockdown could be rescued by vitamin C. As expected and shown earlier 
(Figure 13E-F), a significant increase in apoptosis was evident in HepG2 cells 48 h after 
transfection of regucalcin and not control siRNA (Figure 14E).  However, the presence of 
vitamin C in culture media led to a near-complete amelioration of the apoptosis brought about by 
regucalcin knockdown (Figure 14E).   
It was interesting to note that ascorbic acid repletion led to the rescue of cell survival 
following siRNA-mediated regucalcin knockdown. Since human cells lack L-gulonolactone 
oxidase and are unable to synthesize vitamin C, we wondered if the rescue effect of ascorbate 
was specific to vitamin C deficiency brought about by regucalcin knockdown or through the 
general anti-oxidant effect of vitamin C [381]. To test this hypothesis, we utilized N-
acetylcysteine (NAC), another well-known anti-oxidant, to determine its effect on regucalcin-
siRNA mediated apoptosis of HepG2 cells [390]. A significant decrease in apoptosis was evident 
in NAC-treated HepG2 cells secondary to regucalcin knockdown (Figure 14F). These 
observations suggest that regucalcin might be important in cell survival in humans through 
regulation of oxidative stress, which may be independent of vitamin C biosynthetic function 
(Figure 15). 
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 Figure 14: Decreased regucalcin expression in the absence of β-catenin negatively affects ascorbate levels and 
cell survival. (A) RT-PCR identified a dramatic decrease in L-gulonolactone oxidase expression in β-catenin-
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deficient livers as compared to the WT livers. (B) A greater than 3-fold decrease in serum ascorbate levels was 
evident in the β-catenin KO mice (n=3) as compared to the WT littermates and the difference is statistically 
significant (**p<0.001). (C) β-Catenin-deficient hepatocytes (KO) exhibit loss of viability after 48 h in culture as 
shown by phase contrast microscopy (upper left panel) and increased TUNEL-positive nuclei (bottom left panel). 
Inclusion of vitamin C in the culture prevented loss of hepatocyte viability (upper right) along with a dramatic 
decrease in the TUNEL-positive hepatocytes (lower right). (D) Quantitative analysis of TUNEL 
immunohistochemistry identifies an extremely significant decrease in apoptosis in KO hepatocytes in the presence 
of vitamin C (p<0.0001). (E) Regucalcin siRNA induces significant apoptosis in HepG2 cells over the control-
siRNA-transfected cultures (p=0.01). Addition of 0.2mM ascorbic acid significantly reduces apoptosis observed in 
response to regucalcin knockdown only (p=0.005) and does not impact the basal apoptosis in control siRNA treated 
HepG2 cells. (F) A similar rescue of apoptosis in HepG2 cells brought about by regucalcin knockdown is observed 
in the presence of 20mM of NAC (p=0.01). 
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 Figure 15: Regucalcin regulates oxidative stress and apoptosis in β-catenin conditional KO mice and in 
HepG2 cells.  In the absence of β-catenin, both regucalcin and L-gulonolactone oxidase (L-gulo) expression is 
decreased in hepatocytes.  This leads to a deficiency in ascorbate production, resulting in increased oxidative stress 
and apoptosis, which can be rescued by the addition of ascorbate to the culture media.  The HepG2 human hepatoma 
cell line contains a mutated consitutively activated form of β-catenin and consequently has increased levels of 
regucalcin and (presumably) L-gulo expression.  However, when HepG2 cells are treated with regucalcin siRNA, a 
modest but significant increase in both oxidative stress and apoptosis is observed, which can be rescued by the 
addition of anti-oxidants to the culture media.  
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3.5 DISCUSSION 
β-catenin is the crucial downstream effector of the canonical Wnt pathway, and plays 
many roles in development and adult tissue homeostasis in various organs. Since it is a 
transcriptional co-activator, it is critical to identify the target genes that in turn are responsible 
for the pleiotropic roles of the pathway in diverse cellular and tissue processes.  β-catenin has 
critical roles in regulating cell proliferation, differentiation, apoptosis, and adhesion in the liver, 
which in turn makes it relevant in liver development, regeneration, zonation, metabolism and 
cancer [34, 96, 124, 331, 392]. In the current study, we establish regucalcin as a novel target of 
β-catenin in the liver. Furthermore, we identified an important role of β-catenin in vitamin C 
biosynthesis and cell survival through the regulation of regucalcin and L-gulonolactone oxidase 
expression.  
The first evidence of regulation of regucalcin/SMP30 by β-catenin came from the gene 
array analysis using livers from β-catenin conditional KO and wild-type littermates [94]. This 
was directly investigated in the current study, which showed that decrease in regucalcin 
correlated with β-catenin loss in KO livers.  Similarly, β-catenin TG mice, which display 
elevated levels of β-catenin, also showed elevated levels of regucalcin protein in the nucleus and 
cytosol of hepatocytes as compared to controls.  It is important to highlight the observed 
difference in regucalcin during steady state in the adult livers between the two wild-type samples 
that belonged to C57BL/6 and FVB strains. Clearly, a wider regucalcin expression in all zones 
was observed in C57BL/6 livers although it was more pronounced around central veins, as 
compared to the FVB livers, which showed a narrow centrizonal regucalcin expression only. 
This coincides with β-catenin signaling that is typically limited to centrizonal areas in normal 
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adult livers [124]. Strain-specific differences in the basal regucalcin expression adds to the 
category of a growing list of genes and proteins that exhibit such phenomena and might 
eventually be the basis of diverse responses or phenotypes observed in response to a similar 
stimuli [393]. 
To further reaffirm the regulation of SMP30 by β-catenin we examined a series of models 
that are known to exhibit β-catenin activation. Results of the liver regeneration studies show an 
increase in regucalcin protein expression as early as 1h after partial hepatectomy in the rat.  This 
expression remains increased over T0 (with the exception of 12h post-PHx) until approximately 
D3.  This expression corresponds to that of β-catenin during liver regeneration after partial 
hepatectomy, where nuclear translocation of β-catenin is observed within 5 min after 
hepatectomy and is retained in the hepatocyte nucleus until around 48h [126].  Moreover, 
regucalcin expression mirrored the expression pattern of GS, a known target of β-catenin, during 
liver regeneration [34]. Others have found that liver regucalcin mRNA levels are clearly 
increased 1-5 days after hepatectomy, in comparison with that of sham-operated rats [177].  
Human hepatocellular carcinomas containing activating β-catenin mutations were also 
investigated for regucalcin expression, which was clearly elevated in these samples [339]. 
Similarly, those tumors with unknown β-catenin gene mutation status, but exhibiting β-catenin 
staining in the nucleus and/or cytosol, also showed an increase in both regucalcin and GS 
expression. Finally, we were interested to examine any impact of exogenous Wnt stimulation on 
regucalcin expression. Indeed, treatment of rat hepatocytes with Wnt3a induced β-catenin 
nuclear translocation as well as regucalcin expression. In an in vivo mouse study, we successfully 
delivered Wnt-1 plasmid DNA hydrodynamically through the tail vein [53], followed by partial 
hepatectomy, and harvested livers at 30 h. This led to an increase in nuclear β-catenin and 
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regucalcin expression in the livers of Wnt-1-injected and not pcDNA-injected mice. Thus, higher 
regucalcin levels are observed in the event of Wnt/β-catenin activation in mice, rats, and HCC 
patients.  It has been previously suggested that regucalcin may function as an inhibitor of 
proliferation during liver regeneration in rats.  Thus the role of regucalcin in cell proliferation 
will need to be investigated further as a primary or perhaps a secondary event due to its ability to 
regulate cell viability. 
It was interesting to note that not only was the expression of regucalcin regulated by β-
catenin, but that it associated with β-catenin in Hep3B and HepG2 cells, as well as in resting 
wild-type mouse livers (data not shown). This is not unusual in Wnt signaling since several 
regulators of the pathway are in fact transcriptional targets of β-catenin/TCF4, including TCF-1 
[29], Axin-2 [394] and DKK1 [395].  Whether regucalcin itself is able to have an impact on Wnt 
signaling remains under investigation. 
An important role of regucalcin has been reported in vitamin C biosynthesis [193]. 
Indeed β-catenin KO mice show significantly lower ascorbate levels secondary to decreased 
expression of both regucalcin and L-gulonolactone oxidase, both critical in vitamin C synthesis 
in murine hepatocytes [381]. It is also relevant to note that β-catenin KO livers show an increase 
in basal hepatocyte apoptosis, which is aggravated during liver regeneration [94]. To 
demonstrate a direct role of β-catenin in regulating apoptosis through vitamin C homeostasis, we 
cultured hepatocytes from β-catenin KO mice. These cells displayed massive apoptosis within 48 
hours of culture. When cultured in the presence of vitamin C, there was a complete rescue of 
apoptosis of the β-catenin-deficient hepatocytes. This is in agreement with previous studies 
where regucalcin overexpression has been shown to suppress cell death [189]. Our results are 
also concordant with previous studies where mice containing a germline null mutation of SMP30 
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have been shown to be highly susceptible to both TNF-α and Fas-mediated apoptosis, thereby 
indicating that SMP30 plays a role in protection from apoptosis and contributes to cell survival 
[191, 192]. 
A significant increase in apoptosis was also evident following regucalcin suppression in 
HepG2 cells, although the increase in apoptosis was not nearly as pronounced as in the murine 
hepatocytes. Moreover, the apoptosis in regucalcin siRNA-transfected hepatoma cells was 
rescued by supplementation with ascorbic acid or NAC. Since both molecules possess strong 
anti-oxidant properties, these results suggest that decreased regucalcin in human hepatoma cells 
might be inducing cell death through oxidative stress.  Thus, regucalcin may be regulating cell 
survival through regulation of redox state of the cell and independent of vitamin C biosynthesis 
in human cells.  However, in murine cells, regucalcin might be regulating cell survival through 
distinct, yet unexplored apoptotic pathways as well as through control of oxidative stress, and 
both might be significantly contributed by its role in vitamin C biosynthesis.  In fact, previous 
publications from our lab have documented increased oxidative stress and apoptosis in prenatal 
β-catenin KO livers [96], MCD-induced liver injury [396], and in adult livers from β-catenin 
conditional KOs [94, 397].  Altogether, these studies suggest that one mechanism by which β-
catenin might be promoting cell survival is through regulation of regucalcin expression.   
 94 
4.0  BETA-CATENIN KNOCKOUT MICE ARE PROTECTED FROM TNF-ALPHA 
MEDIATED APOPTOSIS 
4.1 ABSTRACT 
Wnt/β-catenin signaling plays an important role in hepatic homeostasis.  Loss of β-
catenin signaling in hepatocyte-specific conditional knockout (KO) mice led to a basal increase 
in the number of apoptotic hepatocytes.  Additionally, β-catenin loss during liver development or 
in hepatoma cells often manifests as enhanced cell death. Knowing the role of TNF-α in 
regulating cell death, we explored the susceptibility of KO and their wildtype littermate controls 
(WT) to intraperitoneal (i.p.) injection of lipopolysaccharide (LPS) or TNF-α after D-
galactosamine (GalN) or actinomycin D (ActD) pre-treatment. Paradoxically, KO mice are 
refractory to GalN/LPS, ActD/LPS and GalN/TNF-α and showed significantly lower morbidity 
than the WT animals. Furthermore, gross and histological examination of KO livers verified a 
dramatically lower injury than in the WT.  Analysis of liver enzymes, TUNEL staining and 
caspase activity confirmed the presence of massive hepatic injury in the WT but not in the KO. 
To determine the possible mechanism of protection from TNF-α-induced injury, we analyzed the 
anti-apoptotic transcription factor NF-κB.  Levels of NF-κB (p65 and p50) were elevated in the 
KO along with its downstream targets as compared to WT that show lack thereof. We also 
observed a basal increase in NF-κB signaling in KO reflected by elevated phosphoserine-536-
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p65, along with greater expression of targets such as Fas and Traf-1. We next addressed the 
mechanism of basal increase in NF-κB activation, which may be responsible for protection 
against TNF-α injury in KO.  Higher expression of TLR4, a receptor for LPS that is normally 
present in portal circulation, was observed in KO livers.  Increased numbers of CD45+ve 
inflammatory cells that are a source of cytokines such as TNF-α and IL-6 were also evident in 
KO livers along with higher expression of several TNF-α-induced gene transcripts. In addition, 
p65-β-catenin association which has been shown to prevent NF-κB activation was lacking in KO 
hepatocytes. Phosphorylated p65 is seen in the nucleus as early as 1 hour after LPS 
administration in KOs but not in WTs, suggesting that the absence of β-catenin lowers the 
threshold of NF-κB activation by facilitating p65 nuclear translocation.  Thus, we observed a 
paradoxical protection from TNF-α-mediated apoptosis in β-catenin conditional KO animals 
owing to preexisting priming of the liver through NF-κB activation which is due to multiple 
mechanisms.  Therefore, β-catenin through its interactions with NF-κB may be an important 
component of balancing hepatocyte life and death and therefore regulating liver homeostasis. 
4.2 INTRODUCTION 
Hepatic inflammation due to a number of etiologies, such as viruses, alcohol, and others, is a 
common cause of acute hepatic injury and liver cell death.  In fact, the liver is one of the organs 
most affected by septic shock, and treatment with various agents to recapitulate such injury is a 
useful method to study the role of cell death, or apoptosis, in this system [398].  Liver has a 
particular susceptibility to apoptosis, due to a rich expression of death receptors such as TNF-R1 
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and Fas [195].  For these reasons, much of our current knowledge on the subject of hepatocyte 
apoptosis has been derived from experimental induction of liver failure.  Apoptosis can be 
induced through two major death-receptor mediated pathways in the liver: the Fas pathway and 
the TNF-α pathway.  Fas-mediated apoptosis can be stimulated by intravenous injection of the 
anti-Fas antibody Jo-2 into mice.  Jo-2 binds to the Fas receptor to directly induce apoptosis, 
which causes acute liver failure leading to lethality within hours of administration [399].   
However, unlike Fas-mediated apoptosis, stimulation of the TNF-α pathway requires hepatocyte 
sensitization, which is usually accomplished by pretreatment with either D-galactosamine (GalN) 
or actinomycin D (ActD) before administration of either TNF-α ligand or lipopolysaccharide 
(LPS). GalN is a hepatotoxic agent that depletes UTP, thus inhibiting de novo RNA synthesis 
and sensitizing hepatocytes to the effects of endotoxin [256].   ActD is a different class of 
transcriptional inhibitor that binds DNA duplexes and prevents synthesis of protective proteins 
[261].  Treatment with LPS after GalN or ActD sensitivity causes hepatotoxicity and lethality, 
which is primarily mediated by release of TNF-α from macrophages that accumulate in response 
to LPS administration [257].  In addition, administration of recombinant TNF-α directly after 
sensitization causes hepatotoxicity identical to that seen in LPS-treated mice, which also 
suggests that TNF-α is the major mediator of endotoxin lethality [256].  Cell death caused by 
activation of the TNF-α pathway is believed to occur primarily by apoptosis, followed by 
necrosis. 
In addition to initiating the cell death machinery, binding of TNF-α to its receptor (or binding 
of LPS to TLR-4) stimulates formation of signaling complexes that prevent cell death, 
culminating in the activation of nuclear factor kappa B (NF-κB) [400].  NF-κB is a group of 
dimeric transcription factors that initiate a wide variety of cellular programs in response to 
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inflammation and injury.  Inactive NF-κB is sequestered in the cytoplasm by members of the IκB 
complex, which become phosphorylated and degraded in response to TNF-α signaling [242].  
Loss of the IκB complex liberates NF-κB, which then translocates to the nucleus, where it 
becomes phosphorylated and fully activated [241].  Recently, NF-κB has also been recognized as 
a key apoptosis inhibitor through its activation of genes including IAPs, c-FLIP, TRAFs, and Bcl 
family members, among others [253, 254].  Expression and activation of these proteins 
suppresses caspase activation and thus allows the cell to avoid undergoing apoptosis.  Activation 
of NF-κB by LPS or TNF-α can directly antagonize the pro-apoptotic effects of the latter [254], 
as demonstrated in experimental models, where p65 is required for protection from TNF-α-
mediated apoptosis [401-403].  However, treatment with LPS or TNF-α alone does not cause any 
hepatocyte injury and thus requires agents like GalN, whose pre-treatment prevents NF-κB-
mediated pro-survival target gene expression for up to 3-4 hours.  In summary, signaling through 
the TNF-α pathway can result in either life or death for the cell depending on physiological 
context and pathway crosstalk, which favors activation of one pathway over another [404]. 
In recent years, the Wnt/β-catenin pathway has been increasingly recognized as an essential 
component of liver biology.  Despite the wealth of knowledge on β-catenin in such processes as 
liver development, regeneration, and cancer formation, to our knowledge, no study has been 
conducted to precisely address the role of β-catenin in cell survival.  Nonetheless, evidence exists 
that ablation of β-catenin renders hepatocytes more susceptible to apoptosis.  Our laboratory has 
previously shown an increase in apoptosis following inhibition of β-catenin by β-catenin 
antisense morpholino oligomer in developing (E10) livers [89].  We also observed a higher 
number of apoptotic nuclei in the livers of β-catenin conditional knockout mice as compared 
with the wild-type livers after partial hepatectomy (PHx) [94].  Another group has demonstrated 
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that apoptosis is induced in cells treated with Dkk-1, a Wnt/β-catenin pathway inhibitor, via a 
downregulation of the anti-apoptotic protein Bcl-2 and an upregulation of the pro-apoptotic 
protein Bax [262].  β-catenin can also directly promote survival in renal epithelial cells by 
inhibiting Bax through activation of Akt [265].  Further, canonical Wnt signaling exerts an anti-
apoptotic effect in human hepatic stellate cells and thus enhances their survival [264].  However, 
the mechanisms underlying Wnt-mediated regulation of hepatocyte apoptosis are incompletely 
understood.   
To determine the molecular mechanisms underlying the basal increase in apoptosis seen 
in our KO mice, and to elucidate the role of Wnt/β-catenin signaling in hepatocyte apoptosis, we 
utilized the β-catenin conditional knockout (KO) mice referred above and challenged these KOs 
and their wild-type (WT) counterparts with transcriptional inhibitors followed by activators of 
the TNF-α mediated apoptotic pathway.  We chose to investigate activation of the TNF-α 
pathway because preliminary gene array analysis revealed an upregulation of several TNF-α 
dependent genes in the KO livers at baseline (Table 2), suggesting that this pathway may be 
stimulated basally in the KOs.  We monitored the animals for morbidity following LPS or TNF-α 
administration after GalN or ActD pre-treatment and then harvested the livers and serum from 
both genotypes and analyzed them histologically and chemically for liver injury and apoptosis.  
Surprisingly, we found that KO animals are more resistant to damage from TNF-α mediated 
apoptosis than WTs and showed decreased morbidity over time.  Examination of various time 
points after GalN/LPS injection reveals that KOs show a rapid onset and partial resolution of 
hepatic injury which is limited as opposed to WTs, which accumulate irreversible and 
progressive damage.  Investigation of potential protective mechanisms in the livers of KO mice 
reveals that NF-κB is upregulated both basally and after GalN/LPS treatment, possibly as a result 
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of increased endogenous inflammation in the KO.  Finally, we describe the kinetics of β-
catenin/p65 dissociation after LPS administration and show that loss of β-catenin in KO mice 
may allow for a more rapid translocation and activation of p65 after injury, which appears to 
occur through multiple mechanisms.  Through these studies, we demonstrate that β-catenin KO 
mice are protected from TNF-α mediated apoptosis through NF-κB pathway activation, and that 
β-catenin through its interaction with NF-κB components may be playing a key role in balancing 
hepatocyte survival. 
 
Table 2: Changes in basal expression of TNF-α induced genes, anti-death genes, caspase genes, and others in 
β-catenin KO mice at baseline and after partial hepatectomy 
RESTING LIVER 
Fold 
change 
LPS-induced TNF-alpha factor 1.35 
LPS-induced TNF-alpha factor 1.38 
BCL2-antagonist of cell death 6.94 
BCL6 5.42 
HGF 9.27 
caspase 9, apoptosis-related cysteine peptidase -6.30 
CASP8 and FADD-like apoptosis regulator -4.19 
C-Rel -3.08 
40H Post-PHx   
LPS-induced TNF-alpha factor 1.34 
LPS-induced TNF-alpha factor 1.79 
TNF-alpha induced adipose related protein  2.13 
TNF-alpha induced protein 2 2.41 
Fas-activated serine threonine kinase 6.90 
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4.3 MATERIALS AND METHODS 
4.3.1 Animals 
Conditional β-catenin knockout mice were generated as described previously [94].  
Briefly, homozygous floxed β-catenin mice were bred to albumin-cre mice (both on a C57BL/6 
background); the mice carrying a floxed β-catenin allele and cre-allele were backcrossed to 
homozygous floxed β-catenin mice that resulted in conditional null mice with the genotype 
Ctnnb1loxp/loxp; Alb-Cre+/− (referred as knockout or KO mice from here on) and controls with the 
genotype Ctnnb1loxp/loxp; Alb-Cre−/− or Ctnnb1loxp/Wt; Alb-Cre−/− (referred to as wild-type or WT 
mice).  Mice were maintained under specific pathogen free conditions in the Animal Facility in 
the University of Pittsburgh and were used under the approval of the University of Pittsburgh’s 
Institutional Animal Care and Use Committee and in accordance with National Institutes of 
Health guidelines. 
4.3.2 Induction of liver injury through the TNF-α pathway 
TNF-α-mediated liver injury was induced by administration of D-galactosamine (GalN; 
Sigma, St. Louis MO) and lipopolysaccharide (LPS; Sigma L-2630, Escherichia coli 0111:B4); 
actinomycin D (ActD) (Sigma) and LPS; or GalN and recombinant mouse TNF-α (R&D 
Systems, Minneapolis MN).  For the GalN/LPS studies, both WT and KO animals (either male 
or female) were injected intraperitoneally with GalN at a dose of 700mg/kg of body weight.  
Thirty minutes later, they were treated with LPS intraperitoneally at 50μg/kg of body weight 
[238, 405].  For the ActD/LPS studies, WT and KO female animals were injected 
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intraperitoneally with ActD at a dose of 800mg/kg of body weight, followed 30 minutes later by 
intraperitoneal injection of LPS at a dose of 50μg/kg of body weight [406].  For the GalN/TNF-α 
studies, WT and KO female animals were were injected intraperitoneally with GalN at a dose of 
700mg/kg of body weight, followed 1 hour later by intravenous injection of 2μg/kg TNF-α as 
described previously [405].  In all treatment groups, mice were closely monitored and sacrificed 
at the first signs of morbidity (hunched posture, decreased core temperature, and decreased 
movement).  Livers were harvested and frozen at -80C0 for subsequent analysis. A portion of the 
liver was fixed in 10% formalin for paraffin embedding.  Kaplan-Meier survival analysis was 
performed using XLSTAT (Addinsoft, New York, NY). 
4.3.3 Measurement of serum AST and ALT levels 
Whole blood from mice injected with GalN/LPS was collected through retro-orbital 
bleeding and spun at 4000 RPM for 10 minutes to separate the serum.  To assess hepatocellular 
injury after LPS treatment, serum alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) levels were measured by the In Situ Hybridization Laboratory within the 
Department of Pathology [407]. 
4.3.4 Histology, Immunohistochemistry, and TUNEL staining 
Liver tissue fixed in 10% formalin and embedded in paraffin were sectioned 4 µm in 
thickness onto Superfrost Plus glass slides (Thermo Fisher Scientific, Pittsburgh, PA) and heat-
fixed overnight at 37°C.  The sections were stained with hematoxylin and eosin (H&E).  
Apoptotic nuclei were detected by the terminal deoxynucleotidyl transferase-mediated dUTP 
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nick-end labeling (TUNEL) staining using the ApopTag Peroxidase kit (Intergen Company, 
Purchase, NY) as previously described [89]. 
Immunohistochemistry on paraffin-embedded sections of mouse livers was performed as 
previously described [387].  Briefly, 4 µm thick tissue sections were microwaved in citrate 
buffer, pretreated with 3% H2O2 to eliminate endogenous peroxidases, and blocked using Ultra V 
Block (Lab Vision Products, Fremont, CA).  Primary antibodies used for this project were anti-
NF-κB p65 (A) (used at a 1:10 dilution and incubated 30 minutes) and anti-CD45 (used at a 
1:100 dilution and incubated 1 hour) (both from Santa Cruz Biotechnology, Santa Cruz, CA).  
Biotinylated goat anti-rabbit secondary (Chemicon, Temecula, CA) was used at either a 1:200 or 
1:500 dilution.  Immunohistochemistry was performed using the Vectastain ABC Elite kit 
(Vector Laboratories, Inc., Burlingame, CA) and developed using DAB (Vector Laboratories, 
Inc., Burlingame, CA).  The slides were counterstained with Shandon’s hematoxylin (Thermo 
Fisher Scientific, Pittsburgh, PA) and mounted with cytoseal (Biomeda Corp., Foster City, CA).   
4.3.5 Protein Extraction and Western Blots 
Whole-cell lysates from mouse livers were prepared by homogenization using RIPA 
buffer (9.1 mmol/L dibasic sodium phosphate, 1.7 mmol/L monobasic sodium phosphate, 150 
mmol/L sodium chloride, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium 
dodecylsulfate [pH adjusted to 7.4]) containing fresh protease and phosphatase inhibitor 
cocktails (Sigma, St. Louis, MO) [52].  Nuclear extracts were prepared using the NE-PER 
Nuclear and Cytoplasmic Extraction Reagents kit as per the instructions (Thermo Fisher 
Scientific, Rockford, IL).  The concentration of the protein in all lysates was determined by the 
bicinchoninic acid assay using BSA as a standard.  
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Proteins were subjected to electrophoresis and blotted as described previously [126].  
Briefly, 50-100 μg of protein from liver lysate was resolved on 7.5%, 12%, or 4-15% precast 
SDS-PAGE gels (ISC BioExpress, Kaysville, UT) using the mini-PROTEIN 3-electrophoresis 
module assembly (Biorad, Hercules, CA), followed by transfer to Immobilon-PVDF membrane 
(Millipore, Bedford, MA).  The membrane was stained with Ponceau-S solution to confirm equal 
loading and then blocked in either 5% nonfat dry milk or 5% BSA in blotto solution (20mM 
TRIS-HCl pH 7.5, 150 mM NaCl, 0.1% Tween 20), followed by incubation with primary 
antibody diluted in either 5% milk/blotto or 5%BSA/blotto for 2 hours.  The membranes were 
washed and incubated in horseradish-peroxidase conjugated secondary antibodies for 1 hour 
followed by washing in blotto.  Proteins were detected by Super-Signal West Pico 
Chemiluminescent Substrate (Pierce, Rockford, IL) and visualized by autoradiography.  
Antibodies used in this study were as follows: NF-κB p65 (A, F-6, and C-20 clones), NF-κB 
p50, Fas, Stat3, Traf-1, GAPDH, TNF-R1, TLR-4, TRADD, FADD, GSK-3β, Ser-9 GSK-3β, 
IL-6, E-cadherin, EGFR, Met, Glutamine Synthetase, Axin2/Conductin (Santa Cruz 
Biotechnology, Santa Cruz, CA; all used at 1:200 dilution); β-catenin (used at 1:500 dilution; BD 
Biosciences, San Jose, CA); Bcl-2 and pser536 p65 (both used at 1:1000 dilution; Cell Signaling 
Technology, Danvers, MA);  and cyclin-D1 (used at 1:500 dilution; Neomarkers, Fremont, CA). 
Secondary antibodies were horseradish peroxidase-conjugated goat anti-mouse (1:35,000), 
donkey anti-rabbit (1:35,000), and donkey anti-goat (1:15,000) (Millipore, Temecula, CA).    
4.3.6 Analysis of Caspase Activities 
Caspase activities were analyzed as described in a previous study [218, 405]. Briefly, 
RIPA extracts from whole liver lysates (50-100 ug) were subjected to SDS-PAGE followed by 
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Western blotting with an anti-caspase 8, anti-caspase 3, or anti-cleaved caspase 3 (p17/p19 
subunits) antibodies (Cell Signaling Technology, Danvers, MA).  In addition, caspase activities 
were analyzed by incubating RIPA extracts (15 μg) with 20 μM site-specific fluorescent 
tetrapeptide substrates (DEVD-AFC for caspases 3, EMD Chemicals, Gibbstown, NJ) at 37 °C 
for 4 hours. Fluorescence was detected by a fluorescence spectrometer (PerkinElmer Life 
Sciences LS50-B) at 400 nm excitation and 505 nm emission wavelengths. The signals 
representative of caspase activities were standardized relative to wild-type baseline controls. 
4.3.7 cDNA plate array 
mRNA was isolated from WT and KO livers using TRIzol (Invitrogen, Carlsbad, CA) as 
previously described [408].   mRNA was then analyzed for NF-κB-regulated gene expression 
with a mouse NF-κB-regulated cDNA plate array (Signosis, Sunnyvale, CA) as per the 
manufacturer’s instructions.  Briefly, mRNA was reverse transcribed using a biotin-labeled NF-
κB primer mix, mixed with hybridization buffer, and added to a plate containing 21 target genes.  
The plate was then incubated at 450C overnight, washed the next day, blocked, and developed 
with substrate.  The plate was read on a BioTek HT (BioTek, Winooski, VT) with no filter to 
detect luminiescence.  
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4.4 RESULTS 
4.4.1 β-catenin conditional knockout mice are resistant to TNF-α induced apoptosis 
We wanted to determine if loss of β-catenin contributed to a basal increase in apoptosis 
through activation of the TNF-α pathway.  To do this, we administrated a transcriptional 
inhibitor, D-galactosamine (GalN), followed 30 minutes later by bacterial lipopolysaccharide 
(LPS), a major inducer of endotoxic shock, to both WT and KO mice.  The GalN/LPS model is 
an established and well-documented method of inducing hepatocyte apoposis through the TNF-α 
pathway [258, 260].  Animals were monitored closely for signs of morbidity (ruffled fur, 
inactivity) and sacrificed upon observation of these indicators.  Table 3 summarizes the 
observations after GalN/LPS administration in WT and KO animals.  Nine of nine (9/9) WT 
mice became lethargic and moribund approximately 6 hours after GalN/LPS administration, 
which represents the average time to sickness in WT animals [260, 409, 410].  Surprisingly, most 
(14/15) of the KO mice survived past 6 hours, with some KOs seemingly uncompromised and 
healthy as late as 12 hours post-treatment (Figure 16A).  These mice displayed normal physical 
activity, did not assume a hunched posture, and responded well to external stimulation.  Thus, 
although stimulation of the TNF-α pathway caused predictable morbidity in WT mice, KO mice 
showed a clear decrease in morbidity and mortality.   
 
Table 3: Status and time to morbidity of WT and KO mice after GalN/LPS injection 
Genotype Sex Time to Sac Status LW/BW
KO F 6 hr. moribund 7.24%
KO F 7.5 hr. alive 3.03%
KO F 7.5 hr. alive 4.24%
KO F 7.5 hr. moribund 5.14%
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KO F 7.5 hr. moribund 5.86%
KO F 7.5 hr. alive 3.81%
KO M 5.5 hr. alive 4.03%
KO M 6 hr. alive 4.29%
KO M 5.5 hr. alive 3.77%
KO M 5.75 hr. alive 5.11%
KO F 12 hr. alive 3.48%
KO F 7.5 hr. moribund 6.26%
KO F 10.5 hr. moribund 5.19%
KO F 12.5 hr. alive 3.55%
KO F 8 hr. dead 7.97%
WT F 6 hr. moribund 7.44%
WT F 6.5 hr. moribund 8.22%
WT F 6 hr. moribund 9.04%
WT F 6 hr. moribund 8.18%
WT F 6 hr. moribund 7.13%
WT F 5 hr. moribund 8.63%
WT F 5 hr. moribund 8.37%
WT M 5.25 hr. dead 7.69%
WT M 5.75 hr. dead 6.11%
 
To further substantiate these findings we used actinomycin D (ActD), a different class of 
transcriptional inhibitor that intercalates DNA [261] instead of GalN, followed 30 minutes later 
by LPS treatment.  As with GalN/LPS, the KO mice continued to exhibit resistance to the effects 
of ActD/LPS while WT mice displayed morbidity around 5 hours after LPS (Table 4). 
 
Table 4: Status and time to morbidity of WT and KO mice after ActD/LPS injection 
Genotype Sex Time to Sac Status LW/BW
KO F 5 hr. alive 4.14%
KO F 4.45 hr. alive 4.86%
KO F 5 hr. dead 5.42%
KO F 5.5 hr. alive 4.32%
KO F 5.5 hr. alive 4.06%
WT F 5 hr. dead 6.02%
WT F 4.75 hr. dead 7.21%
WT F 5 hr. dead 8.68%
WT F 4.5 hr. moribund 8.56%
WT F 5.25 hr. alive 5.27%
WT F 5.5 hr. dead 7.73%
WT F 5.5 hr. moribund 6.41%
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Finally, to confirm the specificity of TNF-α apoptotic pathway activation in these 
animals, we administered GalN followed by intravenous injection of soluble TNF-α, a major 
mediator of LPS-induced hepatotoxicity [411, 412].  The KO mice were refractory to 
GalN/TNF-α treatment as well; while 3/3 WT animals were moribund or dead by 6.5 hours after 
treatment, 2/2 KO animals lacked any morbidity at the time of harvest (Table 5). 
 
Table 5: Status and time to morbidity of WT and KO mice after GalN/TNF-α injection 
Genotype Sex Time to Sac Status LW/BW
KO F 6 hr. alive 3.30%
KO F 6.5 hr. alive 4.43%
WT F 6.25 hr. moribund 6.93%
WT F 6.5 hr. dead 8.25%
WT F 6 hr. moribund 5.98%
 
4.4.2 Histological and biochemical analysis of WT and KO livers after GalN/LPS 
treatment shows that KO mice are protected from apoptosis and necrosis  
Livers from WT and KO animals injected with GalN/LPS were harvested at the time of 
sacrifice.  Morphologically, the WT livers appear dark-red in color and enlarged.  In contrast, the 
KO livers, which are typically small and pale, maintain these characteristics and look nearly 
normal after treatment (Figure 16B).  Serum analysis from sacrificed WT mice revealed a 40-
fold increase in serum alanine aminotransferase (ALT), indicating severe liver damage [413], as 
compared to minimal injury in the KO mice (average 8,605 IU/L for WT vs. 169 IU/L for KO, 
normal <40).  Additionally, there was a 20-fold increase in serum aspartate animotransferase 
(AST), another circulating marker of liver damage, in WTs as compared to KO mice (average 
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5,918 IU/L for WT vs. 234 for KO, normal <40) (Figure 16C).   Histologically, the WT livers 
after GalN/LPS had areas of intense inflammation, massive cell death, and blood cell 
accumulation and sequestration, with only a few spared periportal cells.  In contrast, KO livers 
showed very little damage; most of the hepatocytes appeared healthy, there was almost no red 
blood cell sequestration in the sinusoidal spaces, and the liver architecture was for the most part 
intact, with some sinusoidal dilation (Figure 16D).  Assaying the livers of both genotypes for 
apoptosis revealed that GalN/LPS-treated WT livers had sustained widespread damage and 
contained numerous apoptotic hepatocytes.  The KO livers, however, had dramatically fewer 
hepatocytes displaying TUNEL-positive apoptotic nuclei (Figure 16E).   Finally, WT and KO 
livers were assessed for the presence of activated caspases by both Western blot (Figure 16F) 
and by fluorometric assay measuring cleavage of the caspase-3 peptide substrate DEVD-AFC at 
6 hours post-GalN/LPS (Figure 16G).  WT livers have significantly more caspase-3 and caspase-
8 activation 6 hours after LPS than do KO livers, confirming the increased induction of the 
apoptotic machinery in WTs and lack thereof in KOs at this time. 
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 Figure 16: β-catenin KO mice are protected from injury induced via the TNF-α pathway.  (A) Kaplan-Meier 
survival analysis of WT and KO mice after treatment witth GalN/LPS shows that KOs have prolonged survival 
compared to their WT counterparts. (B) Gross liver specimens from WT and KO mice injected with GalN/LPS 
demonstrate that WT livers become engorged with blood 6 hours post-injection, while the KO livers still appear 
relatively normal at the time of sacrifice.  (C) Serum AST and ALT levels are higher in WT mice than in KO mice 
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after GalN/LPS treatment, indicating that KO mice have less hepatic injury after injection of GalN/LPS as compared 
to WT mice.  (D) Injection with GalN/LPS results in a necrotic inflammatory histology in WT livers but not in β-
catenin KO livers, as shown by hematoxylin and eosin staining.  (E)  The number of apoptotic hepatocytes after 
GalN/LPS injection is decreased in KO mice as compared to WT controls.  Apoptotic cells were detected by 
TUNEL assay on paraffin embedded sections.  (F) Cleaved caspase-3 and caspase-8 is increased in WTs compared 
to KOs after GalN/LPS treatment, as assessed by Western blotting.  (G) The level of active caspase-3 activity is 
increased in WTs treated with GalN/LPS compared to KOs as measured by fluorometric assay.  
 
4.4.3 KOs show an earlier peak of mild injury which is self-limited whereas WTs 
accumulate irreparable damage and succumb over time after GalN/LPS 
Next, we injected WT and KO animals with GalN/LPS and harvested at various time 
points to compare the kinetics of injury escalation in the WTs and KOs.  Livers from WT and 
KO animals were harvested at 3, 4, and 5 hours after GalN/LPS treatment and processed for 
histological analysis.  TUNEL assay shows few apoptotic cells in either WTs or KOs 3 hours 
after GalN/LPS.  Interestingly, at 4 hours post-treatment, KO animals display more TUNEL+ 
nuclei than WTs, which was opposite to the results seen at 6H, the time of morbidity in WT 
mice.  However, at 5 hours post-GalN/LPS, the liver injury in KOs has not progressed or maybe 
even shown some resolution, while extensive apoptosis is evident in WTs, just like the 
observation at 6H (Figure 17A).  H&E staining confirms the presence of significant hepatic 
damage in the WT at 5 hours after LPS while limited injury is evident in KOs (Figure 17B).  
AST and ALT measured from serum taken at the time of harvest shows an increase in AST in the 
KO animals at 4 hours after GalN/LPS, concurrent with the increase in apoptosis at this time.  
However, by 5 hours post-GalN/LPS – the time at which the WTs begin to show increased 
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TUNEL positivity and histologic injury – both AST and ALT are significantly higher in WTs 
than in KOs (Figure 17C).  The AST levels jumped around 15-fold (from 100 to 1500) from 4H 
to 5H in WT, whereas there was only a 2-fold increase (from 250 to 500) in KO showing a 
dramatic deceleration of injury.  These observations suggest that the decrease in liver damage 
seen in KOs after GalN/LPS is preceded by rapid onset and resolution of injury, while in the 
WTs, liver damage accumulates slowly and irreversibly. 
 
 
Figure 17: Accumulated damage to WT livers after GalN/LPS is irreversible, while damage in KO livers is 
arrested after an early onset. (A) TUNEL assay shows more positive cells in KOs as compared to WTs at 4H post-
GalN/LPS.  At 5 hours post-GalN/LPS, however, there is a rapid increase in the number of apoptotic cells in the 
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WTs compared to the KOs, which show levels of TUNEL positivity similar to or less than at 4H post-GalN/LPS.  
(B) H&E staining shows that WTs have significantly more damage than KOs as early as 5 hours after GalN/LPS.  
(C) Measurements of serum AST and ALT levels in WTs and KOs at various time points after GalN/LPS treatment 
shows increased liver injury in KOs at 4H, while at 5H the liver injury in WTs has caught up to and far surpassed 
that seen in the KOs.  
4.4.4 NF-κB and its downstream targets are upregulated in KO livers 6H post-GalN/LPS 
To determine the mechanism behind the protection from TNF-α mediated apoptosis seen 
in β-catenin KO animals, we first examined the expression of NF-κB in both WT and KO mice 6 
hours after treatment with GalN/LPS.  NF-κB was chosen as a potential inhibitor of cell death in 
our model because it is a transcription factor whose rapid translocation to the nucleus and 
subsequent activation of cytoprotective genes is known to play an important role in protection 
against pathogenic signals [414, 415].  Indeed, 6 hours after GalN/LPS treatment, there is a clear 
increase in the amount of total p65 (a subunit of NF-κB) in KOs as compared to WTs, as 
analyzed by Western blotting (Figure 18A).  This increase may represent either an inhibition of 
p65 protein degradation or a re-synthesis of p65, since the effects of GalN are ameliorated 
approximately 3-4 hours after administration [259].  Cell fractionation demonstrates the presence 
of p65 protein in the hepatocyte nuclei of KO livers but not in WT livers, and its phosphorylation 
at the Ser-536 residue indicates that it is indeed transcriptionally active [416] (Figure 18B).  
Immunohistochemistry on WT and KO livers 5 hours after GalN/LPS treatment confirms the 
presence of extensive cytoplasmic and nuclear p65 in KO but not in WT livers (Figure 18C).  
Additionally, the presence of GSK-3β, a known NF-κB activator [417], as well as its Ser-9 
phosphorylated form, is increased in KO as compared to WTs 6 hours after GalN/LPS treatment 
(Figure 18A,B), suggesting a possible mechanism for the phosphorylation of p65.   
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Examination of several downstream targets of NF-κB activation, such as Traf-1 [253] and 
Fas [418], as well as Stat3, which is itself a target of the NF-κB target gene IL-6 [419], shows 
that expression of these proteins is also higher in KO livers after GalN/LPS as compared to WT 
livers (Figure 19A).  Indeed, many of the components of the LPS-induced NF-κB protective 
machinery, including toll-like receptor 4 (TLR-4; the receptor for LPS) [420], and tumor 
necrosis factor receptor type 1-associated DEATH domain protein (TRADD; an adaptor 
molecule that mediates cell death and NF-κB activation) [235] are increased in KOs compared to 
WT, while other proteins, such as TNF-R1 (the TNF receptor) [233] and Fas-associated death 
domain protein (FADD; an adaptor molecule that recruits caspases to the activated TNF-R1 or 
Fas receptors) [211] are unchanged between WTs and KOs after GalN/LPS treatment. Further, 
additional NF-κB targets, including inflammatory mediators and cytokines, were analyzed by 
cDNA array and found to be upregulated in KOs in comparison to WTs 6 hours after treatment 
(Figure 19B).    
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 Figure 18: Cytoprotective proteins are higher in KO livers than in WT livers 6H post-GalN/LPS.  (A)  
Western blot analysis shows that both p65 and GSK-3β are increased in whole-liver lysates from KOs as compared 
to WTs.  (B) Both p65 and GSK-3β are localized mainly to the nuclei of the KO livers, as demonstrated by Western 
blot of cell fractionation extracts.  Additionally, p65 is present in its active, phosphorylated form in both the 
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cytoplasm and nucleus of KO livers.  (C) Immunohistochemistry for p65 shows a marked increase in p65 expression 
in the KOs as compared to WTs 5 hours after GalN/LPS administration.   
 
To further confirm that NF-κB is playing a protective role in the KO animals after LPS 
injury, we examined p65 nuclear expression in KO animals that displayed a range of 
susceptibility to GalN/LPS.  As shown in Table 3, around 7.5 hours after GalN/LPS, 6/15 KO 
animals displayed susceptibility, whereas 9/15 were resistant to LPS-induced apoptosis.  
Analysis from representative samples is shown in Figure 19C.  The animals protected from 
GalN/LPS (that is, the ones that are still alive at 7.5 hours after treatment) have higher levels of 
nuclear p65 than those animals who exhibited susceptiblity, indicating a direct correlation 
between p65 nuclear expression and protection from apoptosis seen in some KO animals. 
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 Figure 19: Expression of downstream NF-κB targets is increased in KO animals compared to WT animals 
after GalN/LPS.  (A) Western blot of TNF-α/LPS pathway members and NF- κB target genes shows that 
expression of targets and some effectors is higher in KOs compared to WTs after GalN/LPS.  (B) cDNA analysis of 
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selected NF-κB targets after treatment with GalN/LPS shows that the KOs have a several-fold increase in the 
expression of many NF-κB-induced genes compared to WTs.  (C)  Nuclear extracts from KO animals displaying 
differential susceptibility to GalN/LPS at 7.5 hours after treatment show that p65 is higher in KO animals that are 
protected from apoptosis as compared to those that are susceptible. 
4.4.5 NF-κB is activated basally in KO animals 
Since the KOs were still resistant to LPS even after administration of ActD, which has a 
prolongsed half-life compared to GalN, we wanted to address if any basal differences in NF-κB 
activity may be responsible for incurring prolonged protection in KOs.  We examined whole-cell 
extracts from unstimulated WT and KO livers for the expression of NF-κB subunits and 
downstream targets.  As shown in Figure 20A, there is no difference in total p65 expression 
between WTs and KOs at baseline.  However, there is increased Ser536 phosphorylation in the 
KOs, indicative of activated p65.  Additionally, p50, another NF-κB subunit, was higher in KOs 
as well, as are the NF-κB downstream targets Traf-1 and Fas.  Immunohistochemistry confirms 
the presence of active p65 in KOs around the periportal and centrizonal areas, while in WTs, 
activation of p65 is absent (Figure 20B). 
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 Figure 20: p65 is activated in KO livers at baseline.  (A) RIPA extracts from unstimulated WT and KO livers 
show that although total p65 is unchanged, Ser536 p65 is increased in KOs, as are downstream targets Traf-1 and 
Fas.  (B) Immunohistochemistry for phosphor-p65 confirms the presence of active p65 in the periportal and 
centrizonal regions of KO livers but not in WTs. 
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4.4.6 Basal increase in NF-κB activation occurs in KOs through several mechanisms  
NF-κB, a common pro-survival pathway, is usually activated in response to injury or 
inflammation through diverse mechanisms [421].  To determine the cause of NF-κB activation in 
KO mice, we explored several inflammatory markers under unstimulated conditions.  Expression 
of toll-like microbial pattern recognition receptor-4 or TLR-4, which is an important part of the 
innate immune response, is increased in KO as compared to WT at baseline (Figure 21A).  In 
addition, increased TLR-4 (which is also a receptor for LPS) makes the hepatocytes more 
sensitive to endogenous LPS that is present in portal circulation emanating from the gut flora.  
LPS binding to TLR-4 induces NF-κB signaling through phosphorylation-induced degradation of 
IκBα, which is known to prevent nuclear translocation of NF-κB subunits. Immunohistochemical 
staining for CD45, a cell-surface marker for leukocytes [422], revealed greater numbers of 
macrophages including Kupffer cells in the unstimulated KO livers (Figure 21B).  Taken 
together, these data indicate that KOs have a more robust endogenous inflammatory response, 
perhaps due to the presence of chronic inflammation, which in turn is known to stimulate 
activation of the NF-κB pathway. 
TLR-4 activation is also known to trigger cell apoptosis [423].  Another method of 
stimulating apoptosis is through disruption of the interaction between Fas and the HGF receptor, 
Met.  Since it is known that Met sequestration of the Fas receptor prevents hepatocyte apoptosis 
[424], we compared Met protein expression in WTs and KOs by Western blotting.  We found a 
significant reduction in the levels of Met receptor in KOs under unstimulated conditions, 
simultaneous with an increase in the expression of Fas (Figure 21C).  Interestingly a Fas-β-
catenin association was identified in WT livers and was dramatically lower in KO (Figure 21D). 
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Previous reports have shown that another receptor tyrosine kinase, epidermal growth factor 
receptor (EGFR), which plays a key role in liver regeneration [425], can also prevent Fas-
induced liver injury [426].  As shown in Figure 21C, expression of EGFR was found to be 
decreased in the KOs at baseline as well.  The reduction in these two key growth factor 
receptors, together with a concurrent increase in TLR-4 and Fas receptor expression and a 
decrease in Fas-β-catenin interactions, may render the KO animals more susceptible to apoptosis. 
As shown in Figure 21E and mentioned previously, the KO livers display a basal increase 
in apoptosis, as demonstrated by an increase in caspase-3, active caspase-3, and caspase-8 
proteins.  Previous work has shown that NF-κB can be directly activated during the induction of 
apoptosis [427].  Thus, the presence of a modest yet significant activation of the apoptotic 
machinery may lead to a compensatory upregulation of NF-κB in the KOs, which provides yet 
another mechanism of baseline NF-κB activation in these animals. 
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 Figure 21: Activation of NF-κB in KO livers may occur through multiple mechanisms.  (A) Western blot shows 
a basal increase in TLR-4 in KOs.  (B) KO livers contain higher numbers of inflammatory macrophages and/or 
Kupffer cells, as shown by immunohistochemistry for CD45. (C) Expression of Met and EGFR is decreased in KOs 
compared to WTs at baseline, while expression of Fas is increased, as assessed by Western blot. (D) 
Immunoprecipitation shows that Fas and β-catenin associate strongly in WT livers at baseline and that this 
association is absent in KO livers.  (E) Caspase expression and activation is higher in KOs than in WTs at baseline, 
although the levels of Bcl-2 are unchanged.  
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4.4.7 p65 associates with β-catenin in WT livers but not in KOs and may be part of an 
innate response to injury 
In addition to its well-known interaction with the IκB complex, p65 has also been shown 
to physically associate with β-catenin in the context of colon, breast, and liver cancer.  This 
association has been shown to inhibit p65 transactivation and prevent NF-κB target gene 
expression [266, 267].  To determine if the p65/β-catenin complex is present in hepatocytes as 
well, we immunoprecipitated protein lysates from both WT and KO livers with p65 and probed 
the blots for β-catenin.  Figure 22A shows coprecipitation of β-catenin and p65 in both WT and 
KO livers.  However, the association in KO livers is dramatically reduced and may represent 
association in the non-parenchymal cell compartment in which β-catenin is still present. 
Because dissociation of p65 and β-catenin is a critical step in activation of NF-κB, we 
wanted to know if the p65/β-catenin complex contributes to the injury response in our model.  
We hypothesized that KO livers, which lack β-catenin, would have a lower threshold of p65 
activation after apoptotic stimulus and thus respond more rapidly when challenged.  To test this, 
we treated WT and KO animals with LPS only (no GalN), and harvested 1 hour after treatment.  
NF-κB nuclear translocation is known to peak approximately 1.5 hours after LPS stimulation 
[415, 428, 429], so any differences between WT and KO p65 activation should be evident by 1 
hour.  Figure 22B shows an increase in both p65 and p50 in the nucleus of KO livers as 
compared to WTs 1 hour after LPS treatment.  Further, expression of IL-6, an acute downstream 
target of NF-κB [430], is also increased in the cytoplasmic fraction of KOs at this time.   
To determine the kinetics of β-catenin/p65 dissociation, nuclear translocation and 
activation, we harvested WT livers at baseline as well as 1 hour and 2 hours after LPS 
stimulation and examined them by immunoprecipitation, Western blot, and 
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immunohistochemistry.  Dissociation of β-catenin and p65 occurs as early as 1 hour after LPS in 
the WT (Figure 22D), with p65 nuclear translocation occurring simultaneously (Figure 22C).  
However, p65 does not seem to be transcriptionally active until 2 hours after LPS treatment, at 
which time the phosphorylated form appears in the nuclear fraction (Figure 22E and 22F).  While 
increase in total p65 is evident in the nuclei 1 hour post-LPS injection, its peak of maximal 
phosphorylation is evident at 2 hours in WT, suggesting a small lag between its translocation and 
phosphorylation-dependent activation.  Interestingly, p65/β-catenin co-precipitates again 2 hours 
after LPS treatment, and nuclear localization of p65 also decreases to near-baseline levels, 
indicating that the p65/β-catenin complex may be re-forming after initial dissociation.  Nuclear 
β-catenin remains unchanged from baseline at 1 hour after LPS, indicating that p65 and β-catenin 
are not translocating to the nucleus simultaneously.  In contrast to the WT kinetics, in the KOs 
p65 is phosphorylated and active as early as 1 hour after LPS treatment, with approximately 50% 
of hepatocyte nuclei staining positive for Ser536 p65 (Figure 22E).  Thus, loss of β-catenin in the 
KOs lowers the threshold of p65 nuclear translocation and activation in reponse to stimulation 
which allows for more rapid protection in response to injury. 
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Figure 22: The decreased association of p65 and β-catenin in KOs may contribute to protection from injury 
after LPS treatment.  (A) Immunoprecipitation shows that p65 and β-catenin associate strongly in WT livers at 
baseline but less so in KO livers.  (B) Western blotting of nuclear extracts shows that NF-κB subunits and 
downstream targets are increased in KOs 1 hour after LPS as compared to WTs.  (C) p65 translocates to the nucleus 
1 hour after LPS injection in the WTs, while expression of nuclear β-catenin remains the same as baseline, as shown 
by Western blotting. (D) Association of p65/β-catenin decreases after administration of LPS in the WT, as assessed 
by immunoprecipitation. (E) NF-κB is active in the nucleus 1 hour after LPS treatment in the KOs but at 2 hours 
after LPS treatment in the WTs, as shown by immunohistochemistry for the phosphorylated form of p65.  (F) 
Western blotting for the phosphorylated form of p65 indicates maximal activity in the nucleus 2 hours after LPS 
administration in WT livers. 
4.4.8 β-catenin is degraded in WT livers in response to GalN/LPS treatment 
Finally, to determine if Wnt/β-catenin pathway components may themselves undergo any 
changes after TNF-α mediated apoptosis, we examined expression of β-catenin and some of its 
downstream targets in WT livers at various time points, both before and after GalN/LPS 
treatment.  Figure 23 shows that β-catenin decreases as early as 3 hours post-GalN/LPS.  By 6 
hours, β-catenin cleavage and degradation is pronounced, as shown by the appearance of a 
truncated form of β-catenin at the expense of the full-length form, and is most likely due to N-
terminal truncation by caspases [431, 432].  GSK-3β, a kinase known to phosphoryate β-catenin 
and promote its degradation, was modestly downregulated.  Although expression of some 
downstream targets such Axin2, and glutamine synthetase remain relatively unchanged over 
time, others, such as cyclin-D1, show a marked decrease in protein expression which coincides 
with β-catenin degradation starting 3 hours after GalN/LPS.  In addition, expression of E-
cadherin, which along with β-catenin is a critical component of cell-cell adhesion, decreases 5 
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hours after administration of GalN/LPS.  This time point corresponds to the onset of hepatocyte 
necrosis and apoptosis in WT livers (Figure 17).  Thus, β-catenin levels and activity decrease 
over the course of GalN/LPS treatment in WT animals and therefore does not appear to protect 
hepatocytes from apoptosis.  On the contrary, degradation of β-catenin and reduced protein 
expression of some of its downstream targets, especially cyclin-D1, may contribute to the 
apoptotic phenotype. 
 
Figure 23: β-catenin is degraded over the course of GalN/LPS treatment, and expression of some of its 
downstream targets changes as well.  Western blots show that β-catenin begins to be cleaved as early as 3 hours 
after GalN/LPS treatment in WT livers, with near-complete degradation occurring by 6 hours.  Expression of some 
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β-catenin targets such as Axin2 remains unchanged over time, while others such as cyclin-D1 decrease with 
increasing β-catenin degradation. 
4.5 DISCUSSION 
β-catenin plays multiple roles in liver health and disease through regulation of processes 
such as proliferation, differentiation and adhesion. However its role in hepatic injury remains 
unexplored, albeit β-catenin conditional KO mice display a basal increase in TUNEL-positive 
apoptotic nuclei.  To determine the role of β-catenin in hepatocyte survival, we compared injury 
and survival between KO and control animals after GalN/LPS, which is a major mode of 
hepatocyte apoptosis.  Here, we demonstrate that, contrary to our expectations, loss of β-catenin 
in hepatocytes protects against TNF-α mediated apoptosis through a compensatory upregulation 
of the NF-κB pathway, which is activated basally and temporally after LPS-induced liver injury 
in the β-catenin KO livers.   
The time to morbidity in WT C57Bl/6 mice following GalN/LPS treatment is generally 
6-8 hrs [433].  In our system, we observed that, following LPS treatment, all (100%) of the WT 
mice were morbid by 6 hours.  In contrast, nearly all (93.3%) of the KO mice were still alive at 
this time, with times to morbidity ranging from 7.5 hours to 10.5 hours after LPS (Table 3).  In 
fact, a few KO mice remained in relative health until they were sacrificed at the outer limit of the 
predicted survival time (12 hours).  Examination of gross liver morphology, along with 
histological analysis, reveals significant damage in the WT mice treated with GalN/LPS.  
Measurement of serum AST and ALT, a marker of hepatocellular injury which is often elevated 
due to activation of inflammatory pathways [434], shows that liver damage is also increased 
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dramatically in WT mice as compared to KO mice at the time of sacrifice.  Caspase cleavage and 
activation is also strongly induced in WTs by the time of sacrifice, confirming the presence of 
massive apoptosis in WT but not in KO livers (Figure 16). 
As mentioned previously, there is a perturbation in vitamin C biosynthesis in β-catenin 
KO mice [38], which could result in accumulation of D-glucuronate, a precursor of vitamin C 
[381].  D-galactosamine is known to reduce the hepatic content of UDP-glucose [259], which 
would decrease the amount of glucuronate, as well as inhibit the formation of de-novo 
glucuronate by depleting UDP-glucuronate [435].  Since β-catenin also plays a role in regulating 
glucose metabolism [436] and xenobiotic metabolism through regulation of various P450s [35, 
94], there may therefore be altered metabolism of D-galactosamine, which may in turn impact its 
effect on transcriptional suppression prior to LPS administration.  However, pretreatment of KO 
and control mice with actinomycin D, which is an independent class of transcriptional inhibitor, 
prior to LPS resulted in the recapitulation of the observations seen in GalN/LPS-treated KOs and 
controls (Table 4).     
The transcription factor NF-κB plays a key role in both innate and adaptive immunity.  It 
is known to positively regulate the transcription of anti-apoptotic genes such as c-IAPs, Trafs, 
Bcl-XL, and c-FLIP [255], and is a common pro-survival factor.  In addition, NF-κB plays a 
direct role in hepatocyte survival and regeneration [114, 243, 437], making it a likely candidate 
for imparting a phenotype to our KO model in response to TNF-α-mediated injury.  Indeed, our 
results demonstrate that mRNA and protein expression of NF-κB subunits and downstream 
targets is increased in KO mice as compared to their WT counterparts at the time of sacrifice, 
and further examination reveals that p65 is activated basally in KOs as well (Figures 18-20).  
Although it was initially unclear why there was some inter-animal variability within the KO 
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genotype in response to TNF-α-mediated injury, the heterogeneity in the activation of NF-κB in 
the KOs may be due to factors that are yet to be determined.  However, these results further 
strengthen the argument that the level of NF-κB expression determines an animal’s fate after 
GalN/LPS.  A similar phenotype is also seen in the Met-KO hepatocytes, which demonstrate 
hypersensitivity to Fas-induced apoptosis.  These mice exhibit an intrinsic basal activation of 
NF-κB, which is most likely an adaptive response to both apoptosis and oxidative stress [438].   
Interestingly, the c-Rel gene, a transcriptionally active member of the Rel/NF-kappaB family 
[439], is downregulated basally in our KO livers, perhaps to counter the increase in p65/RelA 
phosphorylation and activation.    
As mentioned, an analysis of genes upregulated in KO mice in both resting and 
regenerating liver reveals several that are related to or induced by TNF-α stimulation (Table 2).  
Since release of TNF-α is one of the hallmarks of a classic inflammatory response, we 
investigated the presence of inflammatory markers in our KO livers and found a basal increase in 
expression of the TLR-4 receptor and CD45-positive cells, both indicative of an innate immune 
response (Figure 21).  In addition, as discussed in the previous chapter, regucalcin, a critical 
component of anti-oxidant metabolism in hepatocytes through ascorbic acid biosynthesis and 
other mechanisms, is missing in KOs, which is also contributing to increased basal apoptosis.  
Therefore, we believe that levels of NF-κB are basally increased in order to counteract increased 
inflammation and increased oxidative stress, thus accounting for the protection seen in KO livers 
after challenge with GalN/LPS.   
We analyzed gene array data from KO and WT mice and found a basal increase in anti-
death genes such as Bcl-2 and Bcl-6 in our KOs, as well as decreased expression of caspases, 
including caspase-9, which has been linked to the mitochondrial death pathway [440] (Table 2).  
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This suggests that hepatocytes lacking β-catenin may overexpress anti-apoptotic genes and 
repress capase gene expression as a compensatory cytoprotective mechanism to counteract a 
basal apoptosis.  Although our current studies have not yet elucidated the mechanism of 
increased apoptosis, indirect evidence suggests that it maybe due to activation of the Fas 
pathway.  For example, we found an increase in Fas protein expression in the KOs at baseline 
and after GalN/LPS treatment.  Additionally, Fas-activated serine threonine kinase was 
upregulated 6.9–fold in KO livers 40 hours after partial hepatectomy (PHx) in the KO, which 
corresponds to a time in which KOs are displaying suboptimal regeneration and a 2.5-fold 
increase in apoptosis [94].   
Our laboratory has reported that β-catenin and the hepatocyte growth factor (HGF) 
receptor c-Met associate at the cell surface [49, 51].  Upon binding of HGF to c-Met, β-catenin 
becomes phosphorylated at tyrosine residues 654 and 670, dissociates from c-Met, and 
translocates to the nucleus, where it upregulates target genes [52, 53].   Other groups have shown 
that c-Met sequestration of the Fas receptor can prevent Fas-mediated apoptosis in hepatocytes 
[228], and that mice lacking c-Met were hypersensitive to Fas-induced apoptosis[229].  
Intriguingly, expression of HGF mRNA is upregulated 9.27-fold in the KOs at baseline (Table 
2), simultaneous with a dramatic reduction in the protein levels of Met receptor in KOs (Figure 
21C).  We have identified a novel interaction of Fas and β-catenin and based on existing 
knowledge of Fas-Met and Met-β-catenin complexes, it is likely that the three proteins interact to 
eventually impact Fas’s availability to bind to its ligand.  Lack of β-catenin may be inducing Fas-
mediated apoptosis through lack of Fas-β-catenin interaction, decreased Met levels and enhanced 
free-Fas levels, which are further complemented by enhanced basal NF-κB activation.  Based on 
this information, we hypothesize that in homeostasis, c-Met and β-catenin may be conferring 
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protection from Fas-mediated apoptosis, and that the absence of β-catenin would shift the 
balance toward a Fas-induced apoptotic fate.  The role of β-catenin in Fas-mediated apoptosis, 
however, remains to be elucidated. 
 Our results suggest that although β-catenin is often thought to play a pro-survival role in 
liver biology, loss of β-catenin can paradoxically contribute to protection from apoptosis, likely 
through upregulation of anti-apoptotic machinery (Figure 24).  The pivotal role of β-catenin in 
determining the mode of apoptosis in hepatocytes could be exploited for clinical therapies that 
enhance cell survival in liver diseases associated with massive cell death, such as alcoholic 
hepatitis, hepatic inflammation, viral hepatitis, cholestatic liver disease, and ischemia-
reperfusion injury. 
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 Figure 24: A proposed mechanism for resistance to TNF-α mediated apoptosis in β-catenin KO mice.  
Decreased Met and a simultaneous increase in Fas leads to a basal level of apoptosis, which can stimulate activation 
of NF-κB.  A robust endogenous inflammatory response, indicated by an increase in CD45+ cells, can also activate 
NF-κB.  CD45+ cells secrete TNF-α, which can bind to its receptor TNF-R1 and stimulate either apotosis or NF-κB 
activation.  Basally increased TLF-4 in KOs would also respond to LPS normally present in portal circulation to 
induce basal NF-κB activation and apoptosis.  Finally, the absence of β-catenin in KOs allows increased p65 
translocation to the nucleus.  In conclusion, levels of NF-κB in KOs are increased basally as well as after GalN 
clearance following LPS injection through several mechanisms, thus supporting the notion that these livers may be 
“primed” for protection against exogenous insult.   
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5.0  GENERAL DISCUSSION 
5.1 BETA-CATENIN IN LIVER REGENERATION 
The importance of β-catenin to liver regeneration was first described in the rat model [126]. 
Additional studies since then have highlighted the importance of β-catenin in regeneration in 
many species including zebrafish, mice, and humans [350, 351].  Decreased proliferation and 
liver/body weight ratio were noted as early as 24 hours in rats administered a β-catenin antisense 
oligonucleotide after 2/3 PHx [127].  β-catenin conditional knockout mice showed a delayed 
regeneration by 24 hours [94]. These results were independently corroborated by another 
laboratory that demonstrated a 12-24 hour delay in DNA synthesis and cell cycle progression in 
liver-specific β-catenin knockout mice [128].  In light of the above observations, it would be of 
translational significance to determine if activation of the Wnt/β-catenin signaling pathway 
would be beneficial to the process of regeneration.  Indeed, our extensive data suggests not only 
that increased β-catenin enhances regeneration, but also that there is an opportunity to modulate 
Wnt/β-catenin signaling for the purpose of stimulating the regenerative process.  Comparison of 
TG and WT hepatocyte proliferation in culture shows that thymidine incorporation (a measure of 
proliferation) and cell viability is increased in TG hepatocytes as compared to WT.  The TG 
mice express increased cyclin-D1 protein, a key cell cycle regulator, several hours earlier than 
their WT counterparts after PHx. This in turn triggers upregulation of proliferation, as measured 
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by PCNA staining.  Further, we provide evidence to suggest that the Met/β-catenin interaction at 
the cell surface is regulating β-catenin translocation to the nucleus contributing to enhanced 
proliferation.  Finally, activation of β-catenin through Wnt-1 induction elicits similar effects to 
those seen in the TG mice, and confirms that β-catenin is an important intracellular regulator of 
liver regeneration. 
Intriguingly, we did not detect any phenotype or abnormalities in metabolism, zonation, 
or proliferation in TG mice overexpressing S45D-β-catenin in our initial characterization. There 
was a modest increase in LW/BW ratio at 1 month which was transient and secondary to 
increased cyclin-D1 expression and proliferation. By 2 months, however, the TG livers had 
adapted to suppress excessive β-catenin by sequestering it at the hepatocyte membrane [441]. 
This unique means of turning “off” β-catenin signaling is under investigation and may have 
clinical implications in treatment of β-catenin-active tumors in the liver and elsewhere.   
The role of constitutively active β-catenin in postnatal hepatic growth has been examined 
in sseveral mouse models.  Increased cell proliferation leading to hyperplasia and hepatomegaly 
were described in a transgenic mouse that expresses an oncogenic form of β-catenin lacking the 
N-terminus, which is involved in protein stabilization [130].   Another report described enlarged 
livers shortly after adenoviral infection in a mouse strain carrying a mutant inducible form of β-
catenin [131].  Two additional studies have also demonstrated the effect of β-catenin 
stabilization albeit indirectly through ablation of the APC gene, a known negative regulator of 
the pathway.  In the first study, Apc-inactivated mice display both a clear increase in liver size 
and a high incidence of spontaneous hepatocellular cancer [442]. Another recent study has 
showed a regenerative advantage in APC-mutant mice livers after PHx [350]. While β-catenin 
activation was evident robustly in APC-mutant mice, it is unclear what impact loss of APC has 
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on other signaling pathways, as APC has recently been shown to affect cell processes such as 
epithelial integrity and DNA replication independent of β-catenin regulation [443, 444].  This is 
also relevant since APC loss is not evident in hepatocellular cancer in patients except in a case 
report [130-132, 445].   
Intriguingly, no study to date has shown spontaneous HCC in TG mice overexpressing 
wild-type or constitutively active β-catenin [130-132].  For example, TG mice containing a 
deletion of exon-3 lacked spontaneous tumorigenesis; however, in the setting of simultaneous 
mutation of H-ras, this mutant form of β-catenin induced hepatic tumors [131] [446].  Akin to 
such observations, we did not detect spontaneous HCC in our TG mice. In light of observed 
membranous sequestration of excess β-catenin in TG mice, the phenotype, or lack thereof, is not 
surprising. Nonetheless, as in primary cultures or after PHx, diethylnitrosamine (DEN) exposure 
did lead to accelerated tumorigenesis in TG mice due to activation of the mutated  β-catenin 
[441]. Thus, it appears that mutation of β-catenin alone is insufficient to cause spontaneous 
hepatic tumorigenesis and suggests that only after a “first hit”, such as chemical induction or 
mutation of another oncogene, does mutant-β-catenin promote tumorigenesis.   
While cyclin-D1 as a target of β-catenin signaling has been known for quite some time [25, 
26], a direct link between β-catenin activation and expression of cyclin-D1 has been disputed 
[447] and is especially controversial in liver pathobiology [130, 442, 448].  It is of relevance to 
emphasize that that genetic targets of β-catenin signaling are not only tissue-dependent but also 
context–dependent. In the current study we clearly show a positive correlation of cyclin-D1 and 
β-catenin expression in many instances. Conditional disruption of β-catenin in the liver also led 
to a significant loss of expression of cyclin-D1 both during development and in adult liver [94, 
96]. This deficit was more pronounced when a need for proliferation was created in the knockout 
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mice such as after PHx. In additional situations such as postnatal liver development, cyclin-D1 
expression closely correlated with β-catenin expression [129]. It was interesting to observe that 
while cyclin-D1 appeared to be the central mechanism defective in regeneration in the absence of 
β-catenin, the TOPGAL reporter mice, as reported in the latter study, failed to elicit any sign of 
direct β-catenin activation following hepatectomy. The reason for this discrepancy remains 
unidentified and might be due to technical challenges for the use of TOPGAL mice to study β-
catenin activation in adult tissues. It is conceivable that the site of integration for the transgene, 
which is obscure, may be subject to developmental regulation keeping it permissive in prenatal 
or early postnatal stages and rendering it non-permissive in adults. In any case, Wnt/β-catenin 
signaling in rats, mice and more recently in zebrafish is unquestionable [350].  Thus, while we 
are also cognizant of β-catenin-independent regulation of cyclin-D1, it is worth emphasizing that 
β-catenin is indeed one of the chief regulators of cyclin-D1 expression and in turn of cell 
proliferation in the liver and that such relationship would be especially evident during the events 
that require increase in cell proliferation. This observation also highlights the context-
dependence of key genetic targets of Wnt/β-catenin signaling. 
The Wnt/β-catenin pathway may be amenable to manipulation through exogenous activation, 
thus allowing it to be exploited for therapeutic purposes.  Several studies have already addressed 
the effect of Wnt-1 stimulation on β-catenin activation and cell growth.  For example, 
transfection of Wnt-1 plasmid in NIH3T3 cells causes translocation of β-catenin and nuclear 
association with LEF-1 [355].  Similarly, a decrease in GSK-3β activity and an increase in 
nuclear accumulation of β-catenin are seen in mammary epithelial cells transformed with Wnt-1 
[50].  Further, Wnt-1 induces a growth response in cultured Rat-1 fibroblasts [356], which is 
partially mediated through activation of β-catenin [357].  In our study we demonstrate quite 
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clearly that Wnt-1 naked DNA delivered hydrodynamically leads to enhanced Wnt-1 expression, 
which then induces β-catenin activation along with an increase in cyclin-D1 expression and 
hepatocyte proliferation after partial hepatectomy. Thus our report for the first time provides 
evidence that exogenous manipulation of Wnt/β-catenin activation might be a novel way of 
inducing regeneration of the liver, when necessary. Clearly, this will be dependent on the 
availability of modulators of Wnt/β-catenin signaling pathway, which would need additional 
substantiation in preclinical models. While such modulators are not available currently, agents 
such as lithium chloride, which are know to inhibit GSK3β, a known negative regulator of β-
catenin, might be relevant for further investigation in preclinical scenarios in liver regeneration 
[449].   
This work also has the potential to enhance the effectiveness of current regenerative 
technologies in several ways.  First, human hepatocytes genetically engineered with stable β-
catenin may reduce the number of hepatocytes needed for cell transplant therapy and thus 
eliminate the need for serial transplants.  Second, temporal suppression of the β-catenin pathway 
in transplant recipients may allow for more efficient cell engraftment by providing a growth 
advantage to donor cells.  Additionally, inducing Wnt signaling after orthotopic liver transplant 
in the recipient may promote growth and function of the graft especially in small-for-size grafts.  
Finally, Wnt activation may also be of essence in promoting regeneration in acute liver failure.  
Thus, understanding the Wnt/β-catenin pathway may prove to be the key to successfully bridging 
liver biology, tissue engineering, and hepatic regenerative medicine.  
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 5.2 BETA-CATENIN IN REGUCALCIN REGULATION, VITAMIN C SYNTHESIS, 
AND OXIDATIVE STRESS 
The β-catenin signaling pathway is central to liver health and disease, and its activation is 
essential in many aspects of liver physiology including early development, regeneration, 
zonation, and oxidative stress [331].  Mutations in the β-catenin gene that render the protein 
aberrantly active have been implicated in various stages of liver tumorigenesis as well.  Previous 
investigations of β-catenin knockout mice have validated downstream targets of β-catenin in the 
liver, such as glutamine synthetase [34].  Here, we report that regucalcin is a novel target of β-
catenin in the liver, and examine its functional role in some of the canonical activities relevant to 
β-catenin such as regulating cell survival.  In addition, we identify a unique role for β-catenin in 
regulating vitamin C biosynthesis and the redox state of a cell. 
Initial experiments with β-catenin conditional knockout mice reveal the presence of 
regucalcin in wild-type mice and the absence of regucalcin in β-catenin knockout littermates 
after 3 months. The fact that a small amount of regucalcin still persisted in the KO animals at 1 
month after birth can be attributed to the fact that the efficiency of recombination for Alb-Cre 
mice (the conversion from a floxed allele to a deleted allele) is only about 40% at birth and is not 
complete until the mice are 6 weeks old [391].  We examined the KO mice at 3 months of age, at 
which time regucalcin is absent in the livers of these mice.  Similarly, β-catenin TG mice display 
elevated levels of regucalcin protein in the nucleus and cytosol of hepatocytes as compared to 
their WT counterparts.  The strong correlation between regucalcin, GS, and nuclear β-catenin 
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after partial hepatectomy in the rat and in human hepatocellular carcinomas further supports the 
conclusion that β-catenin regulates regucalcin/SMP30 expression in murine, rat, and human 
livers. 
Previous data on regucalcin in hepatocellular carcinomas has been somewhat sparse.  
Serum levels of regucalcin are markedly increased 30 days after administration of carbon 
tetrachloride, suggesting a role for regucalcin as a biomarker for chronic liver injury [450].  
Decreased regucalcin expression was observed in CuZn superoxide dismutase deficient mice 
with fully-developed HCCs [451].  Another study showed that regucalcin RNA was 
downregulated in diethylnitrosamine (DEN)-generated mouse HCCs vs. regenerating (-10.7), 
quiescent (-12.6), and newborn liver (-4.4).  In these samples, β-catenin, which was indirectly 
measured by the detection and measurement of β-catenin putative target genes, was not found to 
be deregulated [452].  Indeed, studies have shown that administration of DEN without 
phenobarbitol (PB) utilizes a non-Wnt pathway to induce HCC, whereas DEN plus PB- induced 
liver tumors display increased β-catenin mutations [453].  Another study of mouse liver 
carcinogenesis has shown that regucalcin was upregulated early in oxazepam-induced 
carcinogenesis, which is known to induce β-catenin gene mutations [365, 454]. This 
demonstrates correlation between β-catenin activation and regucalcin expression.  
Analysis of the promoter region of mouse regucalcin revealed four putative TCF-4/LEF 
binding sites.  These sites are between 750 and 150 bp upstream of the +1 site and are either very 
similar to or identical with consensus sequence sites for TCF-4 binding identified previously [19, 
27, 455].  Using multiple deletion mutants isolated from the promoter region of the human 
regucalcin gene, we identified the specific site at which β–catenin transcriptionally regulates 
regucalcin expression [38].  The regucalcin promoter is also known to contain an AP-1 binding 
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site [170].  One recent study demonstrates that AP-1 and β-catenin can act in synergy to 
transcriptionally activate β-catenin target genes such as cyclin-D1 [456].  In previous studies, 
AP-1 has been shown to mediate regucalcin mRNA expression in hepatocytes by binding to the 
promoter region of the regucalcin gene and activating transcription [170].  The existence of AP-1 
and TCF binding sites in the regucalcin promoter region may suggest a mechanism by which 
regucalcin can contribute to malignancy in HCCs secondary to β-catenin activation.  An 
understanding of these mechanisms may also reveal potential exploitable therapeutic benefits.  
To understand the biological implications of regucalcin especially in hepatoma cells, we 
utilized siRNA suppression of regucalcin. A significant increase in apoptosis in HepG2 cells 
occurred after regulacin suppression. This is in agreement with previous studies where 
regucalcin overexpression has been shown to suppress cell death [189]. Our results are also 
concordant with previous studies where mice containing a germline null mutation of SMP30 
have been shown to be highly susceptible to death-receptor mediated apoptosis, thereby 
indicating that SMP30 plays a role in protection from apoptosis and contributes to cell survival 
[191, 192].  Previous work in our laboratory has also demonstrated that loss of β-catenin results 
in increased hepatocyte death as well [89, 94].  Thus, we suggest that loss of regucalcin in the 
KO mice may be one of the mechanisms by which basal apoptosis is increased, and becomes of 
relevance in cases of basal NF-κB activation. 
Interestingly, inhibition of regucalcin in Hep3B and HepG2 tumor cells had little to no 
effect on proliferation, unlike what has been reported elsewhere [178, 373]. It has been 
previously suggested that regucalcin may have a role as an inhibitor of proliferation during liver 
regeneration in rats.  These seemingly discordant observations may be a function of the multiple 
roles of molecules like regucalcin and β-catenin in cell proliferation, survival, and metabolism; 
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thus, the ultimate biological observations may really be an end result of tipping the balance 
between various responses and may be highly context-dependent. 
We also show for the first time a physical association of β-catenin and regucalcin in 
HepG2 and Hep3B cells.  Since β-catenin has been known to upregulate expression of Wnt 
pathway regulators such as Axin2 and Dkk1, we postulate that regucalcin may in fact be a 
negative regulator of β-catenin in the cytosol of the resting liver.  If this is the case, 
transcriptional control of regucalcin by β-catenin would occur only when cytosolic and nuclear 
levels are excessive, thus limiting the duration of the signal. It might be that during regulated 
liver growth as in regeneration, regucalcin may function primarily as an activator of a feedback 
loop that negatively regulates β-catenin (and consequently cell proliferation) when intracellular 
levels of β-catenin reach a critical mass.  However, in hepatocellular carcinomas, where the 
expression of β-catenin may be dysregulated due to mutations in the β-catenin gene, regucalcin 
(whose expression is amplified due to increased β-catenin) is no longer able to downregulate β-
catenin and may in fact contribute to subsequent tumor formation through its secondary role as a 
promoter of tumor cell survival.  In addition regucalcin has been shown to inhibit activity of 
phosphatases, especially tyrosine phosphatases.  In HCC, where regucalcin expression is 
increased, there may be a greater inhibition of tyrosine phosphatase activity which would lead to 
increased tyrosine phosphorylation of β-catenin (due to the direct association between regucalcin 
and β-catenin), thus creating a positive feedback loop.  Again, the negative and positive impact 
of regucalcin through diverse mechanisms may be dependent on cellular context and will require 
further careful investigation. 
Both regucalcin and L-gulonolactone oxidase, another downstream target of β-catenin, are 
known to have an important role in vitamin C synthesis [193, 381].   We observed a significant 
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decrease in serum ascorbate levels in our KO mice, which have reduced expression levels of both 
genes.  When cultured KO hepatocytes were supplemented with ascorbate, they showed a 
marked increase in cell survival, as measured by MTT uptake (data not shown).  Ascorbate also 
rescued the cells from massive apoptosis which was present after 48 hours in culture.  As we 
have previously noted, our β-catenin KO mouse show an increased basal level of hepatocyte 
apoptosis [94].  Reduction of apoptosis by ascorbate implicates lack of vitamin C synthesis in the 
KO phenotype.  Other studies have also demonstrated a role for regucalcin as a suppressor of cell 
death [189, 191, 192].  Future studies in which β-catenin KO mice are supplemented with 
ascorbate would be needed to address whether vitamin C supplementation rescues the apoptotic 
phenotype observed in these mice. 
Interestingly, we saw increased apoptosis in HepG2 cells and decreased survival in Hep3B 
cells treated with regucalcin siRNA, which was rescued by addition of ascorbate or N-acetyl 
cysteine (NAC) to the cultures.  Both are known anti-oxidants that neutralize the effects of free 
radicals.  Since humans and guinea pigs are unable to synthesize endogenous vitamin C due to 
mutations in the L-gulonolactone oxidase gene [381], the decreased cell survival after regucalcin 
knockdown seen in these human hepatoma cell lines may be a result of oxidative stress rather 
than the physiologic effects of vitamin C depletion.  Other groups have also reported that lack of 
SMP30/regucalcin has been linked to an increase in oxidative stress [185, 186].  Further, 
overexpression of regucalcin leads to a reduction in reactive oxygen species in HepG2 cells 
[184].  We therefore propose that one mechanism for the increased apoptosis seen in our KO 
mice could be the increase in oxidative stress secondary to the loss of ascorbate.  Indeed in our 
unpublished studies, we also observe a modest increase in basal lipid peroxidation, a marker of 
oxidative stress, in β-catenin conditional null mice.  It is possible, therefore, that β-catenin 
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contributes to cell survival through the regulation of regucalcin, which may be an important 
modulator of redox state in hepatocytes.   
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 5.3 BETA-CATENIN IN CELL SURVIVAL AND APOPTOSIS 
Programmed cell death is a complex process regulated by several signaling pathways and 
containing a multitude of different checkpoints.  Although many of these pathways and 
molecules have been well-described, the role of others has yet to be elucidated.  β-catenin is a 
crucial component of the Wnt pathway that plays multiple roles in liver homeostasis through its 
regulation of proliferation, differentiation and regeneration.  However, it is currently unknown 
whether this pathway plays any role in cell survival, and if so, what might be its function.  
Recent work in our laboratory has demonstrated enhanced apoptosis in β-catenin KO livers both 
basally and in the early stages of liver regeneration [94].  We also identified regucalcin as a β-
catenin downstream target, which is implicated in modulating oxidative stress and suppressing 
cell death [38].  In fact, a higher incidence of apoptosis in both cultured hepatocytes from β-
catenin KO mice and HepG2 cells treated with regucalcin siRNA was observed.  Therefore, we 
hypothesized that β-catenin plays a pro-survival role in liver biology, and loss of β-catenin (and 
its downstream targets, including regucalcin) in hepatocytes can contribute to a basal increase in 
oxidative stress and apoptosis.  Since several TNF-α related genes were upregulated basally in 
KO livers, we reasoned that the prevalence of basal apoptosis was occurring through activation 
of the TNF-α pathway, one of the major death-receptor mediated apoptotic pathways in liver.  
Indeed, there was a clear increase in basal inflammation in KO livers, as evidenced by the 
increase in CD45+ve cells, which are a prominent source of TNF-α.  Intriguingly, however, we 
found that our β-catenin KO mice were largely protected from the effects of exogenous 
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GalN/LPS induced hepatotoxicity and apoptosis, while the WT animals died at the expected 
times and with predictable pathologic progression.  All of the hallmarks of apoptotic death, 
which were present in the WTs – including caspase activation, elevated liver enzymes, TUNEL 
positivity, and disintegration of liver architecture – were absent or greatly diminished in the KO 
livers. 
What is the mechanism of prolonged survival in these β-catenin KO mice?  As mentioned 
previously, activation of the TNF-α pathway can stimulate two opposing pathways which result 
in either apoptosis (culminating in activation of caspase-8) or cell survival (culminating in 
activation of NF-κB) [403].  How this pathway is tipped to either direction remains an enigma.  
We do observe a basal increase in apoptosis in KOs but also demonstrate an increase in NF-κB 
pathway activation, and since the animals lack an overt phenotype, the balance clearly tips 
toward survival.  Indeed, we found that levels of NF-κB and many of its downstream targets 
continue to be maintained in KO mice after insult.  In addition, we found NF-κB to be basally 
active in KOs under unstimulated conditions, confirming that NF-κB is exerting a protective 
response in the KO animals. 
 A role for NF-κB in suppression of programmed cell death was first described in RelA 
(p65) knockout mice, which died at embryonic day 15 of massive hepatocyte apoptosis [457].  
This effect is abolished in mice lacking TNF-R1 or TNF-α [458]. However, mice deficient in 
both RelA and TNF-R1 survive until shortly after birth, suggesting that RelA KO mice have an 
enhanced susceptibility to TNF-α, which is expressed in high amounts by hematopoietic 
progenitors [459].  Deletion of IKK2/β and NEMO, subunits of the IKK complex which 
activates NF-κB through phosphorylation of IκB, also result in lethality due to hepatocyte 
apoptosis during midgestation [460, 461].  Thus, proper activation and function of the NF-κB 
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pathway is critical to hepatocyte maturation and survival.  Moreover, transfection of hepatocytes 
with a mutant IκBα superrepressor, which prevents NF-κB activation, sensitizes these cells to 
TNF-α apoptosis [243, 462, 463].  Further, conditional deletion of NEMO, the regulatory subunit 
of the IKK complex, in hepatocytes renders mice susceptible to even low doses of LPS [464], 
further highlighting the indispensible role of NF-κB in protection from TNF-α mediated 
apoptosis.   
It has long been known that constitutive activation of NF-κB suppresses apoptosis in a 
variety of cancers [464].  However, very few experimental models have tested the effects of 
overexpression or constitutive activation of NF-κB on hepatocyte apoptosis.  One study found 
that pretreatment with IL-1 protected mice from the effects of GalN/TNF-α apoptosis through 
activation of NF-κB [465].  To our knowledge, however, ours is the first to report on the effect of 
endogenous rather than inducible NF-κB on hepatocyte survival. 
A recent report has described a mouse strain (Jcl-Imperial Cancer Research (ICR) mice) 
which is less sensitive than C57Bl/6 to GalN/TNF-α induced apoptosis [466].  Induction of NF-
κB binding and activation after GalN/TNF-α treatment was similar in both ICR and C57Bl/6 
mice, which the authors argue is evidence against an increase in NF-κB expression being the 
mechanism of protection from injury.  Interestingly, however, the authors saw increased 
constitutive expression of a short form of c-FLIP, an inhibitor of caspase-8, in the ICR mice, 
which correlated with an increase in survival.  As c-FLIP is a known target of NF-κB signaling, 
it is therefore plausible that basal activation of NF-κB, rather than binding or activation after 
injury, may account for the constitutive upregulation of of this anti-apoptotic protein.  It remains 
to be seen if c-FLIP is also upregulated basally in our β-catenin KO mice, and if it contributes to 
the protection from TNF-α-mediated apoptosis seen in our model as well.  Interestingly, these 
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ICR mice were also found to be more susceptible than C57Bl/6 mice to Jo-2 mediated apoptosis, 
which once again suggests an inverse relationship between resistance to TNF-α-mediated 
apoptosis (concurrent with NF-κB activation) and susceptibility to Fas-mediated apoptosis. 
An important role for β-catenin in inhibiting NF-κB binding and transcriptional activity 
has recently been elucidated in cancer cells [266, 267].  Association of β-catenin with p65 
prevents activation of NF-κB signaling and thus repression of NF-κB has been found in tumors 
with activated β-catenin.  Furthermore, analysis of tumor tissues shows a strong inverse 
correlation between expression of β-catenin and Fas, a target gene of NF-κB [266], as well as 
between β-catenin and iNOS, another NF-κB-dependent gene [267].  It is still unclear whether 
the β-catenin and NF-κB interaction exists as part of a larger protein complex.  Since it is known 
that GSK-3β can phosphorylate both β-catenin and NF-κB, it is plausible that the 
APC/Axin/GSK-3β/β-catenin complex is in close proximity to or in direct physical association 
with the β-catenin/NF-κB/IκK complex.  If true, this association could potentiate the cross-
regulation and signal integration of two distinct cell-survival pathways, thus positioning β-
catenin as the effector molecule of both proliferation and apoptosis.  
In recent years, several small molecule inhibitors of the Wnt/β-catenin pathway have 
been identified.  Since aberrant Wnt pathway activation has been implicated in several types of 
cancers, these antagonists have been touted as the next generation of cancer therapeutics because 
of their anti-proliferative and pro-apoptotic effects [467-469].  Caution must be used, however, 
when prescribing such treatments, as they may have unintended consequences.  As we have 
shown, inhibition of β-catenin does not automatically lead to apoptosis.  Depending on the 
balance of NF-κB and Fas in the cell, as well as other secondary hepatic pathologies, cells treated 
with β-catenin antagonists may actually promote cell survival.  Further pre-clinical work would 
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be necessary in order to determine the long-term effects of NF-κB activation in the context of β-
catenin inhibition.  
 149 
APPENDIX A 
PUBLICATIONS 
Peer-Reviewed Articles: 
 
1. Nejak-Bowen KN, Thompson MD, Singh S, Bowen WC Jr, Dar MJ, Khillan J, Dai C, 
Monga SP.  Accelerated liver regeneration and hepatocarcinogenesis in mice overexpressing 
serine-45 mutant beta-catenin.  Hepatology. 2010 May;51(5):1603-13. 
 
2. Nejak-Bowen KN, Zeng G, Tan X, Cieply B, Monga SP.  Beta-catenin regulates vitamin C 
biosynthesis and cell survival in murine liver. J Biol Chem. 2009 Oct 9;284(41):28115-27. 
Epub 2009 Aug 18. 
 
3. Paranjpe S, Bowen WC, Bell AW, Nejak-Bowen K, Luo JH, Michalopoulos GK. Cell cycle 
effects resulting from inhibition of hepatocyte growth factor and its receptor c-Met in 
regenerating rat livers by RNA interference.  Hepatology. 2007 Jun;45(6):1471-7. 
 
 
Reviews and Book Chapters: 
 
 
1. Thompson M, Nejak-Bowen K, and Monga SPS.  Crosstalk of the Wnt signaling pathway.  
Targeting the Wnt pathway in cancer.  Springer.  (Book chapter, in press). 
 
2. Nejak-Bowen K and Monga SPS.  Wnt/β-catenin signaling in hepatic organogenesis.  
Organogenesis.  2008  4(2): 92-99. 
 
 150 
BIBLIOGRAPHY 
 
 
1. Wodarz, A. and R. Nusse, Mechanisms of Wnt signaling in development. Annu Rev Cell 
Dev Biol, 1998. 14: p. 59-88. 
2. Cadigan, K.M. and R. Nusse, Wnt signaling: a common theme in animal development. 
Genes Dev, 1997. 11(24): p. 3286-305. 
3. Nusse, R., Wnt signaling in disease and in development. Cell Res, 2005. 15(1): p. 28-32. 
4. Logan, C.Y. and R. Nusse, The Wnt signaling pathway in development and disease. Annu 
Rev Cell Dev Biol, 2004. 20: p. 781-810. 
5. Peifer, M. and P. Polakis, Wnt signaling in oncogenesis and embryogenesis--a look 
outside the nucleus. Science, 2000. 287(5458): p. 1606-9. 
6. Willert, K., et al., Wnt proteins are lipid-modified and can act as stem cell growth 
factors. Nature, 2003. 423(6938): p. 448-52. 
7. Polakis, P., Wnt signaling and cancer. Genes Dev, 2000. 14(15): p. 1837-51. 
8. Paul, S. and A. Dey, Wnt signaling and cancer development: therapeutic implication. 
Neoplasma, 2008. 55(3): p. 165-76. 
9. Clevers, H., Wnt/beta-catenin signaling in development and disease. Cell, 2006. 127(3): 
p. 469-80. 
10. Wong, H.C., et al., Direct binding of the PDZ domain of Dishevelled to a conserved 
internal sequence in the C-terminal region of Frizzled. Mol Cell, 2003. 12(5): p. 1251-60. 
11. Cliffe, A., F. Hamada, and M. Bienz, A role of Dishevelled in relocating Axin to the 
plasma membrane during wingless signaling. Curr Biol, 2003. 13(11): p. 960-6. 
12. Zeng, X., et al., Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 
phosphorylation/activation via frizzled, dishevelled and axin functions. Development, 
2008. 135(2): p. 367-75. 
13. Zeng, X., et al., A dual-kinase mechanism for Wnt co-receptor phosphorylation and 
activation. Nature, 2005. 438(7069): p. 873-7. 
14. Cadigan, K.M. and Y.I. Liu, Wnt signaling: complexity at the surface. J Cell Sci, 2006. 
119(Pt 3): p. 395-402. 
15. Yokoya, F., et al., beta-catenin can be transported into the nucleus in a Ran-unassisted 
manner. Mol Biol Cell, 1999. 10(4): p. 1119-31. 
16. Huber, O., et al., Nuclear localization of beta-catenin by interaction with transcription 
factor LEF-1. Mech Dev, 1996. 59(1): p. 3-10. 
 151 
17. Boon, E.M., et al., Wnt signaling regulates expression of the receptor tyrosine kinase met 
in colorectal cancer. Cancer Res, 2002. 62(18): p. 5126-8. 
18. Rodilla, V., et al., Jagged1 is the pathological link between Wnt and Notch pathways in 
colorectal cancer. Proc Natl Acad Sci U S A, 2009. 106(15): p. 6315-20. 
19. Koh, T.J., et al., Gastrin is a target of the beta-catenin/TCF-4 growth-signaling pathway 
in a model of intestinal polyposis. J Clin Invest, 2000. 106(4): p. 533-9. 
20. Brabletz, T., et al., beta-catenin regulates the expression of the matrix metalloproteinase-
7 in human colorectal cancer. Am J Pathol, 1999. 155(4): p. 1033-8. 
21. Zhang, T., et al., Evidence that APC regulates survivin expression: a possible mechanism 
contributing to the stem cell origin of colon cancer. Cancer Res, 2001. 61(24): p. 8664-7. 
22. Hendrix, N.D., et al., Fibroblast growth factor 9 has oncogenic activity and is a 
downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer 
Res, 2006. 66(3): p. 1354-62. 
23. Chamorro, M.N., et al., FGF-20 and DKK1 are transcriptional targets of beta-catenin 
and FGF-20 is implicated in cancer and development. Embo J, 2005. 24(1): p. 73-84. 
24. Shimokawa, T., et al., Involvement of the FGF18 gene in colorectal carcinogenesis, as a 
novel downstream target of the beta-catenin/T-cell factor complex. Cancer Res, 2003. 
63(19): p. 6116-20. 
25. Shtutman, M., et al., The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. 
Proc Natl Acad Sci U S A, 1999. 96(10): p. 5522-7. 
26. Tetsu, O. and F. McCormick, Beta-catenin regulates expression of cyclin D1 in colon 
carcinoma cells. Nature, 1999. 398(6726): p. 422-6. 
27. He, T.C., et al., Identification of c-MYC as a target of the APC pathway. Science, 1998. 
281(5382): p. 1509-12. 
28. Leung, J.Y., et al., Activation of AXIN2 expression by beta-catenin-T cell factor. A 
feedback repressor pathway regulating Wnt signaling. J Biol Chem, 2002. 277(24): p. 
21657-65. 
29. Roose, J., et al., Synergy between tumor suppressor APC and the beta-catenin-Tcf4 target 
Tcf1. Science, 1999. 285(5435): p. 1923-6. 
30. Cadigan, K.M., et al., Wingless repression of Drosophila frizzled 2 expression shapes the 
Wingless morphogen gradient in the wing. Cell, 1998. 93(5): p. 767-77. 
31. Khan, Z., et al., Analysis of endogenous LRP6 function reveals a novel feedback 
mechanism by which Wnt negatively regulates its receptor. Mol Cell Biol, 2007. 27(20): 
p. 7291-301. 
32. Hovanes, K., et al., Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are 
selectively expressed in colon cancer. Nat Genet, 2001. 28(1): p. 53-7. 
33. MacDonald, B.T., K. Tamai, and X. He, Wnt/beta-catenin signaling: components, 
mechanisms, and diseases. Dev Cell, 2009. 17(1): p. 9-26. 
34. Cadoret, A., et al., New targets of beta-catenin signaling in the liver are involved in the 
glutamine metabolism. Oncogene, 2002. 21(54): p. 8293-301. 
35. Loeppen, S., et al., A beta-catenin-dependent pathway regulates expression of 
cytochrome P450 isoforms in mouse liver tumors. Carcinogenesis, 2005. 26(1): p. 239-
48. 
36. Giera, S., et al., Wnt/beta-catenin signaling activates and determines hepatic zonal 
expression of glutathione S-transferases in mouse liver. Toxicol Sci. 115(1): p. 22-33. 
 152 
37. Ovejero, C., et al., Identification of the leukocyte cell-derived chemotaxin 2 as a direct 
target gene of beta-catenin in the liver. Hepatology, 2004. 40(1): p. 167-76. 
38. Nejak-Bowen, K.N., et al., Beta-catenin regulates vitamin C biosynthesis and cell 
survival in murine liver. J Biol Chem, 2009. 284(41): p. 28115-27. 
39. Lilien, J. and J. Balsamo, The regulation of cadherin-mediated adhesion by tyrosine 
phosphorylation/dephosphorylation of beta-catenin. Curr Opin Cell Biol, 2005. 17(5): p. 
459-65. 
40. Orsulic, S., et al., E-cadherin binding prevents beta-catenin nuclear localization and 
beta-catenin/LEF-1-mediated transactivation. J Cell Sci, 1999. 112 ( Pt 8): p. 1237-45. 
41. Aberle, H., et al., Assembly of the cadherin-catenin complex in vitro with recombinant 
proteins. J Cell Sci, 1994. 107 ( Pt 12): p. 3655-63. 
42. Roura, S., et al., Regulation of E-cadherin/Catenin association by tyrosine 
phosphorylation. J Biol Chem, 1999. 274(51): p. 36734-40. 
43. Piedra, J., et al., Regulation of beta-catenin structure and activity by tyrosine 
phosphorylation. J Biol Chem, 2001. 276(23): p. 20436-43. 
44. Theard, D., et al., Cell polarity development and protein trafficking in hepatocytes 
lacking E-cadherin/beta-catenin-based adherens junctions. Mol Biol Cell, 2007. 18(6): p. 
2313-21. 
45. Tang, Y., et al., Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta 
and IL-6 signaling. Proc Natl Acad Sci U S A, 2008. In press. 
46. Peinado, H., M. Quintanilla, and A. Cano, Transforming growth factor beta-1 induces 
snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal 
transitions. J Biol Chem, 2003. 278(23): p. 21113-23. 
47. Katuri, V., et al., Critical interactions between TGF-beta signaling/ELF, and E-
cadherin/beta-catenin mediated tumor suppression. Oncogene, 2006. 25(13): p. 1871-86. 
48. Zarnegar, R., Regulation of HGF and HGFR gene expression. Exs, 1995. 74: p. 33-49. 
49. Monga, S.P., et al., beta-Catenin regulation during matrigel-induced rat hepatocyte 
differentiation. Cell Tissue Res, 2006. 323(1): p. 71-9. 
50. Papkoff, J. and M. Aikawa, WNT-1 and HGF regulate GSK3 beta activity and beta-
catenin signaling in mammary epithelial cells. Biochem Biophys Res Commun, 1998. 
247(3): p. 851-8. 
51. Monga, S.P., et al., Hepatocyte growth factor induces Wnt-independent nuclear 
translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes. Cancer 
Res, 2002. 62(7): p. 2064-71. 
52. Zeng, G., et al., Tyrosine residues 654 and 670 in beta-catenin are crucial in regulation 
of Met-beta-catenin interactions. Exp Cell Res, 2006. 312(18): p. 3620-30. 
53. Apte, U., et al., Activation of Wnt/beta-catenin pathway during hepatocyte growth factor-
induced hepatomegaly in mice. Hepatology, 2006. 44(4): p. 992-1002. 
54. Ishibe, S., et al., Cell confluence regulates hepatocyte growth factor-stimulated cell 
morphogenesis in a beta-catenin-dependent manner. Mol Cell Biol, 2006. 26(24): p. 
9232-43. 
55. Tward, A.D., et al., Distinct pathways of genomic progression to benign and malignant 
tumors of the liver. Proc Natl Acad Sci U S A, 2007. 104(37): p. 14771-6. 
56. Zaret, K.S., Molecular genetics of early liver development. Annu Rev Physiol, 1996. 58: 
p. 231-51. 
 153 
57. Zaret, K.S., Hepatocyte differentiation: from the endoderm and beyond. Curr Opin Genet 
Dev, 2001. 11(5): p. 568-74. 
58. Zaret, K.S., Regulatory phases of early liver development: paradigms of organogenesis. 
Nat Rev Genet, 2002. 3(7): p. 499-512. 
59. Spear, B.T., et al., Transcriptional control in the mammalian liver: liver development, 
perinatal repression, and zonal gene regulation. Cell Mol Life Sci, 2006. 63(24): p. 
2922-38. 
60. Lee, C.S., et al., The initiation of liver development is dependent on Foxa transcription 
factors. Nature, 2005. 435(7044): p. 944-7. 
61. Jung, J., et al., Initiation of mammalian liver development from endoderm by fibroblast 
growth factors. Science, 1999. 284(5422): p. 1998-2003. 
62. Matsumoto, K., et al., Liver organogenesis promoted by endothelial cells prior to 
vascular function. Science, 2001. 294(5542): p. 559-63. 
63. Rossi, J.M., et al., Distinct mesodermal signals, including BMPs from the septum 
transversum mesenchyme, are required in combination for hepatogenesis from the 
endoderm. Genes Dev, 2001. 15(15): p. 1998-2009. 
64. Zhang, W., et al., Regulation of Hex gene expression and initial stages of avian 
hepatogenesis by Bmp and Fgf signaling. Dev Biol, 2004. 268(2): p. 312-26. 
65. Martinez Barbera, J.P., et al., The homeobox gene Hex is required in definitive 
endodermal tissues for normal forebrain, liver and thyroid formation. Development, 
2000. 127(11): p. 2433-45. 
66. Bort, R., et al., Hex homeobox gene controls the transition of the endoderm to a 
pseudostratified, cell emergent epithelium for liver bud development. Dev Biol, 2006. 
290(1): p. 44-56. 
67. Hunter, M.P., et al., The homeobox gene Hhex is essential for proper hepatoblast 
differentiation and bile duct morphogenesis. Dev Biol, 2007. 308(2): p. 355-67. 
68. Duncan, S.A., Transcriptional regulation of liver development. Dev Dyn, 2000. 219(2): 
p. 131-42. 
69. Schmidt, C., et al., Scatter factor/hepatocyte growth factor is essential for liver 
development. Nature, 1995. 373(6516): p. 699-702. 
70. Hentsch, B., et al., Hlx homeo box gene is essential for an inductive tissue interaction 
that drives expansion of embryonic liver and gut. Genes Dev, 1996. 10(1): p. 70-9. 
71. Sosa-Pineda, B., J.T. Wigle, and G. Oliver, Hepatocyte migration during liver 
development requires Prox1. Nat Genet, 2000. 25(3): p. 254-5. 
72. Zaret, K., Early liver differentiation: genetic potentiation and multilevel growth control. 
Curr Opin Genet Dev, 1998. 8(5): p. 526-31. 
73. Zaret, K.S., Liver specification and early morphogenesis. Mech Dev, 2000. 92(1): p. 83-
8. 
74. Odom, D.T., et al., Control of pancreas and liver gene expression by HNF transcription 
factors. Science, 2004. 303(5662): p. 1378-81. 
75. Darlington, G.J., N. Wang, and R.W. Hanson, C/EBP alpha: a critical regulator of genes 
governing integrative metabolic processes. Curr Opin Genet Dev, 1995. 5(5): p. 565-70. 
76. Parviz, F., et al., Hepatocyte nuclear factor 4alpha controls the development of a hepatic 
epithelium and liver morphogenesis. Nat Genet, 2003. 34(3): p. 292-6. 
77. Zhao, R., et al., GATA6 is essential for embryonic development of the liver but 
dispensable for early heart formation. Mol Cell Biol, 2005. 25(7): p. 2622-31. 
 154 
78. Clotman, F., et al., The onecut transcription factor HNF6 is required for normal 
development of the biliary tract. Development, 2002. 129(8): p. 1819-28. 
79. Coffinier, C., et al., Bile system morphogenesis defects and liver dysfunction upon 
targeted deletion of HNF1beta. Development, 2002. 129(8): p. 1829-38. 
80. Lorent, K., et al., Inhibition of Jagged-mediated Notch signaling disrupts zebrafish 
biliary development and generates multi-organ defects compatible with an Alagille 
syndrome phenocopy. Development, 2004. 131(22): p. 5753-66. 
81. Zorn, A.M., K. Butler, and J.B. Gurdon, Anterior endomesoderm specification in 
Xenopus by Wnt/beta-catenin and TGF-beta signalling pathways. Dev Biol, 1999. 
209(2): p. 282-97. 
82. Lemaigre, F. and K.S. Zaret, Liver development update: new embryo models, cell lineage 
control, and morphogenesis. Curr Opin Genet Dev, 2004. 14(5): p. 582-90. 
83. McLin, V.A., S.A. Rankin, and A.M. Zorn, Repression of Wnt/beta-catenin signaling in 
the anterior endoderm is essential for liver and pancreas development. Development, 
2007. 134(12): p. 2207-17. 
84. Finley, K.R., J. Tennessen, and W. Shawlot, The mouse secreted frizzled-related protein 
5 gene is expressed in the anterior visceral endoderm and foregut endoderm during early 
post-implantation development. Gene Expr Patterns, 2003. 3(5): p. 681-4. 
85. Pilcher, K.E. and P.A. Krieg, Expression of the Wnt inhibitor, sFRP5, in the gut 
endoderm of Xenopus. Gene Expr Patterns, 2002. 2(3-4): p. 369-72. 
86. Li, Y., et al., Sfrp5 coordinates foregut specification and morphogenesis by antagonizing 
both canonical and noncanonical Wnt11 signaling. Genes Dev, 2008. 22(21): p. 3050-63. 
87. Yoshida, Y., et al., Calcineurin inhibitors block dorsal-side signaling that affect late-
stage development of the heart, kidney, liver, gut and somitic tissue during Xenopus 
embryogenesis. Dev Growth Differ, 2004. 46(2): p. 139-52. 
88. Ober, E.A., et al., Mesodermal Wnt2b signalling positively regulates liver specification. 
Nature, 2006. 442(7103): p. 688-91. 
89. Monga, S.P., et al., Beta-catenin antisense studies in embryonic liver cultures: role in 
proliferation, apoptosis, and lineage specification. Gastroenterology, 2003. 124(1): p. 
202-16. 
90. Suksaweang, S., et al., Morphogenesis of chicken liver: identification of localized growth 
zones and the role of beta-catenin/Wnt in size regulation. Dev Biol, 2004. 266(1): p. 109-
22. 
91. Micsenyi, A., et al., Beta-catenin is temporally regulated during normal liver 
development. Gastroenterology, 2004. 126(4): p. 1134-46. 
92. Wang, Q.M., et al., [The role of beta-catenin in rat embryonic development and 
tumorigenesis]. Sichuan Da Xue Xue Bao Yi Xue Ban, 2006. 37(6): p. 872-5. 
93. Monga, S.P., et al., Mouse fetal liver cells in artificial capillary beds in three-
dimensional four-compartment bioreactors. Am J Pathol, 2005. 167(5): p. 1279-92. 
94. Tan, X., et al., Conditional deletion of beta-catenin reveals its role in liver growth and 
regeneration. Gastroenterology, 2006. 131(5): p. 1561-72. 
95. Hussain, S.Z., et al., Wnt impacts growth and differentiation in ex vivo liver development. 
Exp Cell Res, 2004. 292(1): p. 157-69. 
96. Tan, X., et al., Beta-catenin deletion in hepatoblasts disrupts hepatic morphogenesis and 
survival during mouse development. Hepatology, 2008. 47(5): p. 1667-79. 
 155 
97. Eisenberg, L.M. and C.A. Eisenberg, Evaluating the role of Wnt signal transduction in 
promoting the development of the heart. ScientificWorldJournal, 2007. 7: p. 161-76. 
98. Tzahor, E., Wnt/beta-catenin signaling and cardiogenesis: timing does matter. Dev Cell, 
2007. 13(1): p. 10-3. 
99. Lickert, H., et al., Expression patterns of Wnt genes in mouse gut development. Mech 
Dev, 2001. 105(1-2): p. 181-4. 
100. Ang, S.J., et al., Spatial and temporal expression of Wnt and Dickkopf genes during 
murine lens development. Gene Expr Patterns, 2004. 4(3): p. 289-95. 
101. Naito, A.T., et al., Developmental stage-specific biphasic roles of Wnt/beta-catenin 
signaling in cardiomyogenesis and hematopoiesis. Proc Natl Acad Sci U S A, 2006. 
103(52): p. 19812-7. 
102. Kim, B.M., et al., Phases of canonical Wnt signaling during the development of mouse 
intestinal epithelium. Gastroenterology, 2007. 133(2): p. 529-38. 
103. Michalopoulos, G.K. and M.C. DeFrances, Liver regeneration. Science, 1997. 
276(5309): p. 60-6. 
104. Higgins, G.M. and R.M. Anderson, Experimental pathology of the liver, 1:Restoration of 
the liver of the white rat following partial surgical removal. . Arch Pathol 1931. 12: p. 
186-202. 
105. Michalopoulos, G.K., Liver regeneration. J Cell Physiol, 2007. 213(2): p. 286-300. 
106. Mars, W.M., et al., Presence of urokinase in serum-free primary rat hepatocyte cultures 
and its role in activating hepatocyte growth factor. Cancer Res, 1996. 56(12): p. 2837-43. 
107. Nakamura, T., et al., Molecular cloning and expression of human hepatocyte growth 
factor. Nature, 1989. 342(6248): p. 440-3. 
108. Stolz, D.B., et al., Growth factor signal transduction immediately after two-thirds partial 
hepatectomy in the rat. Cancer Res, 1999. 59(16): p. 3954-60. 
109. Delehedde, M., et al., Hepatocyte growth factor/scatter factor stimulates migration of rat 
mammary fibroblasts through both mitogen-activated protein kinase and 
phosphatidylinositol 3-kinase/Akt pathways. Eur J Biochem, 2001. 268(16): p. 4423-9. 
110. Xiao, G.H., et al., Anti-apoptotic signaling by hepatocyte growth factor/Met via the 
phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc 
Natl Acad Sci U S A, 2001. 98(1): p. 247-52. 
111. Pediaditakis, P., et al., The processing and utilization of hepatocyte growth factor/scatter 
factor following partial hepatectomy in the rat. Hepatology, 2001. 34(4 Pt 1): p. 688-93. 
112. Lindroos, P.M., R. Zarnegar, and G.K. Michalopoulos, Hepatocyte growth factor 
(hepatopoietin A) rapidly increases in plasma before DNA synthesis and liver 
regeneration stimulated by partial hepatectomy and carbon tetrachloride administration. 
Hepatology, 1991. 13(4): p. 743-50. 
113. Zarnegar, R., et al., Expression of hepatocyte growth factor mRNA in regenerating rat 
liver after partial hepatectomy. Biochem Biophys Res Commun, 1991. 177(1): p. 559-65. 
114. Taub, R., Liver regeneration 4: transcriptional control of liver regeneration. Faseb J, 
1996. 10(4): p. 413-27. 
115. Su, A.I., et al., Gene expression during the priming phase of liver regeneration after 
partial hepatectomy in mice. Proc Natl Acad Sci U S A, 2002. 99(17): p. 11181-6. 
116. White, P., et al., Identification of transcriptional networks during liver regeneration. J 
Biol Chem, 2005. 280(5): p. 3715-22. 
 156 
117. Walker, P.R. and V.R. Potter, Isozyme studies on adult, regenerating, precancerous and 
developing liver in relation to findings in hepatomas. Adv Enzyme Regul, 1972. 10: p. 
339-64. 
118. Rabes, H.M., Kinetics of hepatocellular proliferation as a function of the microvascular 
structure and functional state of the liver. Ciba Found Symp, 1977(55): p. 31-53. 
119. Stocker, E. and W.D. Heine, Regeneration of liver parenchyma under normal and 
pathological conditions. Beitr Pathol, 1971. 144(4): p. 400-8. 
120. Stocker, E., H.K. Wullstein, and G. Brau, [Capacity of regeneration in liver epithelia of 
juvenile, repeated partially hepatectomized rats. Autoradiographic studies after 
continous infusion of 3H-thymidine (author's transl)]. Virchows Arch B Cell Pathol, 
1973. 14(2): p. 93-103. 
121. Grisham, J.W., A morphologic study of deoxyribonucleic acid synthesis and cell 
proliferation in regenerating rat liver; autoradiography with thymidine-H3. Cancer Res, 
1962. 22: p. 842-9. 
122. Nelsen, C.J., et al., Transient expression of cyclin D1 is sufficient to promote hepatocyte 
replication and liver growth in vivo. Cancer Res, 2001. 61(23): p. 8564-8. 
123. Gonzalez, F.J., Role of beta-catenin in the adult liver. Hepatology, 2006. 43(4): p. 650-3. 
124. Benhamouche, S., et al., Apc tumor suppressor gene is the "zonation-keeper" of mouse 
liver. Dev Cell, 2006. 10(6): p. 759-70. 
125. Sekine, S., et al., Liver-specific loss of beta-catenin blocks glutamine synthesis pathway 
activity and cytochrome p450 expression in mice. Hepatology, 2006. 43(4): p. 817-25. 
126. Monga, S.P., et al., Changes in WNT/beta-catenin pathway during regulated growth in 
rat liver regeneration. Hepatology, 2001. 33(5): p. 1098-109. 
127. Sodhi, D., et al., Morpholino oligonucleotide-triggered beta-catenin knockdown 
compromises normal liver regeneration. J Hepatol, 2005. 43(1): p. 132-41. 
128. Sekine, S., et al., Liver-specific loss of beta-catenin results in delayed hepatocyte 
proliferation after partial hepatectomy. Hepatology, 2007. 45(2): p. 361-8. 
129. Apte, U., et al., beta-Catenin is critical for early postnatal liver growth. Am J Physiol 
Gastrointest Liver Physiol, 2007. 292(6): p. G1578-85. 
130. Cadoret, A., et al., Hepatomegaly in transgenic mice expressing an oncogenic form of 
beta-catenin. Cancer Res, 2001. 61(8): p. 3245-9. 
131. Harada, N., et al., Lack of tumorigenesis in the mouse liver after adenovirus-mediated 
expression of a dominant stable mutant of beta-catenin. Cancer Res, 2002. 62(7): p. 
1971-7. 
132. Tan, X., et al., Epidermal growth factor receptor: a novel target of the Wnt/beta-catenin 
pathway in liver. Gastroenterology, 2005. 129(1): p. 285-302. 
133. Diesen, D.L. and P.C. Kuo, Nitric oxide and redox regulation in the liver: Part I. General 
considerations and redox biology in hepatitis. J Surg Res. 162(1): p. 95-109. 
134. Lander, H.M., An essential role for free radicals and derived species in signal 
transduction. Faseb J, 1997. 11(2): p. 118-24. 
135. Sies, H., Oxidative stress: oxidants and antioxidants. Exp Physiol, 1997. 82(2): p. 291-5. 
136. Kang, K.J., Mechanism of hepatic ischemia/reperfusion injury and protection against 
reperfusion injury. Transplant Proc, 2002. 34(7): p. 2659-61. 
137. Han, D., E. Williams, and E. Cadenas, Mitochondrial respiratory chain-dependent 
generation of superoxide anion and its release into the intermembrane space. Biochem J, 
2001. 353(Pt 2): p. 411-6. 
 157 
138. Nohl, H., et al., Are mitochondria a spontaneous and permanent source of reactive 
oxygen species? Redox Rep, 2003. 8(3): p. 135-41. 
139. Sutton, H.C. and C.C. Winterbourn, On the participation of higher oxidation states of 
iron and copper in Fenton reactions. Free Radic Biol Med, 1989. 6(1): p. 53-60. 
140. Kessova, I.G., et al., Alcohol-induced liver injury in mice lacking Cu, Zn-superoxide 
dismutase. Hepatology, 2003. 38(5): p. 1136-45. 
141. Koop, D.R. and D.J. Tierney, Multiple mechanisms in the regulation of ethanol-inducible 
cytochrome P450IIE1. Bioessays, 1990. 12(9): p. 429-35. 
142. Qiu, Y., L.Z. Benet, and A.L. Burlingame, Identification of the hepatic protein targets of 
reactive metabolites of acetaminophen in vivo in mice using two-dimensional gel 
electrophoresis and mass spectrometry. J Biol Chem, 1998. 273(28): p. 17940-53. 
143. Gong, G., et al., Human hepatitis C virus NS5A protein alters intracellular calcium 
levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad 
Sci U S A, 2001. 98(17): p. 9599-604. 
144. Okuda, M., et al., Mitochondrial injury, oxidative stress, and antioxidant gene expression 
are induced by hepatitis C virus core protein. Gastroenterology, 2002. 122(2): p. 366-75. 
145. Zamara, E., et al., 4-Hydroxynonenal as a selective pro-fibrogenic stimulus for activated 
human hepatic stellate cells. J Hepatol, 2004. 40(1): p. 60-8. 
146. McCord, J.M., Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med, 
1985. 312(3): p. 159-63. 
147. Harbrecht, B.G., et al., Nitric oxide synthesis serves to reduce hepatic damage during 
acute murine endotoxemia. Crit Care Med, 1992. 20(11): p. 1568-74. 
148. Kamiya, K., et al., The cytoprotective role of lipopolysaccharide-induced nitric oxide 
against liver damage during early phase of endotoxemia in rats. Shock, 2000. 14(2): p. 
229-33. 
149. Jaeschke, H., Reactive oxygen and mechanisms of inflammatory liver injury. J 
Gastroenterol Hepatol, 2000. 15(7): p. 718-24. 
150. Hug, H., et al., Reactive oxygen intermediates are involved in the induction of CD95 
ligand mRNA expression by cytostatic drugs in hepatoma cells. J Biol Chem, 1997. 
272(45): p. 28191-3. 
151. Poli, G., J.C. Cutrin, and F. Biasi, Lipid peroxidation in the reperfusion injury of the 
liver. Free Radic Res, 1998. 28(6): p. 547-51. 
152. Jaeschke, H., et al., Glutathione peroxidase-deficient mice are more susceptible to 
neutrophil-mediated hepatic parenchymal cell injury during endotoxemia: importance of 
an intracellular oxidant stress. Hepatology, 1999. 29(2): p. 443-50. 
153. Bellezzo, J.M., et al., Modulation of lipopolysaccharide-mediated activation in rat 
Kupffer cells by antioxidants. J Lab Clin Med, 1998. 131(1): p. 36-44. 
154. Adamson, G.M. and R.E. Billings, Tumor necrosis factor induced oxidative stress in 
isolated mouse hepatocytes. Arch Biochem Biophys, 1992. 294(1): p. 223-9. 
155. Hampton, M.B. and S. Orrenius, Dual regulation of caspase activity by hydrogen 
peroxide: implications for apoptosis. FEBS Lett, 1997. 414(3): p. 552-6. 
156. Lemasters, J.J., et al., The mitochondrial permeability transition in cell death: a common 
mechanism in necrosis, apoptosis and autophagy. Biochim Biophys Acta, 1998. 1366(1-
2): p. 177-96. 
 158 
157. Sanchez, A., et al., Apoptosis induced by transforming growth factor-beta in fetal 
hepatocyte primary cultures: involvement of reactive oxygen intermediates. J Biol Chem, 
1996. 271(13): p. 7416-22. 
158. Glantzounis, G.K., et al., The contemporary role of antioxidant therapy in attenuating 
liver ischemia-reperfusion injury: a review. Liver Transpl, 2005. 11(9): p. 1031-47. 
159. Liu, P., et al., Beneficial effects of extracellular glutathione against endotoxin-induced 
liver injury during ischemia and reperfusion. Circ Shock, 1994. 43(2): p. 64-70. 
160. Wefers, H. and H. Sies, Oxidation of glutathione by the superoxide radical to the 
disulfide and the sulfonate yielding singlet oxygen. Eur J Biochem, 1983. 137(1-2): p. 29-
36. 
161. Chance, B., H. Sies, and A. Boveris, Hydroperoxide metabolism in mammalian organs. 
Physiol Rev, 1979. 59(3): p. 527-605. 
162. Zelko, I.N., T.J. Mariani, and R.J. Folz, Superoxide dismutase multigene family: a 
comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene 
structures, evolution, and expression. Free Radic Biol Med, 2002. 33(3): p. 337-49. 
163. Yamaguchi, M., Role of regucalcin in maintaining cell homeostasis and function 
(review). Int J Mol Med, 2005. 15(3): p. 371-89. 
164. Takahasi, H. and M. Yamaguchi, Enhancement of plasma membrane (Ca(2+)-Mg2+)-
ATPase activity in regenerating rat liver: involvement of endogenous activating protein 
regucalcin. Mol Cell Biochem, 1996. 162(2): p. 133-8. 
165. Fujita, T., Senescence marker protein-30 (SMP30): structure and biological function. 
Biochem Biophys Res Commun, 1999. 254(1): p. 1-4. 
166. Yamaguchi, M., Mitochondrial uptake of 45Ca2+ bound to calcium-binding protein 
isolated from rat liver cytosol. Chem Pharm Bull (Tokyo), 1985. 33(8): p. 3390-4. 
167. Takahashi, H. and M. Yamaguchi, Role of regucalcin as an activator of Ca(2+)-ATPase 
activity in rat liver microsomes. J Cell Biochem, 1999. 74(4): p. 663-9. 
168. Yamaguchi, M., Effect of calcium-binding protein regucalcin on Ca2+ transport system 
in rat liver nuclei: stimulation of Ca2+ release. Mol Cell Biochem, 1992. 113(1): p. 63-
70. 
169. Tsurusaki, Y. and M. Yamaguchi, Role of endogenous regucalcin in the regulation of 
Ca(2+)-ATPase activity in rat liver nuclei. J Cell Biochem, 2000. 78(4): p. 541-9. 
170. Murata, T. and M. Yamaguchi, Ca2+ administration stimulates the binding of AP-1 
factor to the 5'-flanking region of the rat gene for the Ca2+-binding protein regucalcin. 
Biochem J, 1998. 329 ( Pt 1): p. 157-63. 
171. Shimokawa, N. and M. Yamaguchi, Calcium administration stimulates the expression of 
calcium-binding protein regucalcin mRNA in rat liver. FEBS Lett, 1992. 305(2): p. 151-
4. 
172. Tsurusaki, Y. and M. Yamaguchi, Role of endogenous regucalcin in transgenic rats: 
suppression of protein tyrosine phosphatase and ribonucleic acid synthesis activities in 
liver nucleus. Int J Mol Med, 2003. 12(2): p. 207-11. 
173. Yamaguchi, M. and M. Isogai, Tissue concentration of calcium-binding protein 
regucalcin in rats by enzyme-linked immunoadsorbent assay. Mol Cell Biochem, 1993. 
122(1): p. 65-8. 
174. Yamaguchi, M. and H. Yoshida, Regulatory effect of calcium-binding protein isolated 
from rat liver cytosol on activation of fructose 1,6-diphosphatase by Ca2+-calmodulin. 
Chem Pharm Bull (Tokyo), 1985. 33(10): p. 4489-93. 
 159 
175. Yamaguchi, M. and H. Tai, Inhibitory effect of calcium-binding protein regucalcin on 
Ca2+/calmodulin-dependent cyclic nucleotide phosphodiesterase activity in rat liver 
cytosol. Mol Cell Biochem, 1991. 106(1): p. 25-30. 
176. Yamaguchi, M., The role of regucalcin in nuclear regulation of regenerating liver. 
Biochem Biophys Res Commun, 2000. 276(1): p. 1-6. 
177. Yamaguchi, M. and Y. Kanayama, Enhanced expression of calcium-binding protein 
regucalcin mRNA in regenerating rat liver. J Cell Biochem, 1995. 57(2): p. 185-90. 
178. Yamaguchi, M. and Y. Kanayama, Calcium-binding protein regucalcin inhibits 
deoxyribonucleic acid synthesis in the nuclei of regenerating rat liver. Mol Cell 
Biochem, 1996. 162(2): p. 121-6. 
179. Yamaguchi, M. and S. Ueoka, Inhibitory effect of calcium-binding protein regucalcin on 
ribonucleic acid synthesis in isolated rat liver nuclei. Mol Cell Biochem, 1997. 173(1-2): 
p. 169-75. 
180. Tsurusaki, Y. and M. Yamaguchi, Suppressive effect of endogenous regucalcin on the 
enhancement of protein synthesis and aminoacyl-tRNA synthetase activity in 
regenerating rat liver. Int J Mol Med, 2000. 6(3): p. 295-9. 
181. Tsurusaki, Y. and M. Yamaguchi, Overexpression of regucalcin modulates tumor-related 
gene expression in cloned rat hepatoma H4-II-E cells. J Cell Biochem, 2003. 90(3): p. 
619-26. 
182. Fukaya, Y. and M. Yamaguchi, Regucalcin increases superoxide dismutase activity in rat 
liver cytosol. Biol Pharm Bull, 2004. 27(9): p. 1444-6. 
183. Yamaguchi, M., H. Takahashi, and Y. Tsurusaki, Suppressive role of endogenous 
regucalcin in the enhancement of nitric oxide synthase activity in liver cytosol of normal 
and regucalcin transgenic rats. J Cell Biochem, 2003. 88(6): p. 1226-34. 
184. Handa, S., N. Maruyama, and A. Ishigami, Over-expression of Senescence Marker 
Protein-30 decreases reactive oxygen species in human hepatic carcinoma Hep G2 cells. 
Biol Pharm Bull, 2009. 32(10): p. 1645-8. 
185. Sato, T., et al., Senescence marker protein-30 protects mice lungs from oxidative stress, 
aging, and smoking. Am J Respir Crit Care Med, 2006. 174(5): p. 530-7. 
186. Son, T.G., et al., SMP30 deficiency causes increased oxidative stress in brain. Mech 
Ageing Dev, 2006. 127(5): p. 451-7. 
187. Kondo, Y., et al., Vitamin C depletion increases superoxide generation in brains of 
SMP30/GNL knockout mice. Biochem Biophys Res Commun, 2008. 377(1): p. 291-6. 
188. Yamaguchi, M. and T. Sakurai, Inhibitory effect of calcium-binding protein regucalcin 
on Ca2(+)-activated DNA fragmentation in rat liver nuclei. FEBS Lett, 1991. 279(2): p. 
281-4. 
189. Izumi, T. and M. Yamaguchi, Overexpression of regucalcin suppresses cell death in 
cloned rat hepatoma H4-II-E cells induced by tumor necrosis factor-alpha or 
thapsigargin. J Cell Biochem, 2004. 92(2): p. 296-306. 
190. Izumi, T. and M. Yamaguchi, Overexpression of regucalcin suppresses cell death and 
apoptosis in cloned rat hepatoma H4-II-E cells induced by lipopolysaccharide, PD 
98059, dibucaine, or Bay K 8644. J Cell Biochem, 2004. 93(3): p. 598-608. 
191. Matsuyama, S., et al., Senescence marker protein-30 regulates Akt activity and 
contributes to cell survival in Hep G2 cells. Biochem Biophys Res Commun, 2004. 
321(2): p. 386-90. 
 160 
192. Ishigami, A., et al., Senescence marker protein-30 knockout mouse liver is highly 
susceptible to tumor necrosis factor-alpha- and Fas-mediated apoptosis. Am J Pathol, 
2002. 161(4): p. 1273-81. 
193. Kondo, Y., et al., Senescence marker protein 30 functions as gluconolactonase in L-
ascorbic acid biosynthesis, and its knockout mice are prone to scurvy. Proc Natl Acad Sci 
U S A, 2006. 103(15): p. 5723-8. 
194. Ding, W.X. and X.M. Yin, Dissection of the multiple mechanisms of TNF-alpha-induced 
apoptosis in liver injury. J Cell Mol Med, 2004. 8(4): p. 445-54. 
195. Yoon, J.H. and G.J. Gores, Death receptor-mediated apoptosis and the liver. J Hepatol, 
2002. 37(3): p. 400-10. 
196. Akazawa, Y. and G.J. Gores, Death receptor-mediated liver injury. Semin Liver Dis, 
2007. 27(4): p. 327-38. 
197. Nagata, S., Apoptosis by death factor. Cell, 1997. 88(3): p. 355-65. 
198. Yin, X.M. and W.X. Ding, Death receptor activation-induced hepatocyte apoptosis and 
liver injury. Curr Mol Med, 2003. 3(6): p. 491-508. 
199. Galle, P.R. and P.H. Krammer, CD95-induced apoptosis in human liver disease. Semin 
Liver Dis, 1998. 18(2): p. 141-51. 
200. Canbay, A., et al., Fas enhances fibrogenesis in the bile duct ligated mouse: a link 
between apoptosis and fibrosis. Gastroenterology, 2002. 123(4): p. 1323-30. 
201. Faouzi, S., et al., Anti-Fas induces hepatic chemokines and promotes inflammation by an 
NF-kappa B-independent, caspase-3-dependent pathway. J Biol Chem, 2001. 276(52): p. 
49077-82. 
202. Galle, P.R., et al., Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver 
damage. J Exp Med, 1995. 182(5): p. 1223-30. 
203. Ribeiro, P.S., et al., Hepatocyte apoptosis, expression of death receptors, and activation 
of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J 
Gastroenterol, 2004. 99(9): p. 1708-17. 
204. Rudiger, H.A. and P.A. Clavien, Tumor necrosis factor alpha, but not Fas, mediates 
hepatocellular apoptosis in the murine ischemic liver. Gastroenterology, 2002. 122(1): p. 
202-10. 
205. Muto, Y., et al., Enhanced tumour necrosis factor and interleukin-1 in fulminant hepatic 
failure. Lancet, 1988. 2(8602): p. 72-4. 
206. McClain, C.J. and D.A. Cohen, Increased tumor necrosis factor production by monocytes 
in alcoholic hepatitis. Hepatology, 1989. 9(3): p. 349-51. 
207. Grove, J., et al., Association of a tumor necrosis factor promoter polymorphism with 
susceptibility to alcoholic steatohepatitis. Hepatology, 1997. 26(1): p. 143-6. 
208. Berke, G., The CTL's kiss of death. Cell, 1995. 81(1): p. 9-12. 
209. Ogasawara, J., et al., Lethal effect of the anti-Fas antibody in mice. Nature, 1993. 
364(6440): p. 806-9. 
210. Peter, M.E. and P.H. Krammer, The CD95(APO-1/Fas) DISC and beyond. Cell Death 
Differ, 2003. 10(1): p. 26-35. 
211. Chinnaiyan, A.M., et al., FADD, a novel death domain-containing protein, interacts with 
the death domain of Fas and initiates apoptosis. Cell, 1995. 81(4): p. 505-12. 
212. Ashkenazi, A. and V.M. Dixit, Death receptors: signaling and modulation. Science, 
1998. 281(5381): p. 1305-8. 
 161 
213. Boldin, M.P., et al., A novel protein that interacts with the death domain of Fas/APO1 
contains a sequence motif related to the death domain. J Biol Chem, 1995. 270(14): p. 
7795-8. 
214. Thorburn, A., Death receptor-induced cell killing. Cell Signal, 2004. 16(2): p. 139-44. 
215. Thornberry, N.A. and Y. Lazebnik, Caspases: enemies within. Science, 1998. 281(5381): 
p. 1312-6. 
216. Scaffidi, C., et al., Two CD95 (APO-1/Fas) signaling pathways. Embo J, 1998. 17(6): p. 
1675-87. 
217. Luo, X., et al., Bid, a Bcl2 interacting protein, mediates cytochrome c release from 
mitochondria in response to activation of cell surface death receptors. Cell, 1998. 94(4): 
p. 481-90. 
218. Yin, X.M., et al., Bid-deficient mice are resistant to Fas-induced hepatocellular 
apoptosis. Nature, 1999. 400(6747): p. 886-91. 
219. de la Coste, A., et al., Differential protective effects of Bcl-xL and Bcl-2 on apoptotic 
liver injury in transgenic mice. Am J Physiol, 1999. 277(3 Pt 1): p. G702-8. 
220. Lacronique, V., et al., Bcl-2 protects from lethal hepatic apoptosis induced by an anti-
Fas antibody in mice. Nat Med, 1996. 2(1): p. 80-6. 
221. Rodriguez, I., et al., A bcl-2 transgene expressed in hepatocytes protects mice from 
fulminant liver destruction but not from rapid death induced by anti-Fas antibody 
injection. J Exp Med, 1996. 183(3): p. 1031-6. 
222. Scaffidi, C., et al., Differential modulation of apoptosis sensitivity in CD95 type I and 
type II cells. J Biol Chem, 1999. 274(32): p. 22532-8. 
223. Tschopp, J., M. Irmler, and M. Thome, Inhibition of fas death signals by FLIPs. Curr 
Opin Immunol, 1998. 10(5): p. 552-8. 
224. Irmler, M., et al., Inhibition of death receptor signals by cellular FLIP. Nature, 1997. 
388(6638): p. 190-5. 
225. Scaffidi, C., et al., The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol 
Chem, 1999. 274(3): p. 1541-8. 
226. Deveraux, Q.L., et al., X-linked IAP is a direct inhibitor of cell-death proteases. Nature, 
1997. 388(6639): p. 300-4. 
227. Daemen, M.A., et al., Functional protection by acute phase proteins alpha(1)-acid 
glycoprotein and alpha(1)-antitrypsin against ischemia/reperfusion injury by preventing 
apoptosis and inflammation. Circulation, 2000. 102(12): p. 1420-6. 
228. Zou, C., et al., Lack of Fas antagonism by Met in human fatty liver disease. Nat Med, 
2007. 13(9): p. 1078-85. 
229. Huh, C.G., et al., Hepatocyte growth factor/c-met signaling pathway is required for 
efficient liver regeneration and repair. Proc Natl Acad Sci U S A, 2004. 101(13): p. 
4477-82. 
230. Zhao, Y., et al., Promotion of Fas-mediated apoptosis in Type II cells by high doses of 
hepatocyte growth factor bypasses the mitochondrial requirement. J Cell Physiol, 2007. 
213(2): p. 556-63. 
231. Smyth, L.A. and H.J. Brady, cMet and Fas receptor interaction inhibits death-inducing 
signaling complex formation in endothelial cells. Hypertension, 2005. 46(1): p. 100-6. 
232. Schwabe, R.F. and D.A. Brenner, Mechanisms of Liver Injury. I. TNF-alpha-induced 
liver injury: role of IKK, JNK, and ROS pathways. Am J Physiol Gastrointest Liver 
Physiol, 2006. 290(4): p. G583-9. 
 162 
233. Chen, G. and D.V. Goeddel, TNF-R1 signaling: a beautiful pathway. Science, 2002. 
296(5573): p. 1634-5. 
234. Hsu, H., et al., TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF 
receptor 1 signal transduction pathways. Cell, 1996. 84(2): p. 299-308. 
235. Hsu, H., J. Xiong, and D.V. Goeddel, The TNF receptor 1-associated protein TRADD 
signals cell death and NF-kappa B activation. Cell, 1995. 81(4): p. 495-504. 
236. Micheau, O. and J. Tschopp, Induction of TNF receptor I-mediated apoptosis via two 
sequential signaling complexes. Cell, 2003. 114(2): p. 181-90. 
237. Wei, M.C., et al., Proapoptotic BAX and BAK: a requisite gateway to mitochondrial 
dysfunction and death. Science, 2001. 292(5517): p. 727-30. 
238. Chen, X., et al., Bid-independent mitochondrial activation in tumor necrosis factor 
alpha-induced apoptosis and liver injury. Mol Cell Biol, 2007. 27(2): p. 541-53. 
239. Harper, N., et al., Fas-associated death domain protein and caspase-8 are not recruited 
to the tumor necrosis factor receptor 1 signaling complex during tumor necrosis factor-
induced apoptosis. J Biol Chem, 2003. 278(28): p. 25534-41. 
240. Stennicke, H.R., et al., Pro-caspase-3 is a major physiologic target of caspase-8. J Biol 
Chem, 1998. 273(42): p. 27084-90. 
241. Chen, L.F. and W.C. Greene, Shaping the nuclear action of NF-kappaB. Nat Rev Mol 
Cell Biol, 2004. 5(5): p. 392-401. 
242. Wajant, H., K. Pfizenmaier, and P. Scheurich, Tumor necrosis factor signaling. Cell 
Death Differ, 2003. 10(1): p. 45-65. 
243. Bellas, R.E., et al., Inhibition of NF-kappa B activity induces apoptosis in murine 
hepatocytes. Am J Pathol, 1997. 151(4): p. 891-6. 
244. Chen, S., et al., Suppression of tumor necrosis factor-mediated apoptosis by nuclear 
factor kappaB-independent bone morphogenetic protein/Smad signaling. J Biol Chem, 
2001. 276(42): p. 39259-63. 
245. Plumpe, J., et al., NF-kappaB determines between apoptosis and proliferation in 
hepatocytes during liver regeneration. Am J Physiol Gastrointest Liver Physiol, 2000. 
278(1): p. G173-83. 
246. Tacke, F., T. Luedde, and C. Trautwein, Inflammatory pathways in liver homeostasis and 
liver injury. Clin Rev Allergy Immunol, 2009. 36(1): p. 4-12. 
247. Devin, A., et al., The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: 
TRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation. Immunity, 2000. 
12(4): p. 419-29. 
248. Perkins, N.D., The Rel/NF-kappa B family: friend and foe. Trends Biochem Sci, 2000. 
25(9): p. 434-40. 
249. Zhong, H., et al., The transcriptional activity of NF-kappaB is regulated by the IkappaB-
associated PKAc subunit through a cyclic AMP-independent mechanism. Cell, 1997. 
89(3): p. 413-24. 
250. Wang, D., et al., Tumor necrosis factor alpha-induced phosphorylation of RelA/p65 on 
Ser529 is controlled by casein kinase II. J Biol Chem, 2000. 275(42): p. 32592-7. 
251. Leitges, M., et al., Targeted disruption of the zetaPKC gene results in the impairment of 
the NF-kappaB pathway. Mol Cell, 2001. 8(4): p. 771-80. 
252. Hoeflich, K.P., et al., Requirement for glycogen synthase kinase-3beta in cell survival 
and NF-kappaB activation. Nature, 2000. 406(6791): p. 86-90. 
 163 
253. Wang, C.Y., et al., NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-
IAP1 and c-IAP2 to suppress caspase-8 activation. Science, 1998. 281(5383): p. 1680-3. 
254. Karin, M. and A. Lin, NF-kappaB at the crossroads of life and death. Nat Immunol, 
2002. 3(3): p. 221-7. 
255. Ghosh, S. and M. Karin, Missing pieces in the NF-kappaB puzzle. Cell, 2002. 109 Suppl: 
p. S81-96. 
256. Lehmann, V., M.A. Freudenberg, and C. Galanos, Lethal toxicity of lipopolysaccharide 
and tumor necrosis factor in normal and D-galactosamine-treated mice. J Exp Med, 
1987. 165(3): p. 657-63. 
257. Shiratori, Y., et al., Role of endotoxin-responsive macrophages in hepatic injury. 
Hepatology, 1990. 11(2): p. 183-92. 
258. Morikawa, A., et al., Apoptotic cell death in the response of D-galactosamine-sensitized 
mice to lipopolysaccharide as an experimental endotoxic shock model. Infect Immun, 
1996. 64(3): p. 734-8. 
259. Decker, K. and D. Keppler, Galactosamine hepatitis: key role of the nucleotide deficiency 
period in the pathogenesis of cell injury and cell death. Rev Physiol Biochem Pharmacol, 
1974(71): p. 77-106. 
260. Galanos, C., M.A. Freudenberg, and W. Reutter, Galactosamine-induced sensitization to 
the lethal effects of endotoxin. Proc Natl Acad Sci U S A, 1979. 76(11): p. 5939-43. 
261. Leist, M., et al., Murine hepatocyte apoptosis induced in vitro and in vivo by TNF-alpha 
requires transcriptional arrest. J Immunol, 1994. 153(4): p. 1778-88. 
262. Shou, J., et al., Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA 
damage and its overexpression sensitizes brain tumor cells to apoptosis following 
alkylation damage of DNA. Oncogene, 2002. 21(6): p. 878-89. 
263. Chen, S., et al., Wnt-1 signaling inhibits apoptosis by activating beta-catenin/T cell 
factor-mediated transcription. J Cell Biol, 2001. 152(1): p. 87-96. 
264. Myung, S.J., et al., Wnt signaling enhances the activation and survival of human hepatic 
stellate cells. FEBS Lett, 2007. 581(16): p. 2954-8. 
265. Wang, Z., et al., Beta-catenin promotes survival of renal epithelial cells by inhibiting 
Bax. J Am Soc Nephrol, 2009. 20(9): p. 1919-28. 
266. Deng, J., et al., beta-catenin interacts with and inhibits NF-kappa B in human colon and 
breast cancer. Cancer Cell, 2002. 2(4): p. 323-34. 
267. Du, Q., et al., Wnt/beta-catenin signaling regulates cytokine-induced human inducible 
nitric oxide synthase expression by inhibiting nuclear factor-kappaB activation in cancer 
cells. Cancer Res, 2009. 69(9): p. 3764-71. 
268. Strom, S.C., J.R. Chowdhury, and I.J. Fox, Hepatocyte transplantation for the treatment 
of human disease. Semin Liver Dis, 1999. 19(1): p. 39-48. 
269. Grossman, M., et al., Successful ex vivo gene therapy directed to liver in a patient with 
familial hypercholesterolaemia. Nat Genet, 1994. 6(4): p. 335-41. 
270. Mito, M., M. Kusano, and Y. Kawaura, Hepatocyte transplantation in man. Transplant 
Proc, 1992. 24(6): p. 3052-3. 
271. Kusano, M. and M. Mito, Observations on the fine structure of long-survived isolated 
hepatocytes inoculated into rat spleen. Gastroenterology, 1982. 82(4): p. 616-28. 
272. Mito, M., et al., Morphology and function of isolated hepatocytes transplanted into rat 
spleen. Transplantation, 1979. 28(6): p. 499-505. 
 164 
273. Sokal, E.M., Liver transplantation for inborn errors of liver metabolism. J Inherit Metab 
Dis, 2006. 29(2-3): p. 426-30. 
274. Fox, I.J., et al., Treatment of the Crigler-Najjar syndrome type I with hepatocyte 
transplantation. N Engl J Med, 1998. 338(20): p. 1422-6. 
275. Strom, S.C., et al., Hepatocyte transplantation as a bridge to orthotopic liver 
transplantation in terminal liver failure. Transplantation, 1997. 63(4): p. 559-69. 
276. Dhawan, A., et al., Hepatocyte transplantation for inherited factor VII deficiency. 
Transplantation, 2004. 78(12): p. 1812-4. 
277. Stephenne, X., et al., Cryopreserved liver cell transplantation controls ornithine 
transcarbamylase deficient patient while awaiting liver transplantation. Am J Transplant, 
2005. 5(8): p. 2058-61. 
278. Muraca, M., et al., Hepatocyte transplantation as a treatment for glycogen storage 
disease type 1a. Lancet, 2002. 359(9303): p. 317-8. 
279. Habibullah, C.M., et al., Human fetal hepatocyte transplantation in patients with 
fulminant hepatic failure. Transplantation, 1994. 58(8): p. 951-2. 
280. Bilir, B.M., et al., Hepatocyte transplantation in acute liver failure. Liver Transpl, 2000. 
6(1): p. 32-40. 
281. Soriano, H.E., et al., Hepatocellular transplantation (HCT) in children with fulminant 
liver failure(FLF). . Hepatology 1997. 26: p. 239A(443). 
282. Asahina, K., K. Teramoto, and H. Teraoka, Embryonic stem cells: hepatic differentiation 
and regenerative medicine for the treatment of liver disease. Curr Stem Cell Res Ther, 
2006. 1(2): p. 139-56. 
283. Lysy, P.A., et al., Stem cells for liver tissue repair: current knowledge and perspectives. 
World J Gastroenterol, 2008. 14(6): p. 864-75. 
284. Sharma, A.D., et al., The role of stem cells in physiology, pathophysiology, and therapy 
of the liver. Stem Cell Rev, 2006. 2(1): p. 51-8. 
285. Si-Tayeb, K., et al., Highly efficient generation of human hepatocyte-like cells from 
induced pluripotent stem cells. Hepatology. 51(1): p. 297-305. 
286. Shiraki, N., et al., Differentiation of mouse and human embryonic stem cells into hepatic 
lineages. Genes Cells, 2008. 
287. Drobinskaya, I., et al., Scalable Selection of Hepatocyte- and Hepatocyte Precursor-like 
Cells from Culture of Differentiating Transgenically Modified Murine ES Cells. Stem 
Cells, 2008. 
288. Jochheim, A., et al., Quantitative gene expression profiling reveals a fetal hepatic 
phenotype of murine ES-derived hepatocytes. Int J Dev Biol, 2004. 48(1): p. 23-9. 
289. Chinzei, R., et al., Embryoid-body cells derived from a mouse embryonic stem cell line 
show differentiation into functional hepatocytes. Hepatology, 2002. 36(1): p. 22-9. 
290. Yamada, T., et al., In vitro differentiation of embryonic stem cells into hepatocyte-like 
cells identified by cellular uptake of indocyanine green. Stem Cells, 2002. 20(2): p. 146-
54. 
291. Tsutsui, M., et al., Characterization of cytochrome P450 expression in murine embryonic 
stem cell-derived hepatic tissue system. Drug Metab Dispos, 2006. 34(4): p. 696-701. 
292. Soto-Gutierrez, A., et al., Reversal of mouse hepatic failure using an implanted liver-
assist device containing ES cell-derived hepatocytes. Nat Biotechnol, 2006. 24(11): p. 
1412-9. 
 165 
293. Sharma, A.D., et al., Human cord blood stem cells generate human cytokeratin 18-
negative hepatocyte-like cells in injured mouse liver. Am J Pathol, 2005. 167(2): p. 555-
64. 
294. Lagasse, E., et al., Purified hematopoietic stem cells can differentiate into hepatocytes in 
vivo. Nat Med, 2000. 6(11): p. 1229-34. 
295. Ishikawa, F., et al., Transplanted human cord blood cells give rise to hepatocytes in 
engrafted mice. Ann N Y Acad Sci, 2003. 996: p. 174-85. 
296. Sandhu, J.S., et al., Stem cell properties and repopulation of the rat liver by fetal liver 
epithelial progenitor cells. Am J Pathol, 2001. 159(4): p. 1323-34. 
297. Wang, X., et al., The origin and liver repopulating capacity of murine oval cells. Proc 
Natl Acad Sci U S A, 2003. 100 Suppl 1: p. 11881-8. 
298. Monga, S.P., et al., Expansion of hepatic and hematopoietic stem cells utilizing mouse 
embryonic liver explants. Cell Transplant, 2001. 10(1): p. 81-9. 
299. Oertel, M., et al., Repopulation of rat liver by fetal hepatoblasts and adult hepatocytes 
transduced ex vivo with lentiviral vectors. Hepatology, 2003. 37(5): p. 994-1005. 
300. Sharma, A.D., et al., Murine embryonic stem cell-derived hepatic progenitor cells engraft 
in recipient livers with limited capacity of liver tissue formation. Cell Transplant, 2008. 
17(3): p. 313-23. 
301. Teramoto, K., et al., Teratoma formation and hepatocyte differentiation in mouse liver 
transplanted with mouse embryonic stem cell-derived embryoid bodies. Transplant Proc, 
2005. 37(1): p. 285-6. 
302. Kobayashi, N., et al., Partial hepatectomy and subsequent radiation facilitates 
engraftment of mouse embryonic stem cells in the liver. Transplant Proc, 2004. 36(8): p. 
2352-4. 
303. Schumacher, I.K., et al., Transplantation of conditionally immortalized hepatocytes to 
treat hepatic encephalopathy. Hepatology, 1996. 24(2): p. 337-43. 
304. Baba, Y., K.P. Garrett, and P.W. Kincade, Constitutively active beta-catenin confers 
multilineage differentiation potential on lymphoid and myeloid progenitors. Immunity, 
2005. 23(6): p. 599-609. 
305. Baba, Y., et al., Constitutively active beta-catenin promotes expansion of multipotent 
hematopoietic progenitors in culture. J Immunol, 2006. 177(4): p. 2294-303. 
306. Simon, M., et al., Constitutive activation of the Wnt/beta-catenin signalling pathway in 
acute myeloid leukaemia. Oncogene, 2005. 24(14): p. 2410-20. 
307. Reya, T., et al., A role for Wnt signalling in self-renewal of haematopoietic stem cells. 
Nature, 2003. 423(6938): p. 409-14. 
308. Natori, S., et al., Hepatocyte apoptosis is a pathologic feature of human alcoholic 
hepatitis. J Hepatol, 2001. 34(2): p. 248-53. 
309. Kurose, I., et al., Oxidative stress-mediated apoptosis of hepatocytes exposed to acute 
ethanol intoxication. Hepatology, 1997. 25(2): p. 368-78. 
310. Zhou, Z., X. Sun, and Y.J. Kang, Ethanol-induced apoptosis in mouse liver: Fas- and 
cytochrome c-mediated caspase-3 activation pathway. Am J Pathol, 2001. 159(1): p. 329-
38. 
311. Feldstein, A.E., et al., Hepatocyte apoptosis and fas expression are prominent features of 
human nonalcoholic steatohepatitis. Gastroenterology, 2003. 125(2): p. 437-43. 
312. Faubion, W.A., et al., Toxic bile salts induce rodent hepatocyte apoptosis via direct 
activation of Fas. J Clin Invest, 1999. 103(1): p. 137-45. 
 166 
313. Strand, S., et al., Hepatic failure and liver cell damage in acute Wilson's disease involve 
CD95 (APO-1/Fas) mediated apoptosis. Nat Med, 1998. 4(5): p. 588-93. 
314. Kountouras, J., C. Zavos, and D. Chatzopoulos, Apoptosis in hepatitis C. J Viral Hepat, 
2003. 10(5): p. 335-42. 
315. Mochizuki, K., et al., Fas antigen expression in liver tissues of patients with chronic 
hepatitis B. J Hepatol, 1996. 24(1): p. 1-7. 
316. Hiramatsu, N., et al., Immunohistochemical detection of Fas antigen in liver tissue of 
patients with chronic hepatitis C. Hepatology, 1994. 19(6): p. 1354-9. 
317. Ramalho, R.M., et al., Apoptosis and Bcl-2 expression in the livers of patients with 
steatohepatitis. Eur J Gastroenterol Hepatol, 2006. 18(1): p. 21-9. 
318. Bird, G.L., et al., Increased plasma tumor necrosis factor in severe alcoholic hepatitis. 
Ann Intern Med, 1990. 112(12): p. 917-20. 
319. Colell, A., et al., Selective glutathione depletion of mitochondria by ethanol sensitizes 
hepatocytes to tumor necrosis factor. Gastroenterology, 1998. 115(6): p. 1541-51. 
320. Marinos, G., et al., Tumor necrosis factor receptors in patients with chronic hepatitis B 
virus infection. Gastroenterology, 1995. 108(5): p. 1453-63. 
321. Kallinowski, B., et al., Induction of tumour necrosis factor (TNF) receptor type p55 and 
p75 in patients with chronic hepatitis C virus (HCV) infection. Clin Exp Immunol, 1998. 
111(2): p. 269-77. 
322. Fang, J.W., et al., Activation of the tumor necrosis factor-alpha system in the liver in 
chronic hepatitis B virus infection. Am J Gastroenterol, 1996. 91(4): p. 748-53. 
323. Tokushige, K., et al., Significance of soluble TNF receptor-I in acute-type fulminant 
hepatitis. Am J Gastroenterol, 2000. 95(8): p. 2040-6. 
324. Malhi, H., M.E. Guicciardi, and G.J. Gores, Hepatocyte death: a clear and present 
danger. Physiol Rev. 90(3): p. 1165-94. 
325. Spahr, L., et al., Combination of steroids with infliximab or placebo in severe alcoholic 
hepatitis: a randomized controlled pilot study. J Hepatol, 2002. 37(4): p. 448-55. 
326. Masuoka, H.C., M.E. Guicciardi, and G.J. Gores, Caspase inhibitors for the treatment of 
hepatitis C. Clin Liver Dis, 2009. 13(3): p. 467-75. 
327. Pockros, P.J., et al., Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower 
aminotransferase activity in patients with chronic hepatitis C. Hepatology, 2007. 46(2): 
p. 324-9. 
328. Valentino, K.L., et al., First clinical trial of a novel caspase inhibitor: anti-apoptotic 
caspase inhibitor, IDN-6556, improves liver enzymes. Int J Clin Pharmacol Ther, 2003. 
41(10): p. 441-9. 
329. Kumar, D. and R.K. Tandon, Use of ursodeoxycholic acid in liver diseases. J 
Gastroenterol Hepatol, 2001. 16(1): p. 3-14. 
330. Rodrigues, C.M. and C.J. Steer, The therapeutic effects of ursodeoxycholic acid as an 
anti-apoptotic agent. Expert Opin Investig Drugs, 2001. 10(7): p. 1243-53. 
331. Thompson, M.D. and S.P. Monga, WNT/beta-catenin signaling in liver health and 
disease. Hepatology, 2007. 45(5): p. 1298-305. 
332. Burke, Z.D., et al., Liver zonation occurs through a beta-catenin-dependent, c-Myc-
independent mechanism. Gastroenterology, 2009. 136(7): p. 2316-2324 e1-3. 
333. Aberle, H., et al., beta-catenin is a target for the ubiquitin-proteasome pathway. Embo J, 
1997. 16(13): p. 3797-804. 
 167 
334. Yokoyama, H.O., et al., Regeneration of mouse liver after partial hepatectomy. Cancer 
Res, 1953. 13(1): p. 80-5. 
335. Kaimori, A., et al., Transforming growth factor-beta1 induces an epithelial-to-
mesenchymal transition state in mouse hepatocytes in vitro. J Biol Chem, 2007. 282(30): 
p. 22089-101. 
336. Seglen, P.O., Preparation of isolated rat liver cells. Methods Cell Biol, 1976. 13: p. 29-
83. 
337. Block, G.D., et al., Population expansion, clonal growth, and specific differentiation 
patterns in primary cultures of hepatocytes induced by HGF/SF, EGF and TGF alpha in 
a chemically defined (HGM) medium. J Cell Biol, 1996. 132(6): p. 1133-49. 
338. Yang, J., et al., Sustained expression of naked plasmid DNA encoding hepatocyte growth 
factor in mice promotes liver and overall body growth. Hepatology, 2001. 33(4): p. 848-
59. 
339. Cieply, B., et al., Unique phenotype of hepatocellular cancers with exon-3 mutations in 
beta-catenin gene. Hepatology, 2008. 
340. Miyazaki, M., et al., Phenobarbital suppresses growth and accelerates restoration of 
differentiation markers of primary culture rat hepatocytes in the chemically defined 
hepatocyte growth medium containing hepatocyte growth factor and epidermal growth 
factor. Exp Cell Res, 1998. 241(2): p. 445-57. 
341. Pediaditakis, P., et al., Differential mitogenic effects of single chain hepatocyte growth 
factor (HGF)/scatter factor and HGF/NK1 following cleavage by factor Xa. J Biol Chem, 
2002. 277(16): p. 14109-15. 
342. Hansen, M.B., S.E. Nielsen, and K. Berg, Re-examination and further development of a 
precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods, 
1989. 119(2): p. 203-10. 
343. Fausto, N., Liver regeneration. J Hepatol, 2000. 32(1 Suppl): p. 19-31. 
344. Ku, N.O., et al., Keratin binding to 14-3-3 proteins modulates keratin filaments and 
hepatocyte mitotic progression. Proc Natl Acad Sci U S A, 2002. 99(7): p. 4373-8. 
345. Boulikas, T., Control of DNA replication by protein phosphorylation. Anticancer Res, 
1994. 14(6B): p. 2465-72. 
346. Wang, X., et al., Increased levels of forkhead box M1B transcription factor in transgenic 
mouse hepatocytes prevent age-related proliferation defects in regenerating liver. Proc 
Natl Acad Sci U S A, 2001. 98(20): p. 11468-73. 
347. Legoix, P., et al., Beta-catenin mutations in hepatocellular carcinoma correlate with a 
low rate of loss of heterozygosity. Oncogene, 1999. 18(27): p. 4044-6. 
348. Yan, H.X., et al., Protein-tyrosine phosphatase PCP-2 inhibits beta-catenin signaling 
and increases E-cadherin-dependent cell adhesion. J Biol Chem, 2006. 281(22): p. 
15423-33. 
349. Bonvini, P., et al., Geldanamycin abrogates ErbB2 association with proteasome-resistant 
beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and 
decreases beta-catenin-sensitive transcription. Cancer Res, 2001. 61(4): p. 1671-7. 
350. Goessling, W., et al., APC mutant zebrafish uncover a changing temporal requirement 
for wnt signaling in liver development. Dev Biol, 2008. 320(1): p. 161-74. 
351. Apte, U., et al., Beta-catenin activation promotes liver regeneration after 
acetaminophen-induced injury. Am J Pathol, 2009. 175(3): p. 1056-65. 
 168 
352. Albrecht, J.H. and L.K. Hansen, Cyclin D1 promotes mitogen-independent cell cycle 
progression in hepatocytes. Cell Growth Differ, 1999. 10(6): p. 397-404. 
353. Bioulac-Sage, P., et al., Hepatocellular adenoma: what is new in 2008. Hepatol Int, 2008. 
2(3): p. 316-21. 
354. Apte, U., et al., Wnt/beta-catenin signaling mediates oval cell response in rodents. 
Hepatology, 2007. 
355. Hsu, S.C., J. Galceran, and R. Grosschedl, Modulation of transcriptional regulation by 
LEF-1 in response to Wnt-1 signaling and association with beta-catenin. Mol Cell Biol, 
1998. 18(8): p. 4807-18. 
356. Young, C.S., et al., Wnt-1 induces growth, cytosolic beta-catenin, and Tcf/Lef 
transcriptional activation in Rat-1 fibroblasts. Mol Cell Biol, 1998. 18(5): p. 2474-85. 
357. Young, C.S., T.N. Masckauchan, and J. Kitajewski, Beta-catenin/Tcf activation partially 
mimics the transforming activity of Wnt-1 in Rat-1 fibroblasts. Differentiation, 2003. 
71(8): p. 477-85. 
358. Haegel, H., et al., Lack of beta-catenin affects mouse development at gastrulation. 
Development, 1995. 121(11): p. 3529-37. 
359. Hugh, T.J., et al., beta-catenin expression in primary and metastatic colorectal 
carcinoma. Int J Cancer, 1999. 82(4): p. 504-11. 
360. Jaiswal, A.S., C.H. Kennedy, and S. Narayan, A correlation of APC and c-myc mRNA 
levels in lung cancer cell lines. Oncol Rep, 1999. 6(6): p. 1253-6. 
361. Rimm, D.L., et al., Frequent nuclear/cytoplasmic localization of beta-catenin without 
exon 3 mutations in malignant melanoma. Am J Pathol, 1999. 154(2): p. 325-9. 
362. Smalley, M.J. and T.C. Dale, Wnt signaling and mammary tumorigenesis. J Mammary 
Gland Biol Neoplasia, 2001. 6(1): p. 37-52. 
363. Morin, P.J., beta-catenin signaling and cancer. Bioessays, 1999. 21(12): p. 1021-30. 
364. Tien, L.T., et al., Expression of beta-catenin in hepatocellular carcinoma. World J 
Gastroenterol, 2005. 11(16): p. 2398-401. 
365. Devereux, T.R., et al., Mutation of beta-catenin is an early event in chemically induced 
mouse hepatocellular carcinogenesis. Oncogene, 1999. 18(33): p. 4726-33. 
366. de La Coste, A., et al., Somatic mutations of the beta-catenin gene are frequent in mouse 
and human hepatocellular carcinomas. Proc Natl Acad Sci U S A, 1998. 95(15): p. 8847-
51. 
367. Wei, Y., et al., Activation of beta-catenin in epithelial and mesenchymal 
hepatoblastomas. Oncogene, 2000. 19(4): p. 498-504. 
368. Fujita, T., et al., Hepatic and renal expression of senescence marker protein-30 and its 
biological significance. J Gastroenterol Hepatol, 1998. 13 Suppl: p. S124-31. 
369. Yamaguchi, M. and S. Ueoka, Expression of calcium-binding protein regucalcin mRNA 
in fetal rat liver is stimulated by calcium administration. Mol Cell Biochem, 1998. 178(1-
2): p. 283-7. 
370. Shinya, N. and M. Yamaguchi, Stimulatory effect of calcium administration on 
regucalcin mRNA expression is attenuated in the kidney cortex of rats ingested with 
saline. Mol Cell Biochem, 1998. 178(1-2): p. 275-81. 
371. Murata, T. and M. Yamaguchi, Molecular cloning of the cDNA coding for regucalcin and 
its mRNA expression in mouse liver: the expression is stimulated by calcium 
administration. Mol Cell Biochem, 1997. 173(1-2): p. 127-33. 
 169 
372. Tsurusaki, Y. and M. Yamaguchi, Role of regucalcin in liver nuclear function: binding of 
regucalcin to nuclear protein or DNA and modulation of tumor-related gene expression. 
Int J Mol Med, 2004. 14(2): p. 277-81. 
373. Tsurusaki, Y. and M. Yamaguchi, Suppressive role of endogenous regucalcin in the 
enhancement of deoxyribonucleic acid synthesis activity in the nucleus of regenerating 
rat liver. J Cell Biochem, 2002. 85(3): p. 516-22. 
374. Tsurusaki, Y. and M. Yamaguchi, Role of endogenous regucalcin in nuclear regulation 
of regenerating rat liver: suppression of the enhanced ribonucleic acid synthesis activity. 
J Cell Biochem, 2002. 87(4): p. 450-7. 
375. Izumi, T., Y. Tsurusaki, and M. Yamaguchi, Suppressive effect of endogenous regucalcin 
on nitric oxide synthase activity in cloned rat hepatoma H4-II-E cells overexpressing 
regucalcin. J Cell Biochem, 2003. 89(4): p. 800-7. 
376. Fukaya, Y. and M. Yamaguchi, Characterization of protein tyrosine phosphatase activity 
in rat liver microsomes: suppressive effect of endogenous regucalcin in transgenic rats. 
Int J Mol Med, 2004. 14(3): p. 427-32. 
377. Inagaki, S., H. Misawa, and M. Yamaguchi, Role of endogenous regucalcin in protein 
tyrosine phosphatase regulation in the cloned rat hepatoma cells (H4-II-E). Mol Cell 
Biochem, 2000. 213(1-2): p. 43-50. 
378. Makino, R. and M. Yamaguchi, Expression of calcium-binding protein regucalcin mRNA 
in hepatoma cells. Mol Cell Biochem, 1996. 155(1): p. 85-90. 
379. Murata, T., N. Shinya, and M. Yamaguchi, Expression of calcium-binding protein 
regucalcin mRNA in the cloned human hepatoma cells (HepG2): stimulation by insulin. 
Mol Cell Biochem, 1997. 175(1-2): p. 163-8. 
380. Misawa, H. and M. Yamaguchi, Transcript heterogeneity of the human gene for Ca2+-
binding protein regucalcin. Int J Mol Med, 2000. 5(3): p. 283-7. 
381. Linster, C.L. and E. Van Schaftingen, Vitamin C. Biosynthesis, recycling and 
degradation in mammals. Febs J, 2007. 274(1): p. 1-22. 
382. Majer, B.J., et al., Genotoxic effects of dietary and lifestyle related carcinogens in human 
derived hepatoma (HepG2, Hep3B) cells. Mutat Res, 2004. 551(1-2): p. 153-66. 
383. Zeng, G., et al., Wnt'er in liver: expression of Wnt and frizzled genes in mouse. 
Hepatology, 2007. 45(1): p. 195-204. 
384. Kohler, C., et al., Expression of Notch-1 and its ligand Jagged-1 in rat liver during liver 
regeneration. Hepatology, 2004. 39(4): p. 1056-65. 
385. Fleige, S., et al., Comparison of relative mRNA quantification models and the impact of 
RNA integrity in quantitative real-time RT-PCR. Biotechnol Lett, 2006. 28(19): p. 1601-
13. 
386. Zeng, G., et al., Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma. 
Neoplasia, 2006. 8(4): p. 279-89. 
387. Michalopoulos, G.K., et al., Histological organization in hepatocyte organoid cultures. 
Am J Pathol, 2001. 159(5): p. 1877-87. 
388. Bell, A.W. and G.K. Michalopoulos, Phenobarbital regulates nuclear expression of 
HNF-4alpha in mouse and rat hepatocytes independent of CAR and PXR. Hepatology, 
2006. 44(1): p. 186-94. 
389. Barroso, M.P., et al., Ascorbate and alpha-tocopherol prevent apoptosis induced by 
serum removal independent of Bcl-2. Arch Biochem Biophys, 1997. 343(2): p. 243-8. 
 170 
390. Bajt, M.L., et al., Acetaminophen-induced oxidant stress and cell injury in cultured 
mouse hepatocytes: protection by N-acetyl cysteine. Toxicol Sci, 2004. 80(2): p. 343-9. 
391. Postic, C. and M.A. Magnuson, DNA excision in liver by an albumin-Cre transgene 
occurs progressively with age. Genesis, 2000. 26(2): p. 149-50. 
392. Nejak-Bowen, K. and S.P. Monga, Wnt/beta-catenin signaling in hepatic organogenesis. 
Organogenesis, 2008. 4(2). 
393. Hanada, S., et al., The genetic background modulates susceptibility to mouse liver 
Mallory-Denk body formation and liver injury. Hepatology, 2008. 48(3): p. 943-52. 
394. Jho, E.H., et al., Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a 
negative regulator of the signaling pathway. Mol Cell Biol, 2002. 22(4): p. 1172-83. 
395. Niida, A., et al., DKK1, a negative regulator of Wnt signaling, is a target of the beta-
catenin/TCF pathway. Oncogene, 2004. 23(52): p. 8520-6. 
396. Behari, J., et al., Liver-specific beta-catenin knockout mice exhibit defective bile acid and 
cholesterol homeostasis and increased susceptibility to diet-induced steatohepatitis. Am J 
Pathol. 176(2): p. 744-53. 
397. Zhang, X.F., et al., Conditional beta-catenin loss in mice promotes chemical 
hepatocarcinogenesis: role of oxidative stress and platelet-derived growth factor 
receptor alpha/phosphoinositide 3-kinase signaling. Hepatology. 52(3): p. 954-65. 
398. Galanos, C., et al., Hypersensitivity to endotoxin and mechanisms of host-response. Prog 
Clin Biol Res, 1988. 272: p. 295-308. 
399. Leist, M., et al., The 55-kD tumor necrosis factor receptor and CD95 independently 
signal murine hepatocyte apoptosis and subsequent liver failure. Mol Med, 1996. 2(1): p. 
109-24. 
400. Guicciardi, M.E. and G.J. Gores, Life and death by death receptors. Faseb J, 2009. 23(6): 
p. 1625-37. 
401. Van Antwerp, D.J., et al., Suppression of TNF-alpha-induced apoptosis by NF-kappaB. 
Science, 1996. 274(5288): p. 787-9. 
402. Beg, A.A. and D. Baltimore, An essential role for NF-kappaB in preventing TNF-alpha-
induced cell death. Science, 1996. 274(5288): p. 782-4. 
403. Wallach, D., et al., Tumor necrosis factor receptor and Fas signaling mechanisms. Annu 
Rev Immunol, 1999. 17: p. 331-67. 
404. Kyriakis, J.M., Life-or-death decisions. Nature, 2001. 414(6861): p. 265-6. 
405. Zhao, Y., et al., Activation of pro-death Bcl-2 family proteins and mitochondria apoptosis 
pathway in tumor necrosis factor-alpha-induced liver injury. J Biol Chem, 2001. 
276(29): p. 27432-40. 
406. Akahori, M., et al., Nitric oxide ameliorates actinomycin D/endotoxin-induced apoptotic 
liver failure in mice. J Surg Res, 1999. 85(2): p. 286-93. 
407. Prince, J.M., et al., Toll-like receptor-4 signaling mediates hepatic injury and systemic 
inflammation in hemorrhagic shock. J Am Coll Surg, 2006. 202(3): p. 407-17. 
408. Stock, P., et al., Platelet-derived growth factor receptor-alpha: a novel therapeutic target 
in human hepatocellular cancer. Mol Cancer Ther, 2007. 6(7): p. 1932-41. 
409. Pritchard, M.T., et al., Early growth response-1 contributes to 
galactosamine/lipopolysaccharide-induced acute liver injury in mice. Am J Physiol 
Gastrointest Liver Physiol, 2007. 293(6): p. G1124-33. 
 171 
410. Feng, B., et al., Dynamic metabonomic analysis of BALB/c mice with different outcomes 
after D-galactosamine/lipopolysaccharide-induced fulminant hepatic failure. Liver 
Transpl, 2008. 14(11): p. 1620-31. 
411. Josephs, M.D., et al., Lipopolysaccharide and D-galactosamine-induced hepatic injury is 
mediated by TNF-alpha and not by Fas ligand. Am J Physiol Regul Integr Comp Physiol, 
2000. 278(5): p. R1196-201. 
412. Bradham, C.A., et al., Mechanisms of hepatic toxicity. I. TNF-induced liver injury. Am J 
Physiol, 1998. 275(3 Pt 1): p. G387-92. 
413. Chang, L., et al., The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-
induced cell death by inducing c-FLIP(L) turnover. Cell, 2006. 124(3): p. 601-13. 
414. Baeuerle, P.A. and T. Henkel, Function and activation of NF-kappa B in the immune 
system. Annu Rev Immunol, 1994. 12: p. 141-79. 
415. Blackwell, T.S., et al., Multiorgan nuclear factor kappa B activation in a transgenic 
mouse model of systemic inflammation. Am J Respir Crit Care Med, 2000. 162(3 Pt 1): p. 
1095-101. 
416. Sakurai, H., et al., IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 
in the transactivation domain. J Biol Chem, 1999. 274(43): p. 30353-6. 
417. Schwabe, R.F. and D.A. Brenner, Role of glycogen synthase kinase-3 in TNF-alpha-
induced NF-kappaB activation and apoptosis in hepatocytes. Am J Physiol Gastrointest 
Liver Physiol, 2002. 283(1): p. G204-11. 
418. Chan, H., D.P. Bartos, and L.B. Owen-Schaub, Activation-dependent transcriptional 
regulation of the human Fas promoter requires NF-kappaB p50-p65 recruitment. Mol 
Cell Biol, 1999. 19(3): p. 2098-108. 
419. Wegenka, U.M., et al., The interleukin-6-activated acute-phase response factor is 
antigenically and functionally related to members of the signal transducer and activator 
of transcription (STAT) family. Mol Cell Biol, 1994. 14(5): p. 3186-96. 
420. Medzhitov, R., P. Preston-Hurlburt, and C.A. Janeway, Jr., A human homologue of the 
Drosophila Toll protein signals activation of adaptive immunity. Nature, 1997. 
388(6640): p. 394-7. 
421. Janeway, C.A., Jr. and R. Medzhitov, Innate immune recognition. Annu Rev Immunol, 
2002. 20: p. 197-216. 
422. Klein, I., et al., Kupffer cell heterogeneity: functional properties of bone marrow derived 
and sessile hepatic macrophages. Blood, 2007. 110(12): p. 4077-85. 
423. Jung, D.Y., et al., TLR4, but not TLR2, signals autoregulatory apoptosis of cultured 
microglia: a critical role of IFN-beta as a decision maker. J Immunol, 2005. 174(10): p. 
6467-76. 
424. Wang, X., et al., A mechanism of cell survival: sequestration of Fas by the HGF receptor 
Met. Mol Cell, 2002. 9(2): p. 411-21. 
425. Michalopoulos, G.K., et al., HGF-, EGF-, and dexamethasone-induced gene expression 
patterns during formation of tissue in hepatic organoid cultures. Gene Expr, 2003. 11(2): 
p. 55-75. 
426. Li, G., et al., Cyclooxygenase-2 prevents fas-induced liver injury through up-regulation 
of epidermal growth factor receptor. Hepatology, 2009. 50(3): p. 834-43. 
427. Grimm, S., et al., Bcl-2 down-regulates the activity of transcription factor NF-kappaB 
induced upon apoptosis. J Cell Biol, 1996. 134(1): p. 13-23. 
 172 
428. Velasco, M., et al., Rapid Up-regulation of IkappaBbeta and abrogation of NF-kappaB 
activity in peritoneal macrophages stimulated with lipopolysaccharide. J Biol Chem, 
1997. 272(37): p. 23025-30. 
429. Tapalaga, D., G. Tiegs, and S. Angermuller, NFkappaB and caspase-3 activity in 
apoptotic hepatocytes of galactosamine-sensitized mice treated with TNFalpha. J 
Histochem Cytochem, 2002. 50(12): p. 1599-609. 
430. Son, Y.H., et al., Roles of MAPK and NF-kappaB in interleukin-6 induction by 
lipopolysaccharide in vascular smooth muscle cells. J Cardiovasc Pharmacol, 2008. 
51(1): p. 71-7. 
431. Steinhusen, U., et al., Apoptosis-induced cleavage of beta-catenin by caspase-3 results in 
proteolytic fragments with reduced transactivation potential. J Biol Chem, 2000. 
275(21): p. 16345-53. 
432. Van de Craen, M., et al., Proteolytic cleavage of beta-catenin by caspases: an in vitro 
analysis. FEBS Lett, 1999. 458(2): p. 167-70. 
433. Tiegs, G., M. Wolter, and A. Wendel, Tumor necrosis factor is a terminal mediator in 
galactosamine/endotoxin-induced hepatitis in mice. Biochem Pharmacol, 1989. 38(4): p. 
627-31. 
434. Clark, J.M., F.L. Brancati, and A.M. Diehl, The prevalence and etiology of elevated 
aminotransferase levels in the United States. Am J Gastroenterol, 2003. 98(5): p. 960-7. 
435. Linster, C.L. and E. Van Schaftingen, Rapid stimulation of free glucuronate formation by 
non-glucuronidable xenobiotics in isolated rat hepatocytes. J Biol Chem, 2003. 278(38): 
p. 36328-33. 
436. Chafey, P., et al., Proteomic analysis of beta-catenin activation in mouse liver by DIGE 
analysis identifies glucose metabolism as a new target of the Wnt pathway. Proteomics, 
2009. 9(15): p. 3889-900. 
437. Bellas, R.E. and G.E. Sonenshein, Nuclear factor kappaB cooperates with c-Myc in 
promoting murine hepatocyte survival in a manner independent of p53 tumor suppressor 
function. Cell Growth Differ, 1999. 10(5): p. 287-94. 
438. Gomez-Quiroz, L.E., et al., Hepatocyte-specific c-Met deletion disrupts redox 
homeostasis and sensitizes to Fas-mediated apoptosis. J Biol Chem, 2008. 
439. Bernard, D., et al., The c-Rel transcription factor can both induce and inhibit apoptosis in 
the same cells via the upregulation of MnSOD. Oncogene, 2002. 21(28): p. 4392-402. 
440. Hakem, R., et al., Differential requirement for caspase 9 in apoptotic pathways in vivo. 
Cell, 1998. 94(3): p. 339-52. 
441. Nejak-Bowen, K.N., et al., Accelerated liver regeneration and hepatocarcinogenesis in 
mice overexpressing serine-45 mutant beta-catenin. Hepatology. 51(5): p. 1603-13. 
442. Colnot, S., et al., Liver-targeted disruption of Apc in mice activates beta-catenin 
signaling and leads to hepatocellular carcinomas. Proc Natl Acad Sci U S A, 2004. 
101(49): p. 17216-21. 
443. Qian, J., et al., The APC tumor suppressor inhibits DNA replication by directly binding to 
DNA via its carboxyl terminus. Gastroenterology, 2008. 135(1): p. 152-62. 
444. Prosperi, J.R., et al., The APC tumor suppressor is required for epithelial integrity in the 
mouse mammary gland. J Cell Physiol, 2009. 220(2): p. 319-31. 
445. Su, L.K., et al., Biallelic inactivation of the APC gene is associated with hepatocellular 
carcinoma in familial adenomatous polyposis coli. Cancer, 2001. 92(2): p. 332-9. 
 173 
446. Harada, N., et al., Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene 
mutations. Cancer Res, 2004. 64(1): p. 48-54. 
447. Sansom, O.J., et al., Cyclin D1 is not an immediate target of beta-catenin following Apc 
loss in the intestine. J Biol Chem, 2005. 280(31): p. 28463-7. 
448. Prange, W., et al., Beta-catenin accumulation in the progression of human 
hepatocarcinogenesis correlates with loss of E-cadherin and accumulation of p53, but 
not with expression of conventional WNT-1 target genes. J Pathol, 2003. 201(2): p. 250-9. 
449. Manisastry, S.M., M. Han, and K.K. Linask, Early temporal-specific responses and 
differential sensitivity to lithium and Wnt-3A exposure during heart development. Dev 
Dyn, 2006. 235(8): p. 2160-74. 
450. Yamaguchi, M., et al., Potential role of regucalcin as a specific biochemical marker of 
chronic liver injury with carbon tetrachloride administration in rats. Mol Cell Biochem, 
2002. 241(1-2): p. 61-7. 
451. Elchuri, S., et al., Identification of biomarkers associated with the development of 
hepatocellular carcinoma in CuZn superoxide dismutase deficient mice. Proteomics, 
2007. 7(12): p. 2121-9. 
452. Graveel, C.R., et al., Expression profiling and identification of novel genes in 
hepatocellular carcinomas. Oncogene, 2001. 20(21): p. 2704-12. 
453. Calvisi, D.F., et al., Activation of beta-catenin provides proliferative and invasive 
advantages in c-myc/TGF-alpha hepatocarcinogenesis promoted by phenobarbital. 
Carcinogenesis, 2004. 25(6): p. 901-8. 
454. Iida, M., et al., Changes in global gene and protein expression during early mouse liver 
carcinogenesis induced by non-genotoxic model carcinogens oxazepam and Wyeth-
14,643. Carcinogenesis, 2003. 24(4): p. 757-70. 
455. Dihlmann, S., et al., Regulation of AKT1 expression by beta-catenin/Tcf/Lef signaling in 
colorectal cancer cells. Carcinogenesis, 2005. 26(9): p. 1503-12. 
456. Toualbi, K., et al., Physical and functional cooperation between AP-1 and beta-catenin 
for the regulation of TCF-dependent genes. Oncogene, 2006. 
457. Beg, A.A., et al., Embryonic lethality and liver degeneration in mice lacking the RelA 
component of NF-kappa B. Nature, 1995. 376(6536): p. 167-70. 
458. Doi, T.S., et al., Absence of tumor necrosis factor rescues RelA-deficient mice from 
embryonic lethality. Proc Natl Acad Sci U S A, 1999. 96(6): p. 2994-9. 
459. Rosenfeld, M.E., et al., Prevention of hepatic apoptosis and embryonic lethality in 
RelA/TNFR-1 double knockout mice. Am J Pathol, 2000. 156(3): p. 997-1007. 
460. Li, Q., et al., Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. 
Science, 1999. 284(5412): p. 321-5. 
461. Rudolph, D., et al., Severe liver degeneration and lack of NF-kappaB activation in 
NEMO/IKKgamma-deficient mice. Genes Dev, 2000. 14(7): p. 854-62. 
462. Xu, Y., et al., NF-kappaB inactivation converts a hepatocyte cell line TNF-alpha 
response from proliferation to apoptosis. Am J Physiol, 1998. 275(4 Pt 1): p. C1058-66. 
463. Wullaert, A., et al., Hepatic tumor necrosis factor signaling and nuclear factor-kappaB: 
effects on liver homeostasis and beyond. Endocr Rev, 2007. 28(4): p. 365-86. 
464. Luedde, T., et al., Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-
induced apoptosis but protects from ischemia/reperfusion injury. J Clin Invest, 2005. 
115(4): p. 849-59. 
 174 
 175 
465. Libert, C., et al., Involvement of the liver, but not of IL-6, in IL-1-induced desensitization 
to the lethal effects of tumor necrosis factor. J Immunol, 1991. 146(8): p. 2625-32. 
466. Takai, S., et al., Intrinsic resistance to TNF-alpha-induced hepatocyte apoptosis in ICR 
mice correlates with expression of a short form of c-FLIP. Lab Invest, 2007. 87(6): p. 
572-81. 
467. Handeli, S. and J.A. Simon, A small-molecule inhibitor of Tcf/beta-catenin signaling 
down-regulates PPARgamma and PPARdelta activities. Mol Cancer Ther, 2008. 7(3): p. 
521-9. 
468. Lepourcelet, M., et al., Small-molecule antagonists of the oncogenic Tcf/beta-catenin 
protein complex. Cancer Cell, 2004. 5(1): p. 91-102. 
469. Emami, K.H., et al., A small molecule inhibitor of beta-catenin/CREB-binding protein 
transcription [corrected]. Proc Natl Acad Sci U S A, 2004. 101(34): p. 12682-7. 
 
 
